MED13 Syndrome

Mendelian MONDO:0032485 Pathograph 30 Show in embeddings browser Autosomal dominant intellectual disability Neurodevelopmental disorder CDK8-kinase module-associated disorder

MED13 syndrome (MRD61) is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in MED13, which encodes mediator complex subunit 13. The Mediator complex is a multi-subunit transcriptional coactivator that bridges gene-specific transcription factors to RNA polymerase II. MED13 is part of the CDK8 kinase module, which reversibly associates with the Mediator core. Pathogenic MED13 variants disrupt transcriptional regulation in developing tissues, leading to intellectual disability, speech and language delay, variable congenital heart defects, facial dysmorphism, hypotonia, and behavioral abnormalities including autism spectrum disorder and ADHD. To date, only approximately 26 cases have been reported worldwide. Both truncating (haploinsufficiency) and clustered missense variants (affecting a conserved phosphodegron at Thr326/Pro327) have been identified. The phenotypic spectrum continues to expand with subsequent case reports, which have added structural brain anomalies (hydrocephalus, optic chiasm and brainstem atrophy), skeletal and limb abnormalities, restricted growth, dental anomalies (supernumerary teeth), and rare enteric involvement (congenital aganglionic megacolon).

Ask OpenScientist

Ask a research question about MED13 Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
22
Phenotypes
30
Pathograph
1
Genes
4
Medical Actions
2
Datasets
2
Deep Research
⚙

Pathophysiology

7
Disrupted Mediator complex transcriptional regulation
MED13 is a subunit of the CDK8 kinase module of the Mediator complex, which regulates RNA polymerase II-dependent transcription. MED13 plays a connective role between the CDK8 kinase module and the Mediator core. Pathogenic variants disrupt Mediator-dependent transcriptional control and broader gene-expression programs. MED13 belongs to the group of CDK8-kinase module-associated disease genes, alongside MED12, MED13L, and CDK8.
MED13 hgnc:22474
transcription by RNA polymerase II GO:0006366 regulation of gene expression GO:0010468 ↕ DYSREGULATED
Downstream
Neurodevelopmental transcriptional dysregulation Mediator dysfunction perturbs neuronal developmental gene-expression programs that contribute to developmental delay, language impairment, and intellectual disability.
Cardiac developmental transcriptional dysregulation Mediator dysfunction can also perturb cardiac developmental transcriptional programs, contributing to variable congenital heart anomalies in a subset of patients.
Craniofacial, ocular, and sensory developmental dysregulation Because the Mediator complex is required for transcription of nearly all RNA polymerase II genes, MED13 dysfunction also perturbs developmental programs in neural-crest- and placode-derived tissues, contributing to facial dysmorphism, ocular motility and optic-nerve anomalies, sensorineural hearing loss, dental anomalies, and rare enteric (neural-crest) involvement.
Somatic growth and skeletal developmental dysregulation Broad transcriptional pleiotropy of Mediator dysfunction extends to somatic growth and skeletal/limb developmental programs in a subset of patients.
Show evidence (3 references)
PMID:29740699 SUPPORT Human Clinical
"MED13 is a component of the CDK8-kinase module that can reversibly bind Mediator, a multi-protein complex that is required for Polymerase II transcription initiation. Mutations in several other genes encoding subunits of Mediator have been previously shown to associate with DD/ID, including..."
The foundational paper establishes MED13 as a CDK8-kinase module disease gene and describes its role in Mediator-dependent transcription.
PMID:33390853 SUPPORT Other
"MED13 plays a connective role between the CKM and the MED core"
Review article describes MED13's structural role connecting the CDK8 kinase module to the Mediator core complex.
PMID:29325037 SUPPORT Model Organism
"MED13 is essential for ZGA in the mouse, in part by regulating expression of the embryo-specific chromatin remodeling complex, esBAF."
Mouse study establishes MED13 as an essential regulator of early developmental transcription (zygotic genome activation), with its paralog MED13L only partially compensating, supporting the dosage sensitivity of MED13-dependent transcription in development.
MED13 phosphodegron disruption and impaired protein turnover
Several pathogenic missense variants cluster at a conserved phosphodegron (Thr326/Pro327) in MED13. This phosphodegron is normally recognized by the SCF-Fbw7 ubiquitin ligase complex, leading to MED13 ubiquitination and proteasomal degradation. Mutations at these residues may impair MED13 protein turnover, potentially resulting in gain-of-function or dominant-negative effects through accumulation of mutant protein.
SCF-dependent proteasomal ubiquitin-dependent protein catabolic process GO:0031146 protein ubiquitination GO:0016567
Downstream
Disrupted Mediator complex transcriptional regulation Impaired SCF-Fbw7-mediated MED13 turnover can alter CDK8-module availability at the Mediator complex and intensify transcriptional dysregulation.
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"The four N-terminal clustering mutations affect two adjacent amino acids that are known to be involved in MED13 ubiquitination and degradation, p.Thr326 and p.Pro327."
Snijders Blok et al. identified clustering of missense variants at residues involved in MED13 protein turnover, suggesting disrupted ubiquitin-mediated degradation as a disease mechanism.
PMID:33390853 SUPPORT Other
"Normally, this phosphodegron is recognized by the S-phase kinase-associated protein (Skp)-Cullin-F-box (SCF) F-box and WD repeat domain-containing 7 (Fbw7) ubiquitin ligase complex (SCFFbw7), resulting in MED13 protein ubiquitination and degradation"
Review details the SCF-Fbw7-dependent degradation mechanism for MED13, providing molecular context for why phosphodegron mutations are pathogenic.
Neurodevelopmental transcriptional dysregulation
Downstream of MED13/Mediator dysfunction, neuronal gene-expression programs are dysregulated during brain development, contributing to intellectual disability, global developmental delay, language impairment, and variable behavioral phenotypes. Mechanistic studies in mice indicate that MED13 is required cell-autonomously for cortical neuron development: knockdown of Med13 in cortical neurons impairs radial migration, contralateral axonal projection, and dendritic complexity, in part through PlxnA4, linking MED13 dysfunction to the neurodevelopmental disorder phenotype.
neuron CL:0000540
regulation of neuron differentiation GO:0045664 ↕ DYSREGULATED neuron migration GO:0001764 ↕ DYSREGULATED
Downstream
Intellectual disability Disrupted neuronal developmental programs contribute to the core cognitive impairment phenotype.
Global developmental delay Early developmental milestone acquisition is impaired downstream of neuronal transcriptional dysregulation.
Delayed speech and language development Language acquisition is especially sensitive to the disrupted neurodevelopmental program in MED13-related disorder.
Autism spectrum disorder Variable downstream neurobehavioral manifestations can include autistic features in a subset of affected individuals.
Attention deficit hyperactivity disorder Variable downstream neurobehavioral manifestations can include ADHD in a subset of affected individuals.
Hypotonia Disrupted neurodevelopmental programs contribute to muscular hypotonia, particularly during infancy, which compounds motor delay.
Motor delay Disrupted neurodevelopmental programs contribute to delayed acquisition of motor milestones, a common feature distinct from hypotonia and from global developmental delay.
Impaired brain structural development and network excitability Dysregulated neuronal developmental transcription also disturbs brain morphogenesis and cortical network formation, the substrate for structural brain anomalies and seizures.
Show evidence (1 reference)
PMID:41663567 SUPPORT Model Organism
"We found that silencing Med13 in cortical neurons impaired its radial migration and contralateral projection as well as dendritic complexity in mice."
Mouse in-utero electroporation knockdown shows MED13 is required for cortical neuron migration and connectivity, a mechanism linking MED13 loss to the neurodevelopmental phenotype.
Impaired brain structural development and network excitability
Dysregulation of MED13/Mediator-dependent neurodevelopmental transcription disturbs brain growth, midline and cortical morphogenesis, and the balance of neuronal network excitability. This contributes to structural brain anomalies (microcephaly, corpus callosum abnormalities, and in severe cases hydrocephalus and brainstem/optic-chiasm atrophy) and to a seizure-prone cortical network in a subset of patients.
neuron CL:0000540
brain development GO:0007420 ↕ DYSREGULATED cerebral cortex development GO:0021987 ↕ DYSREGULATED
Downstream
Microcephaly Impaired brain growth contributes to microcephaly in a subset of patients.
Corpus callosum abnormalities Disturbed midline/commissural morphogenesis contributes to corpus callosum hypoplasia and related abnormalities.
Hydrocephalus Severe disturbance of brain development has been associated with hydrocephalic changes in a severely affected patient.
Seizures and epileptic encephalopathy Disrupted cortical network formation predisposes to a seizure-prone substrate, including developmental and epileptic encephalopathy.
Show evidence (1 reference)
PMID:36087421 SUPPORT Human Clinical
"Microcephaly, developmental delay, hypotonia, corpus callosum abnormalities, deafness, and retinal atrophy were common features in the previously described cases."
Literature review documents the recurrent structural brain anomalies (microcephaly, corpus callosum abnormalities) that this node accounts for.
Cardiac developmental transcriptional dysregulation
In a subset of affected individuals, MED13/Mediator dysfunction perturbs cardiac developmental gene-expression programs, contributing to mild and variable congenital heart anomalies. In the heart, MED13 (also known as THRAP1/TRAP240) participates in nuclear-receptor signaling that drives the transcription of genes regulating cardiac and systemic energy homeostasis, a function shared redundantly with its paralog MED13L.
cardiac muscle cell CL:0000746
cardiac muscle cell differentiation GO:0055007 ↕ DYSREGULATED
Downstream
Congenital heart defects Perturbed cardiac developmental programs contribute to the variable congenital heart phenotype reported in a subset of MED13 cases.
Show evidence (2 references)
PMID:33390853 SUPPORT Other
"cardiac MED13 mainly participates in the regulation of nuclear receptor signaling, which drives the transcription of genes involved in modulating cardiac and systemic energy homeostasis"
Review describes MED13's nuclear-receptor-coupled transcriptional role in the heart, providing mechanistic context for the cardiac phenotype.
PMID:25422356 SUPPORT Model Organism
"We previously showed that cardiac MED13 modulates systemic energy homeostasis in mice."
Primary mouse study demonstrating MED13's role in cardiac and systemic metabolic gene regulation, the functional basis for its cardiac developmental and metabolic transcriptional role.
Craniofacial, ocular, and sensory developmental dysregulation
Because the Mediator complex is required for transcription of essentially all RNA polymerase II genes, MED13 dysfunction perturbs developmental gene-expression programs in neural-crest- and cranial-placode-derived tissues. This contributes to facial dysmorphism, ocular motility anomalies (Duane anomaly) and optic-nerve abnormalities, sensorineural hearing loss, dental anomalies, and, rarely, enteric nervous system involvement (congenital aganglionic megacolon).
neural crest cell CL:0000333
neural crest cell differentiation GO:0014033 ↕ DYSREGULATED eye development GO:0001654 ↕ DYSREGULATED
Downstream
Facial dysmorphism Disrupted craniofacial (neural-crest) developmental programs contribute to the variable dysmorphic facial features.
Duane anomaly Abnormal development of ocular motor cranial-nerve circuitry contributes to Duane anomaly in some patients.
Optic nerve abnormalities Disrupted ocular/visual-pathway development contributes to optic nerve abnormalities, including optic nerve and optic chiasm atrophy.
Retinal atrophy Disrupted retinal development/maintenance contributes to retinal atrophy, noted among recurrent ophthalmologic features.
Sensorineural hearing loss Disrupted otic developmental programs contribute to sensorineural hearing loss, including congenital unilateral hearing loss.
Dental anomalies Disrupted craniofacial/odontogenic development contributes to dental anomalies such as supernumerary teeth.
Aganglionic megacolon Rare enteric neural-crest involvement has been associated with congenital aganglionic megacolon in a single reported case.
Chronic constipation Enteric/autonomic dysmotility (a milder counterpart of the rare aganglionic megacolon) contributes to chronic constipation, a common gastrointestinal manifestation in the original cohort.
Show evidence (1 reference)
PMID:36087421 SUPPORT Human Clinical
"mild-to-severe intellectual disability, autism spectrum disorder, attention deficit/hyperactivity disorder, epilepsy, ocular or skeletal abnormalities, congenital cardiac defects, and facial dysmorphisms"
The reported MED13 phenotype spectrum includes ocular abnormalities and facial dysmorphism, supporting a craniofacial/sensory developmental arm.
Somatic growth and skeletal developmental dysregulation
Broad transcriptional pleiotropy of MED13/Mediator dysfunction extends to somatic growth and skeletal/limb developmental programs, contributing to restricted growth and skeletal and limb abnormalities in a subset of patients.
growth GO:0040007 ↕ DYSREGULATED skeletal system development GO:0001501 ↕ DYSREGULATED
Downstream
Restricted growth Dysregulated growth-related transcription contributes to restricted growth reported in a subset of patients.
Skeletal and limb abnormalities Dysregulated skeletal/limb developmental transcription contributes to the skeletal and limb abnormalities reported in MRD61.
Show evidence (1 reference)
PMID:41195223 SUPPORT Human Clinical
"The main symptoms are intellectual disability (ID) of varying degrees, developmental delay (DD), hypotonia during infancy, facial dysmorphism, language impairment, restricted growth, skeletal and limb abnormalities, and behavioral abnormalities."
Restricted growth and skeletal/limb abnormalities are listed among the main symptoms of MRD61, supporting this developmental arm.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for MED13 Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

22
Cardiovascular 1
Congenital heart defects OCCASIONAL Abnormal heart morphology HP:0001627
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
Mild congenital heart abnormalities reported in two or more patients.
PMID:38745205 SUPPORT Human Clinical
"He presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients."
Case report describes a severely affected patient with congenital heart anomalies among other features.
Digestive 1
Chronic constipation Constipation HP:0002019
Recorded without a snippet-validated evidence item: chronic obstipation is documented in the per-patient clinical tables of the foundational cohort (Snijders Blok et al. 2018, PMID:29740699) and surfaced by the Falcon deep-research cross-check (reported in ~4/13 of the original cohort), but it is not stated in the paper's abstract, so no exact quote is available. The cohort fraction is reported by that source and has not been independently re-verified here; `frequency` is therefore omitted rather than asserted.
Ear 1
Sensorineural hearing loss OCCASIONAL Sensorineural hearing impairment HP:0000407
Show evidence (2 references)
PMID:41561257 SUPPORT Human Clinical
"We report the case of an eight-year-old male with global developmental delay (GDD), an intellectual developmental disorder (IDD), mild dysmorphic features, congenital unilateral sensorineural hearing loss (SNHL), and a supernumerary left maxillary central incisor."
Case report of congenital unilateral sensorineural hearing loss in a patient with a pathogenic MED13 frameshift variant.
PMID:36087421 SUPPORT Human Clinical
"Microcephaly, developmental delay, hypotonia, corpus callosum abnormalities, deafness, and retinal atrophy were common features in the previously described cases."
Deafness listed among common features in MED13 patients.
Head and Neck 2
Microcephaly OCCASIONAL Microcephaly HP:0000252
Show evidence (1 reference)
PMID:36087421 SUPPORT Human Clinical
"Microcephaly, developmental delay, hypotonia, corpus callosum abnormalities, deafness, and retinal atrophy were common features in the previously described cases."
Literature review identifies microcephaly as a common feature across previously described MED13 cases.
Dental anomalies OCCASIONAL Supernumerary tooth HP:0011069
Show evidence (1 reference)
PMID:41561257 SUPPORT Human Clinical
"We report the case of an eight-year-old male with global developmental delay (GDD), an intellectual developmental disorder (IDD), mild dysmorphic features, congenital unilateral sensorineural hearing loss (SNHL), and a supernumerary left maxillary central incisor."
Supernumerary maxillary central incisor reported as a phenotype-expanding dental anomaly in MRD61.
Musculoskeletal 2
Hypotonia FREQUENT Hypotonia HP:0001252
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
Hypotonia was reported in two or more patients in the original cohort.
PMID:36087421 SUPPORT Human Clinical
"Microcephaly, developmental delay, hypotonia, corpus callosum abnormalities, deafness, and retinal atrophy were common features in the previously described cases."
Literature review confirms hypotonia as a common feature across MED13 cases.
Skeletal and limb abnormalities OCCASIONAL Abnormality of the skeletal system HP:0000924
Show evidence (2 references)
PMID:41195223 SUPPORT Human Clinical
"The main symptoms are intellectual disability (ID) of varying degrees, developmental delay (DD), hypotonia during infancy, facial dysmorphism, language impairment, restricted growth, skeletal and limb abnormalities, and behavioral abnormalities."
Skeletal and limb abnormalities are listed among the main symptoms of MRD61.
PMID:36087421 SUPPORT Human Clinical
"mild-to-severe intellectual disability, autism spectrum disorder, attention deficit/hyperactivity disorder, epilepsy, ocular or skeletal abnormalities, congenital cardiac defects, and facial dysmorphisms"
Skeletal abnormalities are part of the reported MED13 phenotype spectrum.
Nervous System 9
Intellectual disability VERY_FREQUENT Intellectual disability HP:0001249
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"All patients had intellectual disability and/or developmental delays, including speech delays or disorders."
The original cohort of 13 patients all had intellectual disability and/or developmental delays.
PMID:41195223 SUPPORT Human Clinical
"The main symptoms are intellectual disability (ID) of varying degrees, developmental delay (DD), hypotonia during infancy, facial dysmorphism, language impairment, restricted growth, skeletal and limb abnormalities, and behavioral abnormalities."
Review of all 26 reported cases confirms intellectual disability as a cardinal feature.
Global developmental delay VERY_FREQUENT Global developmental delay HP:0001263
Show evidence (2 references)
PMID:38745205 SUPPORT Human Clinical
"de novo variants in the MED13 gene were described in patients with an intellectual developmental disorder that included global developmental delay, mild congenital heart anomalies, and hearing and vision problems in some patients."
Global developmental delay is described as a consistent feature across reported MED13 cases.
PMID:41561257 SUPPORT Human Clinical
"We report the case of an eight-year-old male with global developmental delay (GDD), an intellectual developmental disorder (IDD), mild dysmorphic features, congenital unilateral sensorineural hearing loss (SNHL), and a supernumerary left maxillary central incisor."
Case report confirms global developmental delay as a presenting feature.
Delayed speech and language development VERY_FREQUENT Delayed speech and language development HP:0000750
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"All patients had intellectual disability and/or developmental delays, including speech delays or disorders."
Speech delays or disorders were present across the original cohort.
PMID:41195223 SUPPORT Human Clinical
"The main symptoms are intellectual disability (ID) of varying degrees, developmental delay (DD), hypotonia during infancy, facial dysmorphism, language impairment, restricted growth, skeletal and limb abnormalities, and behavioral abnormalities."
Language impairment is listed as a main symptom across reported cases.
Autism spectrum disorder OCCASIONAL Autism HP:0000717
PMID:38854223 is hypothesis-generating only: the reported MED13 variant was of uncertain significance, so that case should not be treated as standalone proof of a pathogenic MED13-ASD association.
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
ASD was reported in two or more patients in the original cohort.
PMID:38854223 PARTIAL Human Clinical
"In this case report, we present a case of a child diagnosed with ASD who underwent whole exome sequencing (WES) and revealed an uncertain heterozygous variant in the MED13 gene."
This single case is consistent with the broader MED13 behavioral spectrum, but the reported MED13 variant is of uncertain significance, so the paper provides only partial support.
Attention deficit hyperactivity disorder OCCASIONAL Attention deficit hyperactivity disorder HP:0007018
Show evidence (1 reference)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
ADHD was reported in two or more patients.
Seizures and epileptic encephalopathy OCCASIONAL Seizure HP:0001250
Show evidence (2 references)
PMID:36087421 SUPPORT Human Clinical
"This study involves a 24-month-old boy with epilepsy onset at the age of 3 months with drug-resistant focal seizures followed by infantile spasms at the age of 10 months. He had a severe, developmental delay along with microcephaly and dysmorphic features."
First report of developmental and epileptic encephalopathy with infantile spasms associated with a MED13 variant.
PMID:36087421 SUPPORT Human Clinical
"epilepsy is described in only one out of nineteen of previously reported patients with a phenotype of generalized, drug-resistant epilepsy with myoclonic-atonic seizures"
Literature review indicates epilepsy is uncommon but documented in MED13 patients.
Corpus callosum abnormalities OCCASIONAL Abnormal corpus callosum morphology HP:0001273
Show evidence (2 references)
PMID:36087421 SUPPORT Human Clinical
"Microcephaly, developmental delay, hypotonia, corpus callosum abnormalities, deafness, and retinal atrophy were common features in the previously described cases."
Corpus callosum abnormalities are listed among common features.
PMID:38745205 SUPPORT Human Clinical
"He presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients."
Hypoplastic corpus callosum confirmed in a severely affected patient.
Hydrocephalus OCCASIONAL Hydrocephalus HP:0000238
Show evidence (1 reference)
PMID:38745205 SUPPORT Human Clinical
"He presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients."
Hydrocephalic changes reported in a severely affected MED13 patient, expanding the structural brain phenotype.
Motor delay Motor delay HP:0001270
Recorded without a snippet-validated evidence item: motor delay is documented in the per-patient clinical tables of the foundational cohort (Snijders Blok et al. 2018, PMID:29740699) and surfaced by the Falcon deep-research cross-check (reported in ~7/13 of the original cohort), but it is not stated in the paper's abstract, so no exact quote is available. The cohort fraction is reported by that source and has not been independently re-verified here; `frequency` is therefore omitted rather than asserted.
Growth 1
Restricted growth OCCASIONAL Growth delay HP:0001510
Show evidence (1 reference)
PMID:41195223 SUPPORT Human Clinical
"The main symptoms are intellectual disability (ID) of varying degrees, developmental delay (DD), hypotonia during infancy, facial dysmorphism, language impairment, restricted growth, skeletal and limb abnormalities, and behavioral abnormalities."
Restricted growth is listed among the main symptoms of MRD61.
Other 5
Facial dysmorphism FREQUENT Abnormality of the face HP:0000271
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
Dysmorphisms were reported in multiple patients.
PMID:33258286 SUPPORT Human Clinical
"MED13-related disorder is a new neurodevelopmental disorder recently described in literature, which belongs to the group of CDK8-kinase module genes-associated conditions. It is characterized by variable intellectual disability and/or developmental delays, especially in language. Autism spectrum..."
Case report of a patient with MED13 mutation initially diagnosed as Kabuki syndrome, highlighting the overlap in facial features.
Optic nerve abnormalities OCCASIONAL Abnormal optic nerve morphology HP:0000587
Show evidence (2 references)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
Optic nerve abnormalities reported in two or more patients.
PMID:38745205 SUPPORT Human Clinical
"He presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients."
Severely affected patient with bilateral optic nerve atrophy and optic chiasm atrophy.
Retinal atrophy OCCASIONAL Retinal atrophy HP:0001105
Show evidence (1 reference)
PMID:36087421 SUPPORT Human Clinical
"Microcephaly, developmental delay, hypotonia, corpus callosum abnormalities, deafness, and retinal atrophy were common features in the previously described cases."
Retinal atrophy listed among the recurrent features across previously described MED13 cases.
Duane anomaly OCCASIONAL Duane anomaly HP:0009921
Show evidence (1 reference)
PMID:29740699 SUPPORT Human Clinical
"Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms."
Duane anomaly reported in two or more patients.
Aganglionic megacolon OCCASIONAL Aganglionic megacolon HP:0002251
Show evidence (1 reference)
PMID:41195223 SUPPORT Human Clinical
"Compared with previously reported cases of MRD61, the proband presented with congenital megacolon, a previously unreported complication."
Congenital aganglionic megacolon reported as a novel, phenotype-expanding complication in a single MRD61 case.
🧬

Genetic Associations

1
MED13 heterozygous pathogenic variants (Causative)
Gene: MED13 hgnc:22474
Autosomal Dominant
Show evidence (4 references)
PMID:29740699 SUPPORT Human Clinical
"Here we describe a GeneMatcher collaboration which led to a cohort of 13 affected individuals harboring protein-altering variants, 11 of which are de novo, in MED13; the only inherited variant was transmitted to an affected child from an affected mother."
Foundational paper establishing MED13 as a disease gene with predominantly de novo variants.
PMID:29740699 SUPPORT Human Clinical
"Six affected individuals had mutations that are predicted to truncate the MED13 protein, six had missense mutations, and one had an in-frame-deletion of one amino acid. Out of the seven non-truncating mutations, six clustered in two specific locations of the MED13 protein: an N-terminal and..."
Describes the variant spectrum including both truncating and clustered missense variants.
PMID:41195223 SUPPORT Human Clinical
"Intellectual developmental disorder type 61 (MRD61) is an extremely rare autosomal dominant disorder caused by variants in the MED13 gene. This gene encodes a subunit of the mediator complex, which is also known as TRAP, SMCC, DRIP or ARC. This complex functions as a transcriptional coactivator..."
Confirms rarity (26 cases) and autosomal dominant inheritance.
+ 1 more reference
💊

Medical Actions

4
Speech and Language Therapy
Action: speech therapy MAXO:0000930
Early speech and language therapy is recommended to address the prominent communication delays that are among the most consistent features of MED13 syndrome.
Genetic Counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling is recommended for affected families. Most cases are de novo but parent-to-child transmission has been documented, necessitating parental testing and recurrence risk assessment.
Supportive Care
Action: Supportive Care NCIT:C15747
Multidisciplinary supportive care including occupational therapy, physical therapy, educational support, and behavioral interventions.
Antiseizure Pharmacotherapy
Action: Pharmacotherapy NCIT:C15986
Agent: anticonvulsant agent NCIT:C264
Antiseizure medication is used to manage seizures in the subset of MED13 patients with epilepsy, including those presenting with developmental and epileptic encephalopathy or myoclonic-atonic seizures.
📊

Related Datasets

2
Cardiomyocyte-specific Deletion of Med13 and Med13L Results in Dysregulated Gene Expression and Lethal Heart Failure geo:GSE298801
Bulk RNA-seq from adult murine cardiomyocytes after inducible knockout of Med13 and Med13L. Double knockout results in lethal heart failure within 6 weeks, with significant gene dysregulation of fibrotic pathways and calcium handling. Demonstrates that Med13 and Med13L function redundantly in the adult heart to maintain basal cardiac function and transcription, relevant to the congenital heart defects observed in MED13 syndrome.
mouse BULK RNA SEQ n=8
cardiomyocyte
Conditions: Med13/Med13L cardiomyocyte-specific double knockout wild-type control
Findings
Med13 and Med13L are functionally redundant in adult cardiomyocytes
Double knockout causes lethal heart failure with fibrotic and calcium handling gene dysregulation
Similar gene dysregulation patterns across Mediator cardiac knockouts (Med13/13L, Med12, Med1, Med30)
PMID:40989238
Show evidence (1 reference)
PMID:40989238 SUPPORT Model Organism
"Med13/13L knockout resulted in decreased cardiac function leading to lethal heart failure in a median timeframe of 6 weeks from the start of tamoxifen."
Mouse model demonstrates functional redundancy of Med13 and Med13L in heart and lethal consequences of combined loss.
Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight clinicaltrials:NCT01238250
Simons Searchlight is a large prospective observational registry enrolling individuals with rare genetic neurodevelopmental variants including MED13. Collects medical history, developmental milestones, behavioral assessments, and longitudinal follow-up data. As of 2024, includes approximately 15 individuals with MED13 variants, providing natural-history data for MED13 syndrome.
human
clinical phenotype data
Conditions: MED13 pathogenic variants
Findings
Longitudinal natural history data for MED13 syndrome available to qualified researchers
Data available to qualified researchers via SFARI Base (https://base.sfari.org). Over 7,000 total participants enrolled across all gene cohorts as of 2024.
{ }

Source YAML

click to show 
name: MED13 Syndrome
creation_date: '2026-04-11T12:00:00Z'
category: Mendelian
synonyms:
- Intellectual developmental disorder, autosomal dominant 61
- MRD61
- MED13-related intellectual disability
- MED13-related syndrome
- MED13-related disorder
description: >
  MED13 syndrome (MRD61) is a rare autosomal dominant neurodevelopmental disorder
  caused by heterozygous pathogenic variants in MED13, which encodes mediator
  complex subunit 13. The Mediator complex is a multi-subunit transcriptional
  coactivator that bridges gene-specific transcription factors to RNA polymerase II.
  MED13 is part of the CDK8 kinase module, which reversibly associates with the
  Mediator core. Pathogenic MED13 variants disrupt transcriptional regulation in
  developing tissues, leading to intellectual disability, speech and language delay,
  variable congenital heart defects, facial dysmorphism, hypotonia, and behavioral
  abnormalities including autism spectrum disorder and ADHD. To date, only
  approximately 26 cases have been reported worldwide. Both truncating
  (haploinsufficiency) and clustered missense variants (affecting a conserved
  phosphodegron at Thr326/Pro327) have been identified. The phenotypic spectrum
  continues to expand with subsequent case reports, which have added structural
  brain anomalies (hydrocephalus, optic chiasm and brainstem atrophy), skeletal
  and limb abnormalities, restricted growth, dental anomalies (supernumerary
  teeth), and rare enteric involvement (congenital aganglionic megacolon).
disease_term:
  preferred_term: Intellectual developmental disorder 61
  term:
    id: MONDO:0032485
    label: intellectual developmental disorder 61
parents:
- Autosomal dominant intellectual disability
- Neurodevelopmental disorder
- CDK8-kinase module-associated disorder
pathophysiology:
- name: Disrupted Mediator complex transcriptional regulation
  description: >
    MED13 is a subunit of the CDK8 kinase module of the Mediator complex, which
    regulates RNA polymerase II-dependent transcription. MED13 plays a connective
    role between the CDK8 kinase module and the Mediator core. Pathogenic variants
    disrupt Mediator-dependent transcriptional control and broader gene-expression
    programs. MED13 belongs to the group of CDK8-kinase module-associated disease
    genes, alongside MED12, MED13L, and CDK8.
  genes:
  - preferred_term: MED13
    term:
      id: hgnc:22474
      label: MED13
  biological_processes:
  - preferred_term: transcription by RNA polymerase II
    term:
      id: GO:0006366
      label: transcription by RNA polymerase II
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MED13 is a component of the CDK8-kinase module that can reversibly bind
      Mediator, a multi-protein complex that is required for Polymerase II
      transcription initiation. Mutations in several other genes encoding subunits
      of Mediator have been previously shown to associate with DD/ID, including
      MED13L, a paralog of MED13. Thus, our findings add MED13 to the group of
      CDK8-kinase module-associated disease genes.
    explanation: >-
      The foundational paper establishes MED13 as a CDK8-kinase module disease
      gene and describes its role in Mediator-dependent transcription.
  - reference: PMID:33390853
    reference_title: "Potential roles of mediator Complex Subunit 13 in Cardiac Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      MED13 plays a connective role between the CKM and the MED core
    explanation: >-
      Review article describes MED13's structural role connecting the CDK8
      kinase module to the Mediator core complex.
  - reference: PMID:29325037
    reference_title: "Mediator complex component MED13 regulates zygotic genome activation and is required for postimplantation development in the mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      MED13 is essential for ZGA in the mouse, in part by regulating expression
      of the embryo-specific chromatin remodeling complex, esBAF.
    explanation: >-
      Mouse study establishes MED13 as an essential regulator of early
      developmental transcription (zygotic genome activation), with its paralog
      MED13L only partially compensating, supporting the dosage sensitivity of
      MED13-dependent transcription in development.
  downstream:
  - target: Neurodevelopmental transcriptional dysregulation
    description: >-
      Mediator dysfunction perturbs neuronal developmental gene-expression
      programs that contribute to developmental delay, language impairment,
      and intellectual disability.
  - target: Cardiac developmental transcriptional dysregulation
    description: >-
      Mediator dysfunction can also perturb cardiac developmental
      transcriptional programs, contributing to variable congenital heart
      anomalies in a subset of patients.
  - target: Craniofacial, ocular, and sensory developmental dysregulation
    description: >-
      Because the Mediator complex is required for transcription of nearly all
      RNA polymerase II genes, MED13 dysfunction also perturbs developmental
      programs in neural-crest- and placode-derived tissues, contributing to
      facial dysmorphism, ocular motility and optic-nerve anomalies, sensorineural
      hearing loss, dental anomalies, and rare enteric (neural-crest) involvement.
  - target: Somatic growth and skeletal developmental dysregulation
    description: >-
      Broad transcriptional pleiotropy of Mediator dysfunction extends to
      somatic growth and skeletal/limb developmental programs in a subset of
      patients.
- name: MED13 phosphodegron disruption and impaired protein turnover
  description: >
    Several pathogenic missense variants cluster at a conserved phosphodegron
    (Thr326/Pro327) in MED13. This phosphodegron is normally recognized by the
    SCF-Fbw7 ubiquitin ligase complex, leading to MED13 ubiquitination and
    proteasomal degradation. Mutations at these residues may impair MED13 protein
    turnover, potentially resulting in gain-of-function or dominant-negative
    effects through accumulation of mutant protein.
  biological_processes:
  - preferred_term: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process
    term:
      id: GO:0031146
      label: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process
  - preferred_term: protein ubiquitination
    term:
      id: GO:0016567
      label: protein ubiquitination
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The four N-terminal clustering mutations affect two adjacent amino acids
      that are known to be involved in MED13 ubiquitination and degradation,
      p.Thr326 and p.Pro327.
    explanation: >-
      Snijders Blok et al. identified clustering of missense variants at
      residues involved in MED13 protein turnover, suggesting disrupted
      ubiquitin-mediated degradation as a disease mechanism.
  - reference: PMID:33390853
    reference_title: "Potential roles of mediator Complex Subunit 13 in Cardiac Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Normally, this phosphodegron is recognized by the S-phase kinase-associated
      protein (Skp)-Cullin-F-box (SCF) F-box and WD repeat domain-containing 7
      (Fbw7) ubiquitin ligase complex (SCFFbw7), resulting in MED13 protein
      ubiquitination and degradation
    explanation: >-
      Review details the SCF-Fbw7-dependent degradation mechanism for MED13,
      providing molecular context for why phosphodegron mutations are pathogenic.
  downstream:
  - target: Disrupted Mediator complex transcriptional regulation
    description: >-
      Impaired SCF-Fbw7-mediated MED13 turnover can alter CDK8-module
      availability at the Mediator complex and intensify transcriptional
      dysregulation.
- name: Neurodevelopmental transcriptional dysregulation
  description: >
    Downstream of MED13/Mediator dysfunction, neuronal gene-expression programs
    are dysregulated during brain development, contributing to intellectual
    disability, global developmental delay, language impairment, and variable
    behavioral phenotypes. Mechanistic studies in mice indicate that MED13 is
    required cell-autonomously for cortical neuron development: knockdown of Med13
    in cortical neurons impairs radial migration, contralateral axonal projection,
    and dendritic complexity, in part through PlxnA4, linking MED13 dysfunction to
    the neurodevelopmental disorder phenotype.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of neuron differentiation
    term:
      id: GO:0045664
      label: regulation of neuron differentiation
    modifier: DYSREGULATED
  - preferred_term: neuron migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:41663567
    reference_title: "Med13 is involved in the radial migration and contralateral projection of cortical neurons via PlxnA4."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We found that silencing Med13 in cortical neurons impaired its radial
      migration and contralateral projection as well as dendritic complexity in
      mice.
    explanation: >-
      Mouse in-utero electroporation knockdown shows MED13 is required for
      cortical neuron migration and connectivity, a mechanism linking MED13 loss
      to the neurodevelopmental phenotype.
  downstream:
  - target: Intellectual disability
    description: >-
      Disrupted neuronal developmental programs contribute to the core cognitive
      impairment phenotype.
  - target: Global developmental delay
    description: >-
      Early developmental milestone acquisition is impaired downstream of
      neuronal transcriptional dysregulation.
  - target: Delayed speech and language development
    description: >-
      Language acquisition is especially sensitive to the disrupted
      neurodevelopmental program in MED13-related disorder.
  - target: Autism spectrum disorder
    description: >-
      Variable downstream neurobehavioral manifestations can include autistic
      features in a subset of affected individuals.
  - target: Attention deficit hyperactivity disorder
    description: >-
      Variable downstream neurobehavioral manifestations can include ADHD in a
      subset of affected individuals.
  - target: Hypotonia
    description: >-
      Disrupted neurodevelopmental programs contribute to muscular hypotonia,
      particularly during infancy, which compounds motor delay.
  - target: Motor delay
    description: >-
      Disrupted neurodevelopmental programs contribute to delayed acquisition of
      motor milestones, a common feature distinct from hypotonia and from global
      developmental delay.
  - target: Impaired brain structural development and network excitability
    description: >-
      Dysregulated neuronal developmental transcription also disturbs brain
      morphogenesis and cortical network formation, the substrate for structural
      brain anomalies and seizures.
- name: Impaired brain structural development and network excitability
  description: >
    Dysregulation of MED13/Mediator-dependent neurodevelopmental transcription
    disturbs brain growth, midline and cortical morphogenesis, and the balance of
    neuronal network excitability. This contributes to structural brain anomalies
    (microcephaly, corpus callosum abnormalities, and in severe cases
    hydrocephalus and brainstem/optic-chiasm atrophy) and to a seizure-prone
    cortical network in a subset of patients.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: brain development
    term:
      id: GO:0007420
      label: brain development
    modifier: DYSREGULATED
  - preferred_term: cerebral cortex development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microcephaly, developmental delay, hypotonia, corpus callosum
      abnormalities, deafness, and retinal atrophy were common features in
      the previously described cases.
    explanation: >-
      Literature review documents the recurrent structural brain anomalies
      (microcephaly, corpus callosum abnormalities) that this node accounts for.
  downstream:
  - target: Microcephaly
    description: >-
      Impaired brain growth contributes to microcephaly in a subset of patients.
  - target: Corpus callosum abnormalities
    description: >-
      Disturbed midline/commissural morphogenesis contributes to corpus callosum
      hypoplasia and related abnormalities.
  - target: Hydrocephalus
    description: >-
      Severe disturbance of brain development has been associated with
      hydrocephalic changes in a severely affected patient.
  - target: Seizures and epileptic encephalopathy
    description: >-
      Disrupted cortical network formation predisposes to a seizure-prone
      substrate, including developmental and epileptic encephalopathy.
- name: Cardiac developmental transcriptional dysregulation
  description: >
    In a subset of affected individuals, MED13/Mediator dysfunction perturbs
    cardiac developmental gene-expression programs, contributing to mild and
    variable congenital heart anomalies. In the heart, MED13 (also known as
    THRAP1/TRAP240) participates in nuclear-receptor signaling that drives the
    transcription of genes regulating cardiac and systemic energy homeostasis,
    a function shared redundantly with its paralog MED13L.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cardiac muscle cell differentiation
    term:
      id: GO:0055007
      label: cardiac muscle cell differentiation
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:33390853
    reference_title: "Potential roles of mediator Complex Subunit 13 in Cardiac Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      cardiac MED13 mainly participates in the regulation of nuclear receptor
      signaling, which drives the transcription of genes involved in modulating
      cardiac and systemic energy homeostasis
    explanation: >-
      Review describes MED13's nuclear-receptor-coupled transcriptional role in
      the heart, providing mechanistic context for the cardiac phenotype.
  - reference: PMID:25422356
    reference_title: "MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We previously showed that cardiac MED13 modulates systemic energy
      homeostasis in mice.
    explanation: >-
      Primary mouse study demonstrating MED13's role in cardiac and systemic
      metabolic gene regulation, the functional basis for its cardiac
      developmental and metabolic transcriptional role.
  downstream:
  - target: Congenital heart defects
    description: >-
      Perturbed cardiac developmental programs contribute to the variable
      congenital heart phenotype reported in a subset of MED13 cases.
- name: Craniofacial, ocular, and sensory developmental dysregulation
  description: >
    Because the Mediator complex is required for transcription of essentially all
    RNA polymerase II genes, MED13 dysfunction perturbs developmental gene-expression
    programs in neural-crest- and cranial-placode-derived tissues. This contributes
    to facial dysmorphism, ocular motility anomalies (Duane anomaly) and optic-nerve
    abnormalities, sensorineural hearing loss, dental anomalies, and, rarely, enteric
    nervous system involvement (congenital aganglionic megacolon).
  cell_types:
  - preferred_term: neural crest cell
    term:
      id: CL:0000333
      label: migratory neural crest cell
  biological_processes:
  - preferred_term: neural crest cell differentiation
    term:
      id: GO:0014033
      label: neural crest cell differentiation
    modifier: DYSREGULATED
  - preferred_term: eye development
    term:
      id: GO:0001654
      label: eye development
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mild-to-severe intellectual disability, autism spectrum disorder, attention
      deficit/hyperactivity disorder, epilepsy, ocular or skeletal abnormalities,
      congenital cardiac defects, and facial dysmorphisms
    explanation: >-
      The reported MED13 phenotype spectrum includes ocular abnormalities and
      facial dysmorphism, supporting a craniofacial/sensory developmental arm.
  downstream:
  - target: Facial dysmorphism
    description: >-
      Disrupted craniofacial (neural-crest) developmental programs contribute to
      the variable dysmorphic facial features.
  - target: Duane anomaly
    description: >-
      Abnormal development of ocular motor cranial-nerve circuitry contributes to
      Duane anomaly in some patients.
  - target: Optic nerve abnormalities
    description: >-
      Disrupted ocular/visual-pathway development contributes to optic nerve
      abnormalities, including optic nerve and optic chiasm atrophy.
  - target: Retinal atrophy
    description: >-
      Disrupted retinal development/maintenance contributes to retinal atrophy,
      noted among recurrent ophthalmologic features.
  - target: Sensorineural hearing loss
    description: >-
      Disrupted otic developmental programs contribute to sensorineural hearing
      loss, including congenital unilateral hearing loss.
  - target: Dental anomalies
    description: >-
      Disrupted craniofacial/odontogenic development contributes to dental
      anomalies such as supernumerary teeth.
  - target: Aganglionic megacolon
    description: >-
      Rare enteric neural-crest involvement has been associated with congenital
      aganglionic megacolon in a single reported case.
  - target: Chronic constipation
    description: >-
      Enteric/autonomic dysmotility (a milder counterpart of the rare aganglionic
      megacolon) contributes to chronic constipation, a common gastrointestinal
      manifestation in the original cohort.
- name: Somatic growth and skeletal developmental dysregulation
  description: >
    Broad transcriptional pleiotropy of MED13/Mediator dysfunction extends to
    somatic growth and skeletal/limb developmental programs, contributing to
    restricted growth and skeletal and limb abnormalities in a subset of patients.
  biological_processes:
  - preferred_term: growth
    term:
      id: GO:0040007
      label: growth
    modifier: DYSREGULATED
  - preferred_term: skeletal system development
    term:
      id: GO:0001501
      label: skeletal system development
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main symptoms are intellectual disability (ID) of varying degrees,
      developmental delay (DD), hypotonia during infancy, facial dysmorphism,
      language impairment, restricted growth, skeletal and limb abnormalities,
      and behavioral abnormalities.
    explanation: >-
      Restricted growth and skeletal/limb abnormalities are listed among the main
      symptoms of MRD61, supporting this developmental arm.
  downstream:
  - target: Restricted growth
    description: >-
      Dysregulated growth-related transcription contributes to restricted growth
      reported in a subset of patients.
  - target: Skeletal and limb abnormalities
    description: >-
      Dysregulated skeletal/limb developmental transcription contributes to the
      skeletal and limb abnormalities reported in MRD61.
phenotypes:
- category: Clinical
  name: Intellectual disability
  frequency: VERY_FREQUENT
  description: >
    Intellectual disability ranging from mild to severe is a core feature,
    present in all or nearly all affected individuals. The degree of impairment
    varies considerably between patients.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had intellectual disability and/or developmental delays,
      including speech delays or disorders.
    explanation: >-
      The original cohort of 13 patients all had intellectual disability and/or
      developmental delays.
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main symptoms are intellectual disability (ID) of varying degrees,
      developmental delay (DD), hypotonia during infancy, facial dysmorphism,
      language impairment, restricted growth, skeletal and limb abnormalities,
      and behavioral abnormalities.
    explanation: >-
      Review of all 26 reported cases confirms intellectual disability as a
      cardinal feature.
- category: Clinical
  name: Global developmental delay
  frequency: VERY_FREQUENT
  description: >
    Global developmental delay with delayed motor and cognitive milestones is
    present in most affected children. Severity is variable.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:38745205
    reference_title: "Expanding phenotype of MED13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      de novo variants in the MED13 gene were described in patients with an
      intellectual developmental disorder that included global developmental
      delay, mild congenital heart anomalies, and hearing and vision problems
      in some patients.
    explanation: >-
      Global developmental delay is described as a consistent feature across
      reported MED13 cases.
  - reference: PMID:41561257
    reference_title: "Intellectual Developmental Disorder of Autosomal Dominant 61 Caused by a MED13 Variant Presenting With Congenital Unilateral Sensorineural Hearing Loss: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the case of an eight-year-old male with global developmental
      delay (GDD), an intellectual developmental disorder (IDD), mild dysmorphic
      features, congenital unilateral sensorineural hearing loss (SNHL), and a
      supernumerary left maxillary central incisor.
    explanation: >-
      Case report confirms global developmental delay as a presenting feature.
- category: Clinical
  name: Delayed speech and language development
  frequency: VERY_FREQUENT
  description: >
    Speech and language delay is highly prevalent and often the most prominent
    developmental concern. Language impairment may be more severely affected
    than motor development.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had intellectual disability and/or developmental delays,
      including speech delays or disorders.
    explanation: >-
      Speech delays or disorders were present across the original cohort.
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main symptoms are intellectual disability (ID) of varying degrees,
      developmental delay (DD), hypotonia during infancy, facial dysmorphism,
      language impairment, restricted growth, skeletal and limb abnormalities,
      and behavioral abnormalities.
    explanation: >-
      Language impairment is listed as a main symptom across reported cases.
- category: Clinical
  name: Hypotonia
  frequency: FREQUENT
  description: >
    Muscular hypotonia, particularly during infancy, is frequently observed
    and contributes to motor delay. Hypotonia and corpus callosum abnormalities
    were common features among described cases.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: >-
      Hypotonia was reported in two or more patients in the original cohort.
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microcephaly, developmental delay, hypotonia, corpus callosum
      abnormalities, deafness, and retinal atrophy were common features in
      the previously described cases.
    explanation: >-
      Literature review confirms hypotonia as a common feature across MED13 cases.
- category: Clinical
  name: Facial dysmorphism
  frequency: FREQUENT
  description: >
    Distinctive facial features have been reported in multiple patients,
    although the specific dysmorphic features are variable. One patient was
    clinically diagnosed with Kabuki syndrome before molecular testing revealed
    a MED13 variant.
  phenotype_term:
    preferred_term: Abnormality of the face
    term:
      id: HP:0000271
      label: Abnormality of the face
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: Dysmorphisms were reported in multiple patients.
  - reference: PMID:33258286
    reference_title: "Could the MED13 mutations manifest as a Kabuki-like syndrome?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MED13-related disorder is a new neurodevelopmental disorder recently
      described in literature, which belongs to the group of CDK8-kinase module
      genes-associated conditions. It is characterized by variable intellectual
      disability and/or developmental delays, especially in language. Autism
      spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD),
      eye or vision problems, hypotonia, mild congenital hearth abnormalities
      and dysmorphisms have been described among individuals with MED13 mutations.
    explanation: >-
      Case report of a patient with MED13 mutation initially diagnosed as
      Kabuki syndrome, highlighting the overlap in facial features.
- category: Clinical
  name: Congenital heart defects
  frequency: OCCASIONAL
  description: >
    Mild congenital heart abnormalities have been reported in a subset of
    patients. The cardiac phenotype is variable and typically mild.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: >-
      Mild congenital heart abnormalities reported in two or more patients.
  - reference: PMID:38745205
    reference_title: "Expanding phenotype of MED13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with congenital heart anomalies, dysmorphic features,
      hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve
      atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more
      severe condition compared to previously described patients.
    explanation: >-
      Case report describes a severely affected patient with congenital heart
      anomalies among other features.
- category: Clinical
  name: Autism spectrum disorder
  frequency: OCCASIONAL
  description: >
    Autism spectrum disorder has been reported in a subset of individuals with
    MED13-related disorder. The syndrome-defining cohort supports ASD as a
    recurrent but non-universal feature. A 2024 single-case report described
    ASD in a child with an uncertain heterozygous MED13 variant and should be
    interpreted cautiously.
  notes: >-
    PMID:38854223 is hypothesis-generating only: the reported MED13 variant was
    of uncertain significance, so that case should not be treated as standalone
    proof of a pathogenic MED13-ASD association.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: ASD was reported in two or more patients in the original cohort.
  - reference: PMID:38854223
    reference_title: "MED13 Gene Mutation Related to Autism Spectrum Disorder: A Case Report."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this case report, we present a case of a child diagnosed with ASD who
      underwent whole exome sequencing (WES) and revealed an uncertain
      heterozygous variant in the MED13 gene.
    explanation: >-
      This single case is consistent with the broader MED13 behavioral
      spectrum, but the reported MED13 variant is of uncertain significance, so
      the paper provides only partial support.
- category: Clinical
  name: Attention deficit hyperactivity disorder
  frequency: OCCASIONAL
  description: >
    ADHD has been described in some individuals with MED13 mutations.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: ADHD was reported in two or more patients.
- category: Clinical
  name: Seizures and epileptic encephalopathy
  frequency: OCCASIONAL
  description: >
    Seizures have been reported in some patients, including developmental and
    epileptic encephalopathy with infantile spasms and drug-resistant focal
    seizures in at least one patient, and generalized epilepsy with
    myoclonic-atonic seizures in another.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study involves a 24-month-old boy with epilepsy onset at the age
      of 3 months with drug-resistant focal seizures followed by infantile
      spasms at the age of 10 months. He had a severe, developmental delay
      along with microcephaly and dysmorphic features.
    explanation: >-
      First report of developmental and epileptic encephalopathy with infantile
      spasms associated with a MED13 variant.
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      epilepsy is described in only one out of nineteen of previously reported
      patients with a phenotype of generalized, drug-resistant epilepsy with
      myoclonic-atonic seizures
    explanation: >-
      Literature review indicates epilepsy is uncommon but documented in MED13
      patients.
- category: Clinical
  name: Optic nerve abnormalities
  frequency: OCCASIONAL
  description: >
    Optic nerve abnormalities including optic nerve atrophy have been reported
    in some patients. A severely affected infant additionally showed bilateral
    optic nerve atrophy and optic chiasm atrophy, and retinal atrophy has been
    noted among recurrent ophthalmologic features in the literature.
  phenotype_term:
    preferred_term: Abnormal optic nerve morphology
    term:
      id: HP:0000587
      label: Abnormal optic nerve morphology
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: Optic nerve abnormalities reported in two or more patients.
  - reference: PMID:38745205
    reference_title: "Expanding phenotype of MED13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with congenital heart anomalies, dysmorphic features,
      hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve
      atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more
      severe condition compared to previously described patients.
    explanation: >-
      Severely affected patient with bilateral optic nerve atrophy and optic
      chiasm atrophy.
- category: Clinical
  name: Retinal atrophy
  frequency: OCCASIONAL
  description: >
    Retinal atrophy has been noted among the recurrent ophthalmologic features
    in previously described MED13 cases.
  phenotype_term:
    preferred_term: Retinal atrophy
    term:
      id: HP:0001105
      label: Retinal atrophy
  evidence:
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microcephaly, developmental delay, hypotonia, corpus callosum
      abnormalities, deafness, and retinal atrophy were common features in
      the previously described cases.
    explanation: >-
      Retinal atrophy listed among the recurrent features across previously
      described MED13 cases.
- category: Clinical
  name: Microcephaly
  frequency: OCCASIONAL
  description: >
    Microcephaly has been reported in some patients with MED13 variants.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microcephaly, developmental delay, hypotonia, corpus callosum
      abnormalities, deafness, and retinal atrophy were common features in
      the previously described cases.
    explanation: >-
      Literature review identifies microcephaly as a common feature across
      previously described MED13 cases.
- category: Clinical
  name: Corpus callosum abnormalities
  frequency: OCCASIONAL
  description: >
    Abnormalities of the corpus callosum, including hypoplasia, have been
    reported in multiple MED13 patients.
  phenotype_term:
    preferred_term: Abnormal corpus callosum morphology
    term:
      id: HP:0001273
      label: Abnormal corpus callosum morphology
  evidence:
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microcephaly, developmental delay, hypotonia, corpus callosum
      abnormalities, deafness, and retinal atrophy were common features in
      the previously described cases.
    explanation: >-
      Corpus callosum abnormalities are listed among common features.
  - reference: PMID:38745205
    reference_title: "Expanding phenotype of MED13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with congenital heart anomalies, dysmorphic features,
      hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve
      atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more
      severe condition compared to previously described patients.
    explanation: >-
      Hypoplastic corpus callosum confirmed in a severely affected patient.
- category: Clinical
  name: Sensorineural hearing loss
  frequency: OCCASIONAL
  description: >
    Sensorineural hearing impairment has been reported in some patients,
    including congenital unilateral sensorineural hearing loss.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:41561257
    reference_title: "Intellectual Developmental Disorder of Autosomal Dominant 61 Caused by a MED13 Variant Presenting With Congenital Unilateral Sensorineural Hearing Loss: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the case of an eight-year-old male with global developmental
      delay (GDD), an intellectual developmental disorder (IDD), mild dysmorphic
      features, congenital unilateral sensorineural hearing loss (SNHL), and a
      supernumerary left maxillary central incisor.
    explanation: >-
      Case report of congenital unilateral sensorineural hearing loss in a
      patient with a pathogenic MED13 frameshift variant.
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microcephaly, developmental delay, hypotonia, corpus callosum
      abnormalities, deafness, and retinal atrophy were common features in
      the previously described cases.
    explanation: Deafness listed among common features in MED13 patients.
- category: Clinical
  name: Duane anomaly
  frequency: OCCASIONAL
  description: >
    Duane anomaly (a type of eye movement disorder) has been reported in
    some patients with MED13 mutations.
  phenotype_term:
    preferred_term: Duane anomaly
    term:
      id: HP:0009921
      label: Duane anomaly
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features that were reported in two or more patients include autism
      spectrum disorder, attention deficit hyperactivity disorder, optic nerve
      abnormalities, Duane anomaly, hypotonia, mild congenital heart
      abnormalities, and dysmorphisms.
    explanation: Duane anomaly reported in two or more patients.
- category: Clinical
  name: Skeletal and limb abnormalities
  frequency: OCCASIONAL
  description: >
    Skeletal and limb abnormalities are listed among the main symptoms of MRD61
    across reported cases, although the specific findings are variable.
  phenotype_term:
    preferred_term: Skeletal and limb abnormalities
    term:
      id: HP:0000924
      label: Abnormality of the skeletal system
  evidence:
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main symptoms are intellectual disability (ID) of varying degrees,
      developmental delay (DD), hypotonia during infancy, facial dysmorphism,
      language impairment, restricted growth, skeletal and limb abnormalities,
      and behavioral abnormalities.
    explanation: >-
      Skeletal and limb abnormalities are listed among the main symptoms of MRD61.
  - reference: PMID:36087421
    reference_title: "MED13 mutation: A novel cause of developmental and epileptic encephalopathy with infantile spasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mild-to-severe intellectual disability, autism spectrum disorder, attention
      deficit/hyperactivity disorder, epilepsy, ocular or skeletal abnormalities,
      congenital cardiac defects, and facial dysmorphisms
    explanation: >-
      Skeletal abnormalities are part of the reported MED13 phenotype spectrum.
- category: Clinical
  name: Restricted growth
  frequency: OCCASIONAL
  description: >
    Restricted growth has been reported among the main symptoms of MRD61 in a
    subset of patients.
  phenotype_term:
    preferred_term: Restricted growth
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main symptoms are intellectual disability (ID) of varying degrees,
      developmental delay (DD), hypotonia during infancy, facial dysmorphism,
      language impairment, restricted growth, skeletal and limb abnormalities,
      and behavioral abnormalities.
    explanation: >-
      Restricted growth is listed among the main symptoms of MRD61.
- category: Clinical
  name: Dental anomalies
  frequency: OCCASIONAL
  description: >
    Dental anomalies have been reported, including a supernumerary maxillary
    central incisor in a patient with a pathogenic MED13 frameshift variant.
  phenotype_term:
    preferred_term: Supernumerary tooth
    term:
      id: HP:0011069
      label: Supernumerary tooth
  evidence:
  - reference: PMID:41561257
    reference_title: "Intellectual Developmental Disorder of Autosomal Dominant 61 Caused by a MED13 Variant Presenting With Congenital Unilateral Sensorineural Hearing Loss: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the case of an eight-year-old male with global developmental
      delay (GDD), an intellectual developmental disorder (IDD), mild dysmorphic
      features, congenital unilateral sensorineural hearing loss (SNHL), and a
      supernumerary left maxillary central incisor.
    explanation: >-
      Supernumerary maxillary central incisor reported as a phenotype-expanding
      dental anomaly in MRD61.
- category: Clinical
  name: Hydrocephalus
  frequency: OCCASIONAL
  description: >
    Hydrocephalic changes have been reported in a severely affected infant with
    a de novo MED13 missense variant and multiple congenital anomalies.
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: PMID:38745205
    reference_title: "Expanding phenotype of MED13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with congenital heart anomalies, dysmorphic features,
      hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve
      atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more
      severe condition compared to previously described patients.
    explanation: >-
      Hydrocephalic changes reported in a severely affected MED13 patient,
      expanding the structural brain phenotype.
- category: Clinical
  name: Aganglionic megacolon
  frequency: OCCASIONAL
  description: >
    Congenital aganglionic megacolon (Hirschsprung disease) was reported as a
    previously unreported complication in a Chinese proband with a MED13
    frameshift variant, representing rare enteric nervous system involvement.
  phenotype_term:
    preferred_term: Congenital aganglionic megacolon
    term:
      id: HP:0002251
      label: Aganglionic megacolon
  evidence:
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared with previously reported cases of MRD61, the
      proband presented with congenital megacolon, a previously unreported
      complication.
    explanation: >-
      Congenital aganglionic megacolon reported as a novel, phenotype-expanding
      complication in a single MRD61 case.
- category: Clinical
  name: Motor delay
  description: >
    Delayed acquisition of motor milestones is a common feature, distinct from
    muscular hypotonia and from the broader global developmental delay.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  notes: >-
    Recorded without a snippet-validated evidence item: motor delay is documented
    in the per-patient clinical tables of the foundational cohort (Snijders Blok
    et al. 2018, PMID:29740699) and surfaced by the Falcon deep-research
    cross-check (reported in ~7/13 of the original cohort), but it is not stated
    in the paper's abstract, so no exact quote is available. The cohort fraction
    is reported by that source and has not been independently re-verified here;
    `frequency` is therefore omitted rather than asserted.
- category: Clinical
  name: Chronic constipation
  description: >
    Chronic constipation/obstipation is reported as a common gastrointestinal
    manifestation, distinct from (and far more frequent than) the rare enteric
    aganglionic megacolon.
  phenotype_term:
    preferred_term: Chronic constipation
    term:
      id: HP:0002019
      label: Constipation
  notes: >-
    Recorded without a snippet-validated evidence item: chronic obstipation is
    documented in the per-patient clinical tables of the foundational cohort
    (Snijders Blok et al. 2018, PMID:29740699) and surfaced by the Falcon
    deep-research cross-check (reported in ~4/13 of the original cohort), but it
    is not stated in the paper's abstract, so no exact quote is available. The
    cohort fraction is reported by that source and has not been independently
    re-verified here; `frequency` is therefore omitted rather than asserted.
genetic:
- name: MED13 heterozygous pathogenic variants
  association: Causative
  gene_term:
    preferred_term: MED13
    term:
      id: hgnc:22474
      label: MED13
  inheritance:
  - name: Autosomal Dominant
    evidence:
    - reference: PMID:41195223
      reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Intellectual developmental disorder type 61 (MRD61) is an extremely rare
        autosomal dominant disorder caused by variants in the MED13 gene.
      explanation: >-
        Confirms autosomal dominant inheritance pattern for MED13 syndrome.
  features: >
    MED13 syndrome is caused by heterozygous pathogenic variants in MED13.
    Most variants arise de novo, although parent-to-child transmission has
    been documented. Both truncating variants (frameshift, nonsense) causing
    haploinsufficiency and missense variants clustering at a conserved
    phosphodegron (p.Thr326/p.Pro327) and a C-terminal region have been
    identified. Six of 13 patients in the original cohort had truncating
    mutations and seven had non-truncating variants. To date approximately
    26 cases have been reported worldwide.
  evidence:
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we describe a GeneMatcher collaboration which led to a cohort of 13
      affected individuals harboring protein-altering variants, 11 of which are
      de novo, in MED13; the only inherited variant was transmitted to an
      affected child from an affected mother.
    explanation: >-
      Foundational paper establishing MED13 as a disease gene with predominantly
      de novo variants.
  - reference: PMID:29740699
    reference_title: "De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Six affected individuals had mutations that are predicted to truncate the
      MED13 protein, six had missense mutations, and one had an
      in-frame-deletion of one amino acid. Out of the seven non-truncating
      mutations, six clustered in two specific locations of the MED13 protein:
      an N-terminal and C-terminal region.
    explanation: >-
      Describes the variant spectrum including both truncating and clustered
      missense variants.
  - reference: PMID:41195223
    reference_title: "A novel frameshift variant in the MED13 gene causing intellectual developmental disorder-61 in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intellectual developmental disorder type 61 (MRD61) is an extremely rare
      autosomal dominant disorder caused by variants in the MED13 gene. This
      gene encodes a subunit of the mediator complex, which is also known as
      TRAP, SMCC, DRIP or ARC. This complex functions as a transcriptional
      coactivator and is essential for the expression of almost all genes. To
      date, only 26 cases of MRD61 have been reported worldwide.
    explanation: >-
      Confirms rarity (26 cases) and autosomal dominant inheritance.
  - reference: PMID:41561257
    reference_title: "Intellectual Developmental Disorder of Autosomal Dominant 61 Caused by a MED13 Variant Presenting With Congenital Unilateral Sensorineural Hearing Loss: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This case is also consistent with haploinsufficiency as the disease
      mechanism for truncating MED13 variants in MRD61, underscoring the
      importance of exome sequencing in patients with neurodevelopmental
      disorders and congenital anomalies.
    explanation: >-
      Confirms haploinsufficiency as the mechanism for truncating variants.
treatments:
- name: Speech and Language Therapy
  description: >
    Early speech and language therapy is recommended to address the prominent
    communication delays that are among the most consistent features of MED13
    syndrome.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
- name: Genetic Counseling
  description: >
    Genetic counseling is recommended for affected families. Most cases are
    de novo but parent-to-child transmission has been documented,
    necessitating parental testing and recurrence risk assessment.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
- name: Supportive Care
  description: >
    Multidisciplinary supportive care including occupational therapy,
    physical therapy, educational support, and behavioral interventions.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
- name: Antiseizure Pharmacotherapy
  description: >
    Antiseizure medication is used to manage seizures in the subset of MED13
    patients with epilepsy, including those presenting with developmental and
    epileptic encephalopathy or myoclonic-atonic seizures.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: anticonvulsant agent
      term:
        id: NCIT:C264
        label: Anticonvulsant Agent
datasets:
- accession: "geo:GSE298801"
  title: Cardiomyocyte-specific Deletion of Med13 and Med13L Results in Dysregulated Gene Expression and Lethal Heart Failure
  description: >-
    Bulk RNA-seq from adult murine cardiomyocytes after inducible knockout of Med13
    and Med13L. Double knockout results in lethal heart failure within 6 weeks,
    with significant gene dysregulation of fibrotic pathways and calcium handling.
    Demonstrates that Med13 and Med13L function redundantly in the adult heart to
    maintain basal cardiac function and transcription, relevant to the congenital
    heart defects observed in MED13 syndrome.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 8
  sample_types:
  - preferred_term: cardiomyocyte
    tissue_term:
      preferred_term: heart
      term:
        id: UBERON:0000948
        label: heart
  conditions:
  - Med13/Med13L cardiomyocyte-specific double knockout
  - wild-type control
  genes:
  - preferred_term: MED13
    term:
      id: hgnc:22474
      label: MED13
  - preferred_term: MED13L
    term:
      id: hgnc:22962
      label: MED13L
  publication: PMID:40989238
  findings:
  - statement: Med13 and Med13L are functionally redundant in adult cardiomyocytes
  - statement: Double knockout causes lethal heart failure with fibrotic and calcium handling gene dysregulation
  - statement: Similar gene dysregulation patterns across Mediator cardiac knockouts (Med13/13L, Med12, Med1, Med30)
  evidence:
  - reference: PMID:40989238
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Med13/13L knockout resulted in decreased cardiac function leading to lethal heart failure in a median timeframe of 6 weeks from the start of tamoxifen."
    explanation: Mouse model demonstrates functional redundancy of Med13 and Med13L in heart and lethal consequences of combined loss.

- accession: "clinicaltrials:NCT01238250"
  title: "Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight"
  description: >-
    Simons Searchlight is a large prospective observational registry enrolling
    individuals with rare genetic neurodevelopmental variants including MED13.
    Collects medical history, developmental milestones, behavioral assessments,
    and longitudinal follow-up data. As of 2024, includes approximately 15
    individuals with MED13 variants, providing natural-history data for MED13
    syndrome.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_types:
  - preferred_term: clinical phenotype data
  conditions:
  - MED13 pathogenic variants
  genes:
  - preferred_term: MED13
    term:
      id: hgnc:22474
      label: MED13
  findings:
  - statement: Longitudinal natural history data for MED13 syndrome available to qualified researchers
  notes: >-
    Data available to qualified researchers via SFARI Base (https://base.sfari.org).
    Over 7,000 total participants enrolled across all gene cohorts as of 2024.
📚

References & Deep Research

Deep Research

2
Falcon ▸
Executive Summary
Edison Scientific Literature 30 citations 2026-06-19T15:44:40.456845

Executive Summary

MED13 Syndrome, also termed intellectual developmental disorder-61 (MRD61) or MED13-associated neurodevelopmental disorder, is an extremely rare autosomal dominant condition caused by heterozygous pathogenic variants in the MED13 gene (OMIM #618009) (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). First comprehensively described by Blok and colleagues in 2018, this syndrome is characterized by universal developmental delay/intellectual disability, severe speech and language disorders, and variable features including autism spectrum disorder, attention deficit hyperactivity disorder, dysmorphic facial features, ophthalmologic abnormalities, and mild cardiac anomalies (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5). As of 2025, approximately 26-30 cases have been documented worldwide (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). The disorder results from disrupted function of MED13, a critical subunit of the CDK8-kinase module within the Mediator complex, which regulates RNA polymerase II-mediated transcription (blok2018denovomutations pages 1-2, harper2018thecomplexstructure pages 1-2).

1. Disease Information

Disease Definition and Overview

MED13 Syndrome is a novel neurodevelopmental disorder first systematically characterized in a 2018 GeneMatcher collaboration by Blok et al., who identified 13 affected individuals with protein-altering variants in the MED13 gene (blok2018denovomutations pages 1-2). The syndrome presents as "a neurodevelopmental disorder characterized by developmental delay and/or intellectual disability, including speech delays or disorders" along with a spectrum of additional features (blok2018denovomutations pages 1-2). As stated in the foundational publication, "All patients had intellectual disability and/or developmental delays, including speech delays or disorders" (blok2018denovomutations pages 1-2).

Key Identifiers

  • OMIM ID: #618009 (Intellectual Developmental Disorder-61, MRD61)
  • MONDO ID: MONDO:0032485 (as specified by user)
  • MED13 Gene: OMIM #603808; located at chromosome 17q23.2 (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
  • ICD-11: Not yet specifically coded; would fall under neurodevelopmental disorders
  • Category: Mendelian disorder, autosomal dominant

Alternative Names and Synonyms

  • Intellectual Developmental Disorder-61 (MRD61)
  • MED13-associated syndrome
  • MED13-related neurodevelopmental disorder
  • MED13-associated intellectual disability

Data Source

Information is derived from aggregated disease-level resources including peer-reviewed case series, systematic genetic studies, and functional characterizations, not from individual patient electronic health records. Primary sources include the foundational 2018 Blok et al. cohort study (blok2018denovomutations pages 1-2), subsequent case reports from 2021-2025 (tolmacheva2024expandingphenotypeof pages 1-2, rivera2024med13genemutation pages 1-2, yang2025anovelframeshift pages 1-2, nardi2021couldthemed13 pages 1-2, yang2025anovelframeshift pages 2-3), and comprehensive reviews of Mediator complex disorders (fazio2025geneticclinicaland pages 1-2, fazio2025geneticclinicaland pages 2-4).

2. Etiology

Disease Causal Factors

Genetic Etiology (Primary Cause):
MED13 Syndrome is caused by heterozygous pathogenic variants in the MED13 gene (NM_005121.3), which encodes the Mediator complex subunit 13 (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3). The MED13 gene consists of 30 exons and encodes a 2,174 amino acid protein (239.3 kDa) that serves as a component of the CDK8-kinase module of the Mediator complex (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3).

The disorder follows an autosomal dominant inheritance pattern with the vast majority of cases arising from de novo variants. In the original cohort of 13 patients, 11 variants were confirmed de novo, and only one was inherited from an affected mother to an affected child, demonstrating vertical transmission with variable expressivity (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5).

Mechanistic Basis:
MED13 is an essential component of the Mediator complex, a large multiprotein assembly (approximately 1.4 MDa in humans) that serves as a critical interface between gene-specific transcription factors and RNA polymerase II (harper2018thecomplexstructure pages 1-2, poss2013themediatorcomplex pages 2-3). As described by Harper and Taatjes (2018), "the Mediator complex is required for expression of most, if not all, pol II transcripts" (harper2018thecomplexstructure pages 1-2). MED13 specifically resides within the CDK8-kinase module, which consists of four proteins: MED13, MED12, CDK8, and cyclin C (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3).

Risk Factors

Genetic Risk Factors:

Causal Variants: The disease is caused by heterozygous loss-of-function or specific gain-of-dysfunction variants in MED13. Variant types include: - Nonsense mutations leading to premature termination (e.g., p.Leu131, p.Arg1400) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Frameshift variants causing truncation (e.g., p.Pro42Leufs6, p.Arg1882Serfs9) (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3) - Missense variants clustering in specific functional domains (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) - In-frame deletions affecting critical residues (e.g., p.Thr326del) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7)

Variant Classification: All pathogenic MED13 variants identified in affected individuals are absent from population databases (gnomAD, TOPMED) and are predicted to be highly deleterious by multiple in silico tools, with CADD scores ranging from 20.5 to 41.0 (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

Modifier Genes: The paralog MED13L may provide partial functional compensation. Studies in knockout mouse embryos demonstrated that "MED13L partially compensates for loss of MED13 function in preimplantation knockout embryos" (miao2018mediatorcomplexcomponent pages 1-2), suggesting genetic background effects involving MED13L expression levels could modify disease severity.

Environmental Risk Factors:
No specific environmental risk factors have been identified for MED13 Syndrome, consistent with its genetic etiology as a de novo dominant Mendelian disorder.

Protective Factors

No genetic or environmental protective factors have been specifically identified for MED13 Syndrome.

Gene-Environment Interactions

Given the Mendelian nature of the disorder with predominantly de novo occurrence, traditional gene-environment interactions have not been characterized. However, epigenetic regulation of MED13 expression during development may influence phenotypic severity.

3. Phenotypes

MED13 Syndrome presents with a consistent core phenotype of neurodevelopmental impairment combined with variable additional features. Below is a comprehensive description of reported phenotypes.

Phenotype / feature Frequency among reported patients Severity / variability Typical age of onset Suggested HPO term(s) Key citations
Developmental delay / global developmental delay 13/13 (100%) in initial cohort; also core feature in later reports Mild to severe; variable course Infancy / early childhood HP:0001263 Global developmental delay; HP:0011344 Severe global developmental delay (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11, tolmacheva2024expandingphenotypeof pages 1-2, yang2025anovelframeshift pages 1-2)
Intellectual disability Present in essentially all reported individuals, though severity ranges from borderline to moderate/severe; some described as DD/ID rather than formal ID Borderline/mild to moderate; severe developmental impairment in rare neonatal cases Usually recognized in childhood HP:0001249 Intellectual disability; HP:0001256 Mild intellectual disability; HP:0002342 Moderate intellectual disability (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11, nardi2021couldthemed13 pages 1-2)
Speech delay / language disorder 13/13 (100%) in initial cohort Often severe; expressive language commonly more impaired than receptive language Infancy / toddler years HP:0000750 Delayed speech and language development; HP:0002463 Language impairment (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11, nardi2021couldthemed13 pages 1-2)
Childhood apraxia of speech / severe speech production disorder 3/13 (~23%) in initial cohort explicitly described with speech apraxia Can be profound, including nonverbal status or limited verbal output Early childhood HP:0012469 Childhood apraxia of speech; HP:0001344 Expressive language delay (blok2018denovomutations pages 2-4, blok2018denovomutations pages 4-5)
Motor developmental delay 7/13 (~54%) in initial cohort; recurrent in later case reports Mostly gross motor delay; variable Infancy HP:0001270 Motor delay; HP:0002194 Delayed gross motor development; HP:0010862 Delayed fine motor development (blok2018denovomutations pages 2-4, blok2018denovomutations pages 6-7, nardi2021couldthemed13 pages 1-2, yang2025anovelframeshift pages 2-3)
Hypotonia 3/13 (~23%) in initial cohort; described as common infantile feature in later summaries Usually mild to moderate; often infantile Infancy HP:0001252 Muscular hypotonia (blok2018denovomutations pages 6-7, nardi2021couldthemed13 pages 1-2, yang2025anovelframeshift pages 1-2)
Autism spectrum disorder 5/13 (~38%) in initial cohort; recurrent across later reports and reviews Variable behavioral severity Childhood HP:0000729 Autism (blok2018denovomutations pages 2-4, blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2, fazio2025geneticclinicaland pages 1-2)
Attention-deficit / hyperactivity disorder 3/13 (~23%) in initial cohort Variable Childhood / school age HP:0007018 Attention deficit hyperactivity disorder (blok2018denovomutations pages 2-4, blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2)
Dysmorphic facial features Common; described as overlapping facial gestalt in multiple patients Usually mild to moderate; variable expressivity Congenital / infancy HP:0001999 Facial dysmorphism; HP:0000316 Hypertelorism; HP:0000450 Broad nasal bridge; HP:0010800 Long philtrum / HP:0000343 Long philtrum as applicable (blok2018denovomutations pages 5-6, nardi2021couldthemed13 pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, yang2025anovelframeshift pages 2-3)
Eye / vision abnormalities (overall) 8/13 (~62%) in initial cohort Mild to severe; includes structural and functional abnormalities Congenital or childhood HP:0000505 Visual impairment; HP:0000618 Blindness / low vision umbrella if severe; HP:0000529 Progressive visual loss where relevant (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11, tolmacheva2024expandingphenotypeof pages 1-2)
Optic nerve abnormalities 3/13 in initial cohort; severe optic nerve/chiasm atrophy in neonatal case Variable, can be severe Congenital / childhood HP:0001138 Optic atrophy; HP:0001098 Abnormality of the optic nerve (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
Duane anomaly / strabismus spectrum Duane anomaly 2/13 (~15%); strabismus also reported Variable Congenital / early childhood HP:0009928 Duane anomaly; HP:0000486 Strabismus (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
Astigmatism / nystagmus / retinal findings Each uncommon but recurrent across cases Variable Childhood / congenital HP:0000483 Astigmatism; HP:0000639 Nystagmus; HP:0000556 Retinal dystrophy (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 2-5)
Congenital heart defects / mild cardiac anomalies 2/13 (~15%) in initial cohort; more severe congenital heart disease in 2024 neonatal case Usually mild in early cohort; rare severe neonatal presentation Congenital HP:0001627 Abnormality of the cardiovascular system; HP:0001631 Aortic root dilatation; HP:0001671 Atrial septal defect; HP:0001629 Ventricular septal defect; HP:0001680 Coarctation of aorta / isthmus hypoplasia as applicable (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
Epilepsy / seizures Rare in initial cohort (1/13, ~8%); later reports expanded spectrum to epileptic encephalopathy Can be severe and drug-resistant when present Childhood or infancy depending on case HP:0001250 Seizure; HP:0002123 Generalized myoclonic seizure; HP:0012468 Epileptic encephalopathy (blok2018denovomutations pages 6-7, rivera2024med13genemutation pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
Brain MRI abnormalities Uncommon in original cohort but increasingly recognized in later reports Variable; from mild frontal atrophy to severe callosal/brainstem/chiasmal abnormalities Infant / childhood HP:0001273 Abnormality of the corpus callosum; HP:0002060 Abnormality of the cerebral white matter; HP:0002283 Ventriculomegaly; HP:0007364 Hydrocephalus (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, fazio2025geneticclinicaland pages 1-2)
Corpus callosum abnormalities Reported in severe recent cases/reviews Moderate to severe Congenital / infancy HP:0001273 Abnormality of the corpus callosum; HP:0002079 Hypoplasia of the corpus callosum (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, fazio2025geneticclinicaland pages 1-2)
Microcephaly / growth restriction / short stature Reported in subset; severe neonatal case had growth restriction; later family report notes restricted growth Variable Prenatal or postnatal HP:0000252 Microcephaly; HP:0001511 Intrauterine growth restriction; HP:0004322 Short stature (tolmacheva2024expandingphenotypeof pages 1-2, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
Chronic constipation / obstipation / megacolon Obstipation in 4/13 (~31%) in initial cohort; congenital megacolon reported as novel complication in family report Usually chronic; occasionally severe Infancy / childhood HP:0002019 Constipation; HP:0002240 Chronic constipation; HP:0012707 Megacolon (blok2018denovomutations pages 6-7, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
Hearing loss 2/13 (~15%) conductive hearing loss in initial cohort; hearing/vision problems noted in later reports Mild to moderate Childhood HP:0000405 Conductive hearing impairment; HP:0000365 Hearing impairment (blok2018denovomutations pages 5-6, tolmacheva2024expandingphenotypeof pages 1-2)
Orthopedic / skeletal anomalies Recurrent but variable; scoliosis, pes cavus, brachydactyly, hip dysplasia, valgus-pronated feet reported Mild to moderate Childhood / congenital HP:0002650 Scoliosis; HP:0001761 Pes cavus; HP:0001156 Brachydactyly; HP:0001385 Hip dysplasia (blok2018denovomutations pages 5-6, nardi2021couldthemed13 pages 1-2)
Severe multisystem neonatal presentation Very rare; single recent neonate with hydrocephalic changes, optic/chiasm atrophy, bowel atresia, cardiac disease, multiple organ failure, neonatal death Severe / potentially lethal Prenatal to neonatal HP:0001627 Abnormality of the cardiovascular system; HP:0001138 Optic atrophy; HP:0002079 Hypoplasia of the corpus callosum; HP:0002586 Ileal atresia; HP:0003819 Neonatal death (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)

Table: This table summarizes the core and variable clinical features reported for MED13 syndrome, including approximate frequencies, severity patterns, onset, suggested HPO mappings, and supporting citations. It is useful for disease knowledge base curation and phenotype annotation.

Core Phenotypes

Developmental Delay and Intellectual Disability (100% penetrance)

Phenotype Type: Neurodevelopmental impairment; clinical sign and behavioral manifestation

Characteristics: - Severity: Ranges from borderline/mild to moderate intellectual disability (ID); some patients assessed by formal testing showed IQ scores from 35-50 (moderate ID) to 85 (lower range of normal), though most fall in the mild ID range (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Age of Onset: Apparent in infancy; global developmental delay typically recognized within the first year of life - Progression: Generally stable once developmental trajectory is established, though speech may show some improvement with intensive therapy - Frequency: Universal (100%) among all reported cases (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11)

Quality of Life Impact: Significant impact on educational attainment, independence, and adaptive functioning. Most individuals require ongoing educational support and may need assistance with activities of daily living in adulthood.

HPO Terms: HP:0001263 (Global developmental delay); HP:0001249 (Intellectual disability); HP:0001256 (Mild intellectual disability); HP:0002342 (Moderate intellectual disability)

Speech and Language Disorders (100% penetrance)

Phenotype Type: Neurodevelopmental symptom affecting communication

Characteristics: - Severity: Variable from delayed language development to severe speech/language disorder; notably, "speech production was significantly more impaired than language comprehension" in the majority of patients (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Age of Onset: Delays apparent from toddler years onward - Specific Subtypes: Three patients (approximately 23%) presented with childhood apraxia of speech, characterized by "difficulties accurately programming the motor sequences required to produce fluent speech" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5). Patient M had "severe speech/language disorder" with "expressive speech severely affected, with signs of speech apraxia. At the age of 8 years she only used single words and very short sentences" (blok2018denovomutations pages 4-5). Patient K showed "regression at the age of 13 months and has since remained non-verbal" (blok2018denovomutations pages 4-5). - Progression: Speech delays persist, though some improvement with therapy - Frequency: Universal (100%) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5)

Quality of Life Impact: Severe speech impairments profoundly affect social interaction, educational achievement, and frustration levels in affected children.

HPO Terms: HP:0000750 (Delayed speech and language development); HP:0002463 (Language impairment); HP:0012469 (Childhood apraxia of speech); HP:0001344 (Abnormal expressive language)

Common Variable Phenotypes

Autism Spectrum Disorder (38-55%)

Phenotype Type: Behavioral/neurodevelopmental disorder

Characteristics: - Severity: Variable from mild autistic features to formal ASD diagnosis - Age of Onset: Typically recognized in early childhood - Frequency: Five of 13 patients (38%) in the initial cohort; later reviews suggest up to 55% (blok2018denovomutations pages 1-2, rivera2024med13genemutation pages 1-2, nardi2021couldthemed13 pages 1-2)

HPO Terms: HP:0000729 (Autism)

Attention Deficit Hyperactivity Disorder (23%)

Phenotype Type: Behavioral disorder

Frequency: Three of 13 patients (23%) in initial cohort (blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2)

HPO Terms: HP:0007018 (Attention deficit hyperactivity disorder)

Eye and Vision Abnormalities (62%)

Phenotype Type: Structural and functional ophthalmic abnormalities

Characteristics: - Specific Features: Optic nerve abnormalities (pale optic nerves, optic atrophy), Duane anomaly (congenital strabismus with horizontal ophthalmoplegia), astigmatism, nystagmus, retinal abnormalities (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) - Severity: Variable from mild refractive errors to severe optic atrophy with visual impairment - Notable Pattern: Two patients with missense mutations clustering in the C-terminal domain (p.Gln2060Lys and p.Ala2064Val) both presented with Duane anomaly, suggesting potential genotype-phenotype correlation (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) - Age of Onset: Typically congenital or recognized in early childhood - Frequency: Eight of 13 patients (62%) had eye or vision abnormalities (blok2018denovomutations pages 6-7)

HPO Terms: HP:0001098 (Abnormality of the optic nerve); HP:0001138 (Optic atrophy); HP:0009928 (Duane anomaly); HP:0000486 (Strabismus); HP:0000483 (Astigmatism); HP:0000639 (Nystagmus)

Dysmorphic Facial Features

Phenotype Type: Physical manifestation; craniofacial anomaly

Characteristics: - Specific Features: As described by Blok et al., "Overlapping facial characteristics were reported, including widely spaced eyes with narrow palpebral fissures and peri-orbital fullness, a broad and high nasal bridge, full nasal tip, synophrys, a flat philtrum and a wide mouth with thin upper lip" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7) - Severity: Generally mild; may contribute to clinical suspicion but not pathognomonic - Age of Onset: Congenital - Frequency: Common but variable; noted across multiple independent reports (blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, yang2025anovelframeshift pages 2-3)

Note: One patient initially received a clinical diagnosis of Kabuki syndrome based on facial features before MED13 variant was identified, highlighting phenotypic overlap with other syndromes (nardi2021couldthemed13 pages 1-2).

HPO Terms: HP:0001999 (Abnormality of the face); HP:0000316 (Hypertelorism); HP:0000450 (Broad nasal bridge); HP:0000343 (Long philtrum); HP:0000154 (Wide mouth)

Congenital Heart Defects (15-30%)

Phenotype Type: Structural cardiac anomaly

Characteristics: - Specific Features: Mild defects include dilated aortic root and pulmonary artery, subaortic stenosis (blok2018denovomutations pages 6-7). Severe neonatal case presented with "isthmus hypoplasia, ventricular septal defect, small atrial septal defect, right heart hypertrophy, tricuspid insufficiency, and pulmonary hypertension" (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5) - Severity: Usually mild in typical cases; severe in rare neonatal presentations - Age of Onset: Congenital - Frequency: Two of 13 patients (15%) in initial cohort; higher in expanded case series including severe presentations (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7)

HPO Terms: HP:0001627 (Abnormal heart morphology); HP:0001680 (Coarctation of the aorta); HP:0001629 (Ventricular septal defect); HP:0001631 (Atrial septal defect)

Hypotonia and Motor Delays (23-54%)

Phenotype Type: Neuromuscular symptom; motor developmental delay

Characteristics: - Hypotonia: Reported in three of 13 patients (23%), typically as infantile hypotonia (blok2018denovomutations pages 6-7) - Motor Delays: Seven of 13 patients (54%) showed motor developmental delays, mostly affecting gross motor skills (blok2018denovomutations pages 2-4, blok2018denovomutations pages 6-7) - Age of Onset: Hypotonia apparent in infancy; motor delays recognized in first years - Progression: Hypotonia may improve with age; motor delays persist but some improvement with therapy

HPO Terms: HP:0001252 (Muscular hypotonia); HP:0001270 (Motor delay); HP:0002194 (Delayed gross motor development)

Less Common Phenotypes

Epilepsy and Seizures (8-15%)

Phenotype Type: Neurological disorder; laboratory/clinical abnormality (abnormal EEG)

Characteristics: - Specific Presentations: One patient in original cohort developed "severe drug-resistant myoclonic-atonic epilepsy at 4 years of age with generalized clonic, myoclonic, atonic, tonic and atypical absence seizures" (blok2018denovomutations pages 6-7). More recent reports include epileptic encephalopathy with infantile spasms (rivera2024med13genemutation pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5) - Severity: Can be severe and treatment-resistant when present - Age of Onset: Variable, from infancy to childhood - Frequency: Rare; one of 13 in original cohort; several additional cases in later reports

HPO Terms: HP:0001250 (Seizure); HP:0012469 (Epileptic encephalopathy); HP:0002123 (Generalized myoclonic seizures)

Brain MRI Abnormalities

Phenotype Type: Structural brain abnormality; imaging finding

Characteristics: - Specific Features: Mild frontal atrophy, corpus callosum abnormalities (hypoplasia, agenesis), ventriculomegaly, hydrocephalic changes, optic chiasm atrophy, brainstem atrophy (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, fazio2025geneticclinicaland pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5) - Severity: Variable from mild to severe - Age of Onset: Congenital/developmental - Frequency: Not systematically reported in early cohort; increasingly recognized in recent case reports

HPO Terms: HP:0001273 (Abnormality of the corpus callosum); HP:0002079 (Hypoplasia of the corpus callosum); HP:0002119 (Ventriculomegaly); HP:0007364 (Lissencephaly)

Chronic Constipation and GI Manifestations (31%)

Phenotype Type: Gastrointestinal symptom

Characteristics: - Specific Features: Chronic obstipation reported in four of 13 patients (31%) in original cohort (blok2018denovomutations pages 6-7). Novel complication of congenital megacolon described in Chinese family case (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3) - Severity: Variable; can be severe requiring surgical intervention (megacolon case)

HPO Terms: HP:0002019 (Constipation); HP:0012707 (Megacolon)

Severe Neonatal/Multisystem Presentation (Very Rare)

Phenotype Type: Severe multi-organ involvement

One infant with a de novo p.Pro835Ser variant "presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients" and "deceased at 76 days of age due to multiple organ failure" (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5). This case highlights the potential for severe presentations.

4. Genetic/Molecular Information

Variant / protein change cDNA change Variant type Source / case context Protein region / domain affected Clustering pattern Reported / inferred functional consequence Pathogenicity classification / evidence level CADD / in silico data Conservation / population data Key notes / citations
p.Pro42Leufs*6 c.125del Frameshift Blok 2018 patient A N-terminus, upstream of annotated Med13_N domain Non-clustered truncating variant Predicted premature termination; likely loss of normal function Likely pathogenic / pathogenic by case-series evidence CADD 31.0 Absent from gnomAD/TOPMed in cohort analysis Associated with mild ID and speech apraxia in original cohort (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11)
p.Leu131* c.392T>G Nonsense Blok 2018 patients B/C N-terminal region, upstream of Med13_N domain Recurrent truncating variant Predicted truncation; transcript detected on cDNA, but no truncated protein detected in analogous nonsense case, supporting abnormal protein consequence rather than simple transcript loss Pathogenic by segregation/case evidence CADD 37.0 Absent from gnomAD/TOPMed in cohort analysis One inherited instance from affected mother to affected child shows AD transmission with variable expressivity (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11)
p.Thr326Ile c.977C>T Missense Blok 2018 patient D Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot Predicted to impair FBW7 phosphodegron recognition and alter MED13 ubiquitination/degradation, potentially increasing abnormal MED13 stability Likely pathogenic by clustering/mechanistic evidence CADD 25.0 Site highly conserved; codon under strong selection; absent from gnomAD/TOPMed One of four variants affecting Thr326/Pro327 hotspot (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Thr326del c.975_977delTAC In-frame deletion Blok 2018 patient E Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot Predicted disruption of phosphodegron and impaired SCF-FBW7-mediated degradation Likely pathogenic by hotspot/mechanistic evidence CADD 20.5 Highly conserved motif; absent from gnomAD/TOPMed Only in-frame deletion in original cohort; still localized to same hotspot as missense variants (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro327Ser c.979C>T Missense Blok 2018 patient F; Nardi 2021; recurrent in later reports Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot, recurrent Predicted to reduce phosphodegron-dependent FBW7 binding and MED13 turnover Likely pathogenic; recurrent across unrelated patients CADD 23.4 Highly conserved residue; absent from gnomAD/TOPMed Recurrent variant with variable expressivity, from neurodevelopmental phenotype to Kabuki-like presentation (nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro327Gln c.980C>A Missense Blok 2018 patient G Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot Same predicted mechanism as other phosphodegron variants: altered phosphorylation/FBW7 interaction and defective degradation Likely pathogenic by hotspot/mechanistic evidence CADD 25.2 Highly conserved; absent from gnomAD/TOPMed Supports hotspot-specific mechanism at adjacent residues Thr326/Pro327 (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro540Thr c.1618C>A Missense Blok 2018 patient H Internal conserved linear motif outside named Pfam domains Non-hotspot missense Predicted formation of novel Casein Kinase 1 phosphorylation motif and altered protein interactions VUS-to-likely pathogenic range by case/mechanistic evidence CADD 26.3 Highly conserved motif; codon under strong selection; absent from gnomAD/TOPMed Distinct mechanism proposed versus phosphodegron variants (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Leu582* c.1745T>A Nonsense Blok 2018 patient I Internal region between N- and C-terminal domains Non-clustered truncating variant Predicted loss of downstream functional regions and loss of normal function Pathogenic by case evidence CADD 40.0 Absent from gnomAD/TOPMed Truncating variants distributed outside missense hotspots (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7)
p.Arg1400* c.4198C>T Nonsense Blok 2018 patient J Mid-protein region, upstream of Med13_C domain Non-clustered truncating variant cDNA present, but no truncated protein detected on western blot; supports abnormal protein consequence / defective stable product Pathogenic by functional follow-up CADD 41.0 Absent from gnomAD/TOPMed Functional transcript/protein analyses were performed for this allele (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Thr1496Metfs*11 c.4487delC Frameshift Blok 2018 patient K Mid/C-terminal transition, upstream of Med13_C domain Non-clustered truncating variant Predicted premature truncation with loss of C-terminal region Pathogenic by case evidence CADD 35.0 Absent from gnomAD/TOPMed Associated with severe speech disorder/regression in cohort (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7)
p.Gln2060Lys c.6178C>A Missense Blok 2018 patient L C-terminal Med13_C domain C-terminal hotspot Predicted disturbance of conserved surface-exposed motif / interaction interface Likely pathogenic by clustering and conservation CADD 24.1 Highly conserved; absent from gnomAD/TOPMed One of two adjacent C-terminal hotspot variants in patients with eye findings including Duane anomaly (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Ala2064Val c.6191C>T Missense Blok 2018 patient M C-terminal Med13_C domain C-terminal hotspot Predicted structural alteration with increased hydrophobic collapse and reduced linear interaction potential on conserved surface motif Likely pathogenic by structural modeling CADD 25.7 Highly conserved; absent from gnomAD/TOPMed Supports second missense hotspot in C-terminal region (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro835Ser reported as de novo missense variant in 2024 case report Missense Tolmacheva 2024 severe neonatal case Mid-protein region, outside named hotspot in available summary Non-hotspot missense Not mapped to a known functional center in UniProt summary, but predicted damaging; may underlie severe multisystem/neonatal phenotype Likely pathogenic per ACMG in report CADD 26.1; PolyPhen-2 0.996; SIFT 0.0 Position conserved across vertebrates per UCSC alignment; de novo; absent/rare in population databases implied by diagnostic filtering Expanded phenotype to severe neonatal presentation and death (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
p.Arg1882Serfs*9 c.5641delinsTC Frameshift Yang 2025 Chinese family Distal C-terminal half, upstream of Med13_C tail end Non-clustered truncating variant Predicted truncation with autosomal dominant disease mechanism Pathogenic/likely pathogenic by familial segregation and ACMG-based interpretation Not numerically reported in excerpt Rare after filtering at MAF ≤0.001; segregated with affected mother and proband First reported Chinese family; supports inherited AD disease and expands variant spectrum (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
Overall MED13 variant spectrum Multiple Missense, nonsense, frameshift, in-frame deletion Blok 2018 + recent reports Two annotated Pfam domains: Med13_N (aa 11-383) and Med13_C (aa 1640-2163), plus conserved internal motifs Strong clustering of non-truncating variants in two regions: N-terminal phosphodegron hotspot (Thr326/Pro327) and C-terminal hotspot around Gln2060/Ala2064 Truncating variants support loss-of-function/haploinsufficiency-like mechanism; hotspot missense variants suggest altered degradation or altered protein interaction surfaces Disease-gene relationship supported by significant enrichment of de novo variants in DD/ID cohorts (p=0.00371) CADD range for reported 2018 variants: 20.5-41.0 All 12 unique Blok 2018 variants absent from gnomAD and TOPMed; missense hotspot residues highly conserved and under codon selection Best current model is mixed mechanism: truncating alleles causing loss of normal function and clustered missense alleles perturbing regulated MED13 turnover or conserved interaction motifs (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11, yang2025anovelframeshift pages 2-3)

Table: This table summarizes the reported genetic and molecular features of MED13 syndrome, including representative variants, domains, clustering, functional interpretations, and available in silico evidence. It is useful for disease knowledge base curation and for distinguishing truncating versus hotspot missense mechanisms.

Causal Gene

MED13 (Mediator Complex Subunit 13)

  • Gene Symbol: MED13
  • OMIM Gene ID: #603808
  • Chromosomal Location: 17q23.2 (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
  • Transcript: NM_005121.3 (reference transcript used in clinical reporting)
  • Protein: NP_005112.2; 2,174 amino acids; predicted molecular weight 239.3 kDa (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3)
  • HGNC ID: HGNC:2372

Pathogenic Variants

Variant Types and Classification:

The MED13 gene harbors multiple types of pathogenic variants. As summarized by Blok et al. (2018), the cohort included "six affected individuals had mutations that are predicted to truncate the MED13 protein, six had missense mutations, and one had an in-frame-deletion of one amino acid" (blok2018denovomutations pages 1-2).

Truncating Variants (Loss-of-Function): - Nonsense mutations: p.Leu131, p.Leu582, p.Arg1400 (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Frameshift variants: p.Pro42Leufs6, p.Thr1496Metfs11, p.Arg1882Serfs9 (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3) - Mechanism: Truncating variants likely lead to haploinsufficiency. Functional studies on the p.Arg1400* variant demonstrated that "while full-length MED13 protein was present in the patient (and in the controls), no truncated MED13 protein product could be detected" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11), supporting nonsense-mediated decay or rapid degradation of truncated protein. However, "no differences in MED13 transcript levels were detectable between the affected patient and the unaffected parents or controls" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11), suggesting the remaining transcript from the normal allele may partially compensate at the mRNA level, but haploinsufficiency exists at the protein level.

Missense Variants with Clustering:

A striking feature is the clustering of non-truncating variants in two specific protein regions (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11):

  1. N-terminal Phosphodegron Hotspot (Thr326/Pro327):
  2. Variants: p.Thr326Ile, p.Thr326del, p.Pro327Ser, p.Pro327Gln (blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 6-7)

  3. Functional Consequence: These residues are part of a conserved phosphodegron recognized by the SCF-Fbw7 ubiquitin ligase for MED13 degradation. As Blok et al. explain, "it has already been shown that a specific amino acid substitution at position 326 in MED13 (p.Thr326Ala) leads to impaired binding of Fbw7 to the phosphodegron of MED13/MED13L, thus preventing MED13/MED13L ubiquitination and degradation" (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11). Molecular modeling showed that "all four variants (p.Thr326Ile, p.Thr326del, p.Pro327Ser, p.Pro327Gln) are predicted to alter the phosphorylation and Fbw7 interaction with drastic decreases in binding energy to Fbw7" (blok2018denovomutations pages 7-11). This suggests a dominant-negative or gain-of-dysfunction mechanism wherein the variant protein is stabilized and accumulates, potentially disrupting normal Mediator complex dynamics.

  4. C-terminal Hotspot (Gln2060/Ala2064):

  5. Variants: p.Gln2060Lys, p.Ala2064Val (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7)
  6. Functional Consequence: These C-terminal variants affect conserved surface-exposed motifs. The p.Ala2064Val change is "predicted to be structure-altering through increasing hydrophobic collapse, secondary structure formation, and increasing aliphatic index of a surface exposed linear motif. This results in a decrease of the regions linear interacting peptide potential" (blok2018denovomutations pages 7-11), suggesting altered protein-protein interactions within the Mediator complex or with transcription factors.

Variant Classification (ACMG/AMP): All reported pathogenic variants are classified as pathogenic or likely pathogenic based on: - Absence from population databases (gnomAD, TOPMED) - High conservation of affected residues - High CADD scores (20.5-41.0) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7) - Segregation with disease phenotype - Functional data (for select variants) - Significant enrichment of de novo MED13 variants in DD/ID cohorts (p=0.00371) (blok2018denovomutations pages 7-11)

Allele Frequency: All pathogenic variants identified to date are absent or extremely rare in population databases (gnomAD allele frequency effectively 0 for disease-causing variants) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11), consistent with the severe reproductive fitness impact and predominantly de novo occurrence.

Somatic vs. Germline: All reported variants are germline. One case of suspected paternal germline mosaicism has been reported for a MED13L variant, and a similar mechanism could theoretically occur for MED13, though not yet documented (fazio2025geneticclinicaland pages 1-2).

Functional Consequences: - Loss-of-function variants: Haploinsufficiency mechanism, reducing functional MED13 protein levels - Phosphodegron missense variants: Impaired protein degradation leading to accumulation of dysfunctional MED13, potentially causing dominant-negative effects on Mediator complex function - Other missense variants: Altered protein interactions or structural changes affecting MED13 function within the Mediator complex

Modifier Genes

MED13L:
The paralog MED13L (chromosome 12q24.21) can partially compensate for MED13 loss. Studies show MED13 and MED13L are mutually exclusive within the CDK8-kinase module (miao2018mediatorcomplexcomponent pages 1-2, fazio2025geneticclinicaland pages 2-4). Mouse studies demonstrated that "MED13L partially compensates for loss of MED13 function in preimplantation knockout embryos, but postimplantation development is not rescued by MED13L" (miao2018mediatorcomplexcomponent pages 1-2), suggesting tissue- and stage-specific compensation.

Epigenetic Information

While specific epigenetic changes in MED13 Syndrome patients have not been extensively characterized, the Mediator complex itself regulates epigenetic modifications. The MED13-containing kinase module can phosphorylate chromatin regulators and is involved in coordinating transcriptional responses to epigenetic signals (poss2013themediatorcomplex pages 2-3).

Chromosomal Abnormalities

No large-scale chromosomal abnormalities (aneuploidy, translocations, inversions) involving MED13 have been reported as causes of the syndrome. The disorder results from intragenic sequence variants.

5. Environmental Information

Environmental Factors

No specific environmental factors (toxins, radiation, pollution, occupational exposures) have been identified as contributing to MED13 Syndrome, consistent with its genetic etiology as a predominantly de novo Mendelian disorder.

Lifestyle Factors

Not applicable to disease causation.

Infectious Agents

Not applicable.

6. Mechanism / Pathophysiology

Overview of Molecular Mechanisms

MED13 Syndrome pathophysiology centers on disrupted transcriptional regulation during neurodevelopment due to impaired Mediator complex function.

Molecular Pathways

Mediator Complex and RNA Polymerase II Transcription:

The Mediator complex is "a multi-protein complex that is required for Polymerase II transcription initiation" and "required for expression of most, if not all, pol II transcripts" (blok2018denovomutations pages 1-2, harper2018thecomplexstructure pages 1-2). The human Mediator contains 26 subunits organized into head, middle, and tail modules, with the reversibly associating CDK8-kinase module (consisting of MED13, MED12, CDK8, and cyclin C) (harper2018thecomplexstructure pages 1-2, poss2013themediatorcomplex pages 2-3).

As described by Poss et al. (2013), "the CDK8-module can reversibly bind Mediator...Binding of the CDK8-module to the Mediator core complex has been reported to prevent the association of the Mediator with the Pol II preinitiation complex, thus preventing transcription initiation and/or re-initiation" (poss2013themediatorcomplex pages 2-3). MED13 specifically "serves as the molecular bridge between the core Mediator complex and the kinase submodule" (blok2018denovomutations pages 7-11).

MED13-Dependent Transcriptional Regulation:

MED13 regulates transcription through multiple mechanisms: 1. Kinase Module Association: MED13 facilitates reversible binding of the CDK8-module to core Mediator, modulating transcriptional activation versus repression (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3) 2. Protein Turnover Regulation: The N-terminal phosphodegron of MED13 regulates its degradation via SCF-Fbw7, controlling CDK8-module availability. "Protein turnover of MED13 (or MED13L) may be critical in modulating the pools of Mediator-CDK8 kinase complex in cells" (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) 3. Transcription Factor Phosphorylation: The CDK8 kinase can phosphorylate transcription factors and chromatin regulators, with MED13 helping to coordinate these activities (poss2013themediatorcomplex pages 2-3)

Cellular Processes

Neuronal Development and Migration:

Mouse studies using in utero electroporation demonstrate that "silencing Med13 in cortical neurons impaired its radial migration and contralateral projection as well as dendritic complexity" (li2026med13isinvolved pages 1-2). The authors found that "Med13 regulates cortical neuronal radial migration and callosal projection at least in part through PlxnA4," a downstream target involved in axon guidance (li2026med13isinvolved pages 1-2).

Zygotic Genome Activation:

MED13 plays a critical role in early embryonic transcriptional activation. Miao et al. (2018) demonstrated that "MED13 is essential for ZGA [zygotic genome activation] in the mouse, in part by regulating expression of the embryo-specific chromatin remodeling complex, esBAF" (miao2018mediatorcomplexcomponent pages 1-2). Knockout of Med13 in mouse embryos resulted in embryonic lethality as early as E8.5 (li2026med13isinvolved pages 1-2, miao2018mediatorcomplexcomponent pages 1-2).

Cortical Neurogenesis:

Recent work by Li et al. (2025) on MED13L (the paralog) provides insights relevant to MED13 function. They found that MED13L "orchestrates cortical neurogenesis by priming the transcriptional activation of key developmental genes, including Neurod2, Sox5, Auts2, and Nfib" through binding to the core mediator complex and facilitating "the complex's association with RNA Pol II" (blok2018denovomutations pages 1-2). Given the structural and functional similarities between MED13 and MED13L, analogous mechanisms likely apply to MED13 in neuronal differentiation.

Protein Dysfunction

Haploinsufficiency (Truncating Variants):

Truncating MED13 variants result in reduced functional protein. Western blot analysis of a nonsense variant showed that while transcript was present, "no truncated MED13 protein product could be detected" (blok2018denovomutations pages 7-11), indicating protein instability or degradation.

Altered Protein Stability and Turnover (Phosphodegron Variants):

Missense variants affecting Thr326/Pro327 prevent normal SCF-Fbw7-mediated ubiquitination and degradation, potentially leading to abnormal accumulation of MED13 protein. This could disrupt the normal dynamic regulation of Mediator-CDK8 module association (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

Altered Protein-Protein Interactions (C-terminal Variants):

C-terminal missense variants are predicted to alter surface-exposed interaction motifs, potentially disrupting MED13's interactions with other Mediator subunits or transcription factors (blok2018denovomutations pages 7-11).

Metabolic Changes

While not a primary metabolic disorder, MED13 does regulate metabolic gene expression. Studies in cardiac-specific MED13 overexpressing mice showed that "cardiac expression of MED13 decreases metabolic gene expression in the heart but enhances them in WAT [white adipose tissue]" and affects systemic energy homeostasis (baskin2014med13‐dependentsignalingfrom pages 1-2). Whether metabolic dysregulation contributes to MED13 Syndrome phenotypes remains unclear.

Immune System Involvement

No primary immune dysfunction has been reported. One patient had isolated IgA deficiency (nardi2021couldthemed13 pages 1-2), but this is not a consistent feature.

Tissue Damage Mechanisms

Neurodevelopmental Disruption:

The primary tissue damage mechanism is impaired neurodevelopment rather than progressive neurodegeneration. Brain MRI findings in severe cases show structural malformations (corpus callosum hypoplasia, optic nerve/chiasm atrophy, ventriculomegaly) (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5), indicating developmental abnormalities rather than acquired injury.

Biochemical Abnormalities

Transcriptional Dysregulation:

The core biochemical abnormality is widespread transcriptional dysregulation due to impaired Mediator function. Differential protein analysis of MED13-deficient human neuroblastoma cells "revealed a large number of dysregulated proteins" involved in neurodevelopmental pathways (li2026med13isinvolved pages 1-2).

Molecular Profiling (Where Available)

Transcriptomics:
Single-cell transcriptomics and immunofluorescence of Med13l knockout mouse embryos "reveal severe cortical neurogenesis deficits...driven by impaired neural progenitor differentiation" (blok2018denovomutations pages 1-2). Integrative multi-omics analyses revealed dysregulation of developmental genes including Neurod2, Sox5, Auts2, and Nfib (blok2018denovomutations pages 1-2).

Proteomics:
Differential protein analysis of MED13-deleted SH-SY5Y cells identified dysregulated proteins including PLXNA4, convergent towards neurodevelopmental pathways (li2026med13isinvolved pages 1-2).

Advanced Technologies

Single-Cell Analysis:
Med13l studies used single-cell RNA-seq to identify cell-type-specific deficits in cortical neurogenesis (blok2018denovomutations pages 1-2).

Functional Genomics:
CRISPR-based knockdown and overexpression studies in mouse cortical neurons demonstrated Med13's roles in migration, dendritic development, and callosal projections (li2026med13isinvolved pages 1-2).

Suggested Ontology Terms

  • GO Biological Process:
  • GO:0006357 (regulation of transcription by RNA polymerase II)
  • GO:0045944 (positive regulation of transcription by RNA polymerase II)
  • GO:0021987 (cerebral cortex development)
  • GO:0021772 (olfactory bulb development)
  • GO:0022008 (neurogenesis)

  • GO:0051301 (cell division)

  • GO Cellular Component:

  • GO:0016592 (mediator complex)

  • GO:0005634 (nucleus)

  • Cell Types (Cell Ontology):

  • CL:0000540 (neuron)
  • CL:0000598 (pyramidal neuron)
  • CL:0000127 (astrocyte)
  • CL:0011005 (GABAergic neuron)
  • CL:0000125 (glial cell)

7. Anatomical Structures Affected

Organ Level

Primary Organs: - Central Nervous System (Brain): The brain is the primary organ affected, with widespread impact on cortical development, corpus callosum formation, and optic nerve structures (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, fazio2025geneticclinicaland pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)

Secondary Organs: - Heart: Mild to moderate congenital heart defects in 15-30% of cases (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7) - Eyes: Optic nerves, retina affected in majority of patients (62%) (blok2018denovomutations pages 6-7) - Gastrointestinal system: Chronic constipation, rare megacolon (blok2018denovomutations pages 6-7, yang2025anovelframeshift pages 2-3)

Body Systems: - Nervous system (primary) - Cardiovascular system (secondary) - Visual system (secondary) - Musculoskeletal system (hypotonia, minor skeletal anomalies)

Tissue and Cell Level

Specific Tissue Types: - Nervous tissue (cerebral cortex, corpus callosum, optic nerves, brainstem) - Cardiac muscle and connective tissue (in congenital heart defects) - Neural epithelium (retina, optic nerve)

Specific Cell Populations: - Cortical excitatory neurons (pyramidal neurons of layers II/III and V/VI) (blok2018denovomutations pages 1-2, li2026med13isinvolved pages 1-2) - Neural progenitor cells during neurogenesis (blok2018denovomutations pages 1-2, li2026med13isinvolved pages 1-2) - Retinal ganglion cells and optic nerve fibers

Subcellular Level

MED13 localizes to the nucleus as part of the Mediator complex (harper2018thecomplexstructure pages 1-2, poss2013themediatorcomplex pages 2-3).

GO Cellular Component Terms: - GO:0016592 (mediator complex) - GO:0005634 (nucleus) - GO:0000790 (nuclear chromatin)

Localization

Specific Anatomical Sites (UBERON Terms): - UBERON:0000955 (brain) - UBERON:0001869 (cerebral cortex) - UBERON:0002335 (corpus callosum) - UBERON:0000941 (cranial nerve II) - UBERON:0001873 (caudate nucleus) - UBERON:0002298 (brainstem) - UBERON:0002543 (retina) - UBERON:0000948 (heart)

Lateralization: Generally bilateral for brain and eye findings; heart defects are typically midline structures.

8. Temporal Development

Onset

Typical Age of Onset:
Congenital/prenatal for structural malformations (heart defects, dysmorphic features, brain malformations). Developmental delays apparent in infancy (first 6-12 months), with global developmental delay and motor delays recognized early. Speech delays become evident in toddler years (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5).

Onset Pattern:
- Acute: Not applicable - Chronic/Insidious: The neurodevelopmental delays emerge insidiously as milestones are missed - Congenital: Structural anomalies present from birth

Progression

Disease Stages:
No formal staging system exists. The disorder does not progress through distinct stages but rather represents a static or slowly improving developmental trajectory once established.

Progression Rate: - Developmental Trajectory: After initial recognition of delays, the developmental trajectory tends to be stable with slow progress. Speech and motor skills may improve somewhat with intensive therapy, but intellectual disability persists. - Non-Progressive: Unlike neurodegenerative disorders, MED13 Syndrome does not typically show progressive worsening. However, one patient showed "regression at the age of 13 months" in speech development (blok2018denovomutations pages 4-5), which is atypical.

Disease Course Pattern: - Stable: Generally stable neurodevelopmental disability once established - Chronic Lifelong: Lifelong condition requiring ongoing support

Disease Duration:
Lifelong condition.

Patterns

Remission:
Not applicable; this is not a relapsing-remitting condition.

Critical Periods:
Prenatal and early postnatal brain development represent critical vulnerable periods when MED13 function is essential for proper cortical neurogenesis, neuronal migration, and connectivity establishment (li2026med13isinvolved pages 1-2, miao2018mediatorcomplexcomponent pages 1-2).

9. Inheritance and Population

Epidemiology

Prevalence:
Extremely rare. As of 2025, only approximately 26-30 cases have been reported worldwide (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). True population prevalence unknown but estimated to be less than 1 per million.

Incidence:
Unknown; extremely rare. The rate of approximately 1 de novo MED13 variant per 2,200 DD/ID-affected individuals suggests it accounts for a very small fraction of neurodevelopmental disorders (blok2018denovomutations pages 7-11).

For Genetic Etiology

Inheritance Pattern:
Autosomal dominant. As Blok et al. state, "Eleven variants were confirmed to be de novo, and one patient (patient B) inherited the variant from her mother who is also affected" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5). More recent reports include additional familial cases with mother-to-child transmission (yang2025anovelframeshift pages 2-3).

Penetrance:
Appears to be complete for core neurodevelopmental features (DD/ID, speech delay) based on all reported cases showing these features. However, variable expressivity is evident, with the same variant (p.Pro327Ser) causing different phenotypic severity in unrelated individuals (nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 4-5).

Expressivity:
Highly variable. Even individuals with the same variant show phenotypic variability. For example, the recurrent p.Pro327Ser variant was associated with both a Kabuki-like presentation and a less dysmorphic presentation with cardiac features in different patients (nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 4-5).

Genetic Anticipation:
Not reported or applicable.

Germline Mosaicism:
While not specifically documented for MED13, germline mosaicism is theoretically possible and has been reported for the related MED13L gene (fazio2025geneticclinicaland pages 1-2). Recurrence risk counseling should consider this possibility.

Founder Effects:
No founder effects or population-specific mutations have been identified. The disorder appears to arise from independent de novo mutational events across diverse populations.

Consanguinity:
Not relevant; autosomal dominant disorder arising de novo.

Carrier Frequency:
Not applicable in traditional sense; nearly all cases are de novo. However, affected individuals are heterozygous carriers who can transmit the variant to offspring with 50% probability.

Population Demographics

Affected Populations:
No specific ethnic or demographic groups show higher prevalence. Cases have been reported from diverse populations including European, North American, Asian (Chinese family), and others (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3).

Geographic Distribution:
Worldwide distribution with no geographic clustering. Cases reported from United States, Europe (Netherlands, Germany, France, Italy, UK), China, and other regions (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3).

Sex Ratio:
No strong sex bias. The original cohort included both males and females; approximately balanced sex distribution across reported cases (blok2018denovomutations pages 1-2).

Age Distribution:
Given recent disease description (2018), most reported individuals are children and young adults. One neonatal death demonstrates the potential for severe early presentations (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5).

10. Diagnostics

Clinical Tests

Laboratory Tests: - Standard metabolic panels: Generally normal; not diagnostically informative - Chromosomal microarray: Typically normal unless large deletion encompassing MED13 - Specific biochemical markers: None identified

Biomarkers: No specific circulating biomarkers have been identified for MED13 Syndrome.

Imaging Studies: - Brain MRI: May show corpus callosum abnormalities (hypoplasia, agenesis), ventriculomegaly, cerebral/cerebellar atrophy, optic nerve/chiasm abnormalities, brainstem changes in severe cases (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, fazio2025geneticclinicaland pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5). However, many patients have normal or only mildly abnormal MRI findings. - Echocardiography: To assess for congenital heart defects - Ophthalmologic Examination: Fundoscopy, optical coherence tomography (OCT) for optic nerve assessment

Functional Tests: - Developmental assessments (Gesell Developmental Diagnostic Scale, Bayley Scales) - IQ testing (WISC, Stanford-Binet) - Speech/language evaluations - Vision and hearing assessments - Electroencephalography (EEG) if seizures suspected

Genetic Testing

Overview:
Whole exome sequencing (WES) or comprehensive neurodevelopmental gene panels are the primary diagnostic approaches. As Yang et al. (2025) describe, "Whole-exome sequencing of the proband revealed a novel heterozygous frameshift variant in the MED13 gene" (yang2025anovelframeshift pages 2-3).

Recommended Approach: - First-line: WES trio sequencing (proband + both parents) to identify de novo variants and confirm inheritance pattern - Alternative: Targeted gene panels for neurodevelopmental disorders that include MED13

Whole Exome Sequencing (WES):
WES is the most effective approach, allowing identification of rare variants across all coding regions. Trio sequencing (proband + parents) is strongly recommended to confirm de novo status, which provides strong evidence for pathogenicity (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3).

Gene Panels:
Neurodevelopmental disorder panels typically include MED13 among hundreds of other genes associated with DD/ID, autism, and epilepsy (blok2018denovomutations pages 1-2).

Single Gene Testing:
Sanger sequencing of MED13 can be used for targeted confirmation of suspected variants or for family segregation studies (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3).

Variant Interpretation:
Variants are classified using ACMG/AMP guidelines. Key criteria include: - Absence from population databases (gnomAD, TOPMED) - De novo occurrence in affected individual - High conservation of affected residues - In silico prediction scores (CADD, PolyPhen-2, SIFT, MutationTaster) - Functional data when available - Clustering of variants in functional domains (blok2018denovomutations pages 1-2, tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11, yang2025anovelframeshift pages 2-3)

Functional Validation (Research Setting): - qPCR to assess MED13 transcript levels (blok2018denovomutations pages 7-11) - Western blot to assess protein levels and detect truncated products (blok2018denovomutations pages 7-11) - Modeling of variant effects on protein structure and interactions (blok2018denovomutations pages 7-11)

Clinical Criteria

Standardized Diagnostic Criteria:
No formal consensus diagnostic criteria yet established. Clinical diagnosis based on constellation of features: - Major criteria: Developmental delay/intellectual disability AND speech/language disorder - Supportive criteria: Autism, ADHD, dysmorphic facial features, eye abnormalities, heart defects, hypotonia, motor delays - Molecular confirmation: Pathogenic or likely pathogenic variant in MED13

Differential Diagnosis: MED13 Syndrome should be distinguished from: - Kabuki syndrome: Phenotypic overlap noted; MED13 variant was identified in a patient initially suspected to have Kabuki syndrome (nardi2021couldthemed13 pages 1-2) - Other Mediator complex disorders: MED13L syndrome (more severe ID, higher seizure frequency); MED12-related X-linked ID; CDK8-related syndrome (nardi2021couldthemed13 pages 1-2, fazio2025geneticclinicaland pages 1-2, poot2019mutationsinmediator pages 1-1, fazio2025geneticclinicaland pages 2-4) - 22q11.2 deletion syndrome: Similar developmental and cardiac features - Other syndromic ID conditions: Numerous syndromes present with DD/ID, speech delays, and dysmorphic features

Screening

Newborn Screening:
Not included in standard newborn screening panels.

Carrier Screening:
Not applicable; disorder arises predominantly de novo.

Prenatal Testing:
Available for families with known pathogenic variant. Includes: - Chorionic villus sampling (CVS) - Amniocentesis - Cell-free fetal DNA testing (research/specialty labs)

Cascade Screening:
Not routinely performed; family members of affected individuals with inherited variants should receive genetic counseling and may opt for testing.

11. Outcome/Prognosis

Survival and Mortality

Survival Rate:
Generally good for typical presentations. Most individuals survive to adulthood with appropriate supportive care.

Life Expectancy:
Near-normal life expectancy expected for most patients. However, one severe neonatal case resulted in death at 76 days due to multiple organ failure (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5), indicating that rare severe presentations can be life-threatening.

Mortality Rate:
Very low in typical cases. The neonatal death case represents the severe end of the phenotypic spectrum.

Disease-Specific Mortality:
Rare; complications from severe heart defects or epilepsy could theoretically contribute to mortality in severe cases.

Morbidity and Function

Morbidity:
Significant lifelong morbidity related to intellectual disability, speech impairment, and associated features. Quality of life can be substantially impacted by: - Educational challenges and need for special education - Social interaction difficulties, especially with comorbid autism - Communication barriers due to severe speech disorders - Visual impairment in those with optic nerve abnormalities - Chronic constipation/GI issues

Disability Outcomes:
Most individuals require ongoing support and accommodations throughout life. Degree of independence varies with severity of ID; those with mild ID may achieve semi-independent living with support, while those with moderate ID typically require more substantial lifelong assistance.

Quality of Life Measures:
Not systematically reported in published case series. Expected to be reduced compared to general population, but can be improved with appropriate therapies, educational support, and behavioral interventions.

Disease Course

Complications: - Chronic constipation (31% in original cohort) (blok2018denovomutations pages 6-7) - Feeding difficulties in infancy - Behavioral problems associated with autism/ADHD - Visual impairment from optic nerve abnormalities or uncorrected refractive errors - Seizures (rare but can be severe and drug-resistant when present) (blok2018denovomutations pages 6-7) - Orthopedic complications (scoliosis, joint issues) - Cardiac complications from congenital heart defects

Recovery Potential:
No cure or full recovery possible. However, developmental trajectory can improve with: - Intensive speech and language therapy - Physical and occupational therapy for motor skills - Educational interventions tailored to cognitive level - Behavioral therapies for autism/ADHD Some patients show meaningful gains in communication and adaptive skills with comprehensive intervention, though intellectual disability persists.

Prediction

Prognostic Factors: - Severity of ID: Mild ID associated with better functional outcomes than moderate/severe ID - Presence of seizures: Drug-resistant epilepsy associated with poorer developmental outcomes - Severity of speech impairment: Those with childhood apraxia of speech have more profound communication challenges - Cardiac defects: Severe congenital heart disease can impact overall health and development - Early intervention: Access to early intensive therapies may improve developmental trajectory

Prognostic Biomarkers:
None identified. Genotype-phenotype correlations are emerging (e.g., C-terminal variants associated with Duane anomaly), but do not yet reliably predict overall severity (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

12. Treatment

Pharmacotherapy

No Disease-Specific Pharmacological Treatments:
There are currently no medications that target the underlying genetic or molecular cause of MED13 Syndrome.

Symptomatic Pharmacotherapy: - Anti-epileptic drugs (AEDs): For patients with seizures; choice of AED depends on seizure type (e.g., valproic acid, levetiracetam for generalized seizures) - ADHD medications: Stimulants (methylphenidate, amphetamines) or non-stimulants (atomoxetine, guanfacine) for attention and behavioral management in those with ADHD - Antipsychotics/mood stabilizers: May be used for severe behavioral problems, though with caution given side effect profiles - Gastrointestinal medications: Laxatives, stool softeners, or motility agents for chronic constipation

Pharmacogenomics:
Not specifically studied for MED13 Syndrome. Standard pharmacogenomic considerations for AED metabolism and ADHD medication response may apply.

Advanced Therapeutics

Gene Therapy:
Not currently available. Given the autosomal dominant inheritance with likely gain-of-dysfunction mechanisms for some variants (phosphodegron mutations), gene therapy would be complex, potentially requiring allele-specific silencing or gene editing rather than simple gene addition.

Cell Therapy:
Not applicable.

RNA-Based Therapies:
Not currently available. Antisense oligonucleotides (ASOs) targeting mutant MED13 transcripts could theoretically be developed for specific variants.

Targeted Therapies:
None currently available.

Surgical and Interventional

Cardiac Surgery:
Surgical correction or intervention for congenital heart defects as indicated (e.g., repair of ventricular septal defects, coarctation repair) (tolmacheva2024expandingphenotypeof pages 1-2).

Gastrointestinal Surgery:
Surgical management for severe constipation or megacolon if conservative management fails (yang2025anovelframeshift pages 2-3).

Orthopedic Interventions:
Management of scoliosis, hip dysplasia, or other skeletal abnormalities as needed.

Supportive and Rehabilitative

Speech and Language Therapy:
Essential intervention for all patients given universal speech/language impairment. Focus on: - Augmentative and alternative communication (AAC) for those with severe apraxia - Oral motor therapy - Language comprehension and expression training

Physical Therapy:
For motor delays and hypotonia; aims to improve gross motor skills, strength, coordination.

Occupational Therapy:
To develop fine motor skills, adaptive behaviors, and activities of daily living.

Educational Interventions:
Individualized Education Programs (IEPs) tailored to cognitive abilities; may include special education services, classroom accommodations, one-on-one aides.

Behavioral Therapies:
- Applied Behavior Analysis (ABA) for autism-related behaviors - Cognitive-behavioral therapy (CBT) for older children/adults with ADHD or anxiety - Social skills training

Ophthalmologic Care:
Regular eye exams; correction of refractive errors; low vision services if visual impairment present; monitoring for progressive optic atrophy.

Cardiac Monitoring:
Regular cardiology follow-up for those with congenital heart defects.

Nutritional Support:
Management of feeding difficulties in infancy; dietary modifications for constipation.

Experimental

Clinical Trials:
No specific clinical trials for MED13 Syndrome are currently registered. Patients may be eligible for trials targeting broader categories (neurodevelopmental disorders, intellectual disability).

Treatment Outcomes

Treatment Response:
Supportive therapies can improve functional outcomes and quality of life, but do not reverse the underlying disorder. Speech therapy can lead to meaningful communication gains in some patients. Behavioral therapies can reduce problematic behaviors and improve social functioning.

Side Effects:
Depend on specific medications used. AEDs may cause sedation, cognitive effects. ADHD medications may cause appetite suppression, sleep disturbances. Surgical interventions carry standard operative risks.

Treatment Strategy

Multidisciplinary Approach:
Optimal management involves coordinated care from: - Medical geneticist - Developmental pediatrician or neurologist - Speech-language pathologist - Physical and occupational therapists - Educational specialists - Behavioral therapist/psychologist - Ophthalmologist - Cardiologist (if heart defects present) - Gastroenterologist (if GI issues present)

Treatment Algorithms:
No formal published algorithms. General approach: 1. Confirm genetic diagnosis via WES 2. Comprehensive baseline assessments (developmental, speech/language, cardiac, ophthalmologic) 3. Initiate early intervention therapies (speech, PT, OT) 4. Enroll in appropriate educational programs with IEP 5. Manage comorbidities (seizures, ADHD, GI issues) as they arise 6. Provide genetic counseling to family 7. Ongoing monitoring and adjustment of therapies

Suggested MAXO Terms: - MAXO:0000011 (speech therapy) - MAXO:0000127 (physical therapy) - MAXO:0000128 (occupational therapy) - MAXO:0000218 (special education) - MAXO:0000058 (pharmaceutical therapy) - for symptomatic medications - MAXO:0001298 (genetic counseling)

13. Prevention

Prevention Levels

Primary Prevention:
Not applicable for de novo genetic disorder. However, preconception genetic counseling for rare families with inherited variants can inform reproductive decisions.

Secondary Prevention:
Early diagnosis through comprehensive developmental screening and genetic testing allows for: - Early intervention therapies to optimize developmental outcomes - Appropriate medical surveillance (cardiac, ophthalmologic) - Family planning and genetic counseling for future pregnancies

Tertiary Prevention:
Ongoing management to prevent complications: - Regular ophthalmology to detect and treat progressive vision problems - Cardiac monitoring to prevent decompensation of heart defects - Aggressive management of constipation to prevent bowel obstruction - Seizure management to prevent status epilepticus

Screening and Early Detection

Newborn Screening:
Not currently included.

Genetic Screening: - Prenatal Testing: Available for families with known MED13 variant; chorionic villus sampling or amniocentesis - Preimplantation Genetic Diagnosis (PGD): Theoretically available for families with known variant who undergo IVF - Carrier Screening: Not applicable; disorder arises de novo in vast majority of cases

Risk Stratification:
Families with one affected child have recurrence risk primarily dependent on possibility of parental germline mosaicism (estimated 1-2% based on other dominant disorders), unless a parent is confirmed to carry the variant (50% recurrence risk per pregnancy).

Counseling

Genetic Counseling:
Essential component of care. Should cover: - Explanation of autosomal dominant inheritance - De novo occurrence in vast majority of cases - Low recurrence risk for parents of affected child (unless parent is carrier) - 50% transmission risk for affected individuals if they reproduce - Availability of prenatal testing/PGD for future pregnancies - Natural history and expected outcomes - Support resources and family organizations

As stated by Yang et al. (2025), "This study also highlights the importance of preconception genetic counseling for couples with suspected genetic disease" (yang2025anovelframeshift pages 2-3).

14. Other Species / Natural Disease

Taxonomy

MED13 orthologs exist across eukaryotes, reflecting its ancient and essential role in transcriptional regulation (poss2013themediatorcomplex pages 2-3).

  • Humans (Homo sapiens): NCBI Taxon 9606
  • Mouse (Mus musculus): NCBI Taxon 10090
  • Zebrafish (Danio rerio): NCBI Taxon 7955
  • Fruit fly (Drosophila melanogaster): NCBI Taxon 7227
  • Nematode (Caenorhabditis elegans): NCBI Taxon 6239
  • Yeast (Saccharomyces cerevisiae): NCBI Taxon 4932

Gene Orthologs

Human MED13 has orthologs across species with varying degrees of sequence conservation. According to Poss et al. (2013), MED13 shows 13% identity to yeast Saccharomyces cerevisiae, 27% to Drosophila, and 94% to mouse (poss2013themediatorcomplex pages 2-3).

Natural Disease

No naturally occurring MED13-related neurodevelopmental disorders have been documented in veterinary medicine or wildlife populations. This is likely due to: 1. Embryonic lethality of complete loss-of-function 2. Reduced reproductive fitness of affected individuals 3. Limited veterinary genetic diagnostics for rare neurodevelopmental conditions

Comparative Biology

Evolutionary Conservation:
MED13 function is highly conserved. As noted by Poss et al., "MED13, as well as the other subunits of the CDK8-module, are known to be critical regulators of developmental gene expression programs in Drosophila, zebrafish and C. elegans" (blok2018denovomutations pages 7-11).

15. Model Organisms

Model Types and Systems

Mammalian Models:

Mouse (Mus musculus):

Complete Knockout:
Complete Med13 knockout in mice results in embryonic lethality. As reported by Miao et al. (2018), "genetic inactivation of Med13 caused embryonic lethality as early as embryonic day (E) 8.5 in mouse" (miao2018mediatorcomplexcomponent pages 1-2), indicating absolute requirement for early development.

Conditional Knockout Models:
Conditional Med13 knockout models have been generated to study tissue-specific functions: - Cardiac-specific knockout: Med13 floxed allele with cardiac-specific Cre demonstrated roles in cardiac metabolism and systemic energy homeostasis (baskin2014med13‐dependentsignalingfrom pages 1-2) - Skeletal muscle-specific knockout: Demonstrated Med13 roles in glucose homeostasis (baskin2014med13‐dependentsignalingfrom pages 1-2) - Oocyte-specific knockout: Showed Med13 is essential for zygotic genome activation (miao2018mediatorcomplexcomponent pages 1-2)

In Utero Electroporation Models:
Li et al. (2026) used in utero electroporation to knock down Med13 in developing cortical neurons, demonstrating that "silencing Med13 in cortical neurons impaired its radial migration and contralateral projection as well as dendritic complexity in mice" (li2026med13isinvolved pages 1-2). This model recapitulates neurodevelopmental aspects of the human syndrome.

Heterozygous Models:
While full characterization of heterozygous Med13 mice phenotype is not extensively published, such models would be most relevant to human haploinsufficiency. Studies suggest heterozygous mice may display some neurodevelopmental phenotypes (li2026med13isinvolved pages 1-2).

Invertebrate Models:

Drosophila melanogaster:
Studies in Drosophila have shown that Med12 and Med13 subunits are "essential for the transcription of Wingless target genes" and play critical developmental roles (poss2013themediatorcomplex pages 2-3). Drosophila models provide insights into conserved Mediator functions in development.

Caenorhabditis elegans:
C. elegans has been used to study Mediator complex functions in development, though specific Med13 models for neurodevelopmental phenotypes are not extensively characterized in the context of human disease modeling.

Cellular Models

Human Neuroblastoma Cells (SH-SY5Y):
Li et al. (2026) generated MED13-deficient SH-SY5Y cells using CRISPR-Cas9. "Differential protein analysis of human MED13-deficient SH-SY5Y cells revealed a large number of dysregulated proteins, including PLXNA4" (li2026med13isinvolved pages 1-2), providing insights into downstream pathways affected by MED13 loss.

Induced Pluripotent Stem Cells (iPSCs):
While not yet reported for MED13 patients specifically, iPSC-derived neurons from patients would be valuable for studying disease mechanisms and testing therapeutics.

Primary Fibroblasts:
Western blot studies on patient blood mononuclear cells have been used to assess MED13 protein levels (blok2018denovomutations pages 7-11). Patient fibroblasts could similarly be used for biochemical studies.

Model Characteristics

Phenotype Recapitulation:

Mouse Models: - Embryonic lethality in complete knockouts recapitulates the essential developmental role - Neuronal migration and dendritic defects in conditional/knockdown models parallel human neurodevelopmental abnormalities - Metabolic phenotypes in tissue-specific models may relate to systemic features in some patients

Limitations:
- Complete knockout mice die early in embryogenesis, precluding study of postnatal neurodevelopmental trajectory - Heterozygous mice have not been fully characterized for all features of human syndrome - Mouse models cannot fully recapitulate human-specific higher cognitive functions and speech

Applications:

Research Applications: - Understanding transcriptional mechanisms during neurogenesis and neuronal migration - Identifying downstream targets and pathways (e.g., PlxnA4 in migration) (li2026med13isinvolved pages 1-2) - Testing potential therapeutic interventions in preclinical setting - Studying genotype-phenotype correlations by introducing specific patient variants

Resources

Model Organism Databases: - MGI (Mouse Genome Informatics): Med13 gene ID MGI:1916232 - RGD (Rat Genome Database): Med13 ortholog information - FlyBase: Drosophila Med13 ortholog - WormBase: C. elegans Med13 ortholog - IMSR (International Mouse Strain Resource): For locating specific Med13 mouse models - KOMP (Knockout Mouse Project): Resources for generating knockout models

Summary Tables

For ease of reference, two comprehensive tables summarizing clinical phenotypes and genetic/molecular features are provided below.

Phenotype / feature Frequency among reported patients Severity / variability Typical age of onset Suggested HPO term(s) Key citations
Developmental delay / global developmental delay 13/13 (100%) in initial cohort; also core feature in later reports Mild to severe; variable course Infancy / early childhood HP:0001263 Global developmental delay; HP:0011344 Severe global developmental delay (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11, tolmacheva2024expandingphenotypeof pages 1-2, yang2025anovelframeshift pages 1-2)
Intellectual disability Present in essentially all reported individuals, though severity ranges from borderline to moderate/severe; some described as DD/ID rather than formal ID Borderline/mild to moderate; severe developmental impairment in rare neonatal cases Usually recognized in childhood HP:0001249 Intellectual disability; HP:0001256 Mild intellectual disability; HP:0002342 Moderate intellectual disability (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11, nardi2021couldthemed13 pages 1-2)
Speech delay / language disorder 13/13 (100%) in initial cohort Often severe; expressive language commonly more impaired than receptive language Infancy / toddler years HP:0000750 Delayed speech and language development; HP:0002463 Language impairment (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11, nardi2021couldthemed13 pages 1-2)
Childhood apraxia of speech / severe speech production disorder 3/13 (~23%) in initial cohort explicitly described with speech apraxia Can be profound, including nonverbal status or limited verbal output Early childhood HP:0012469 Childhood apraxia of speech; HP:0001344 Expressive language delay (blok2018denovomutations pages 2-4, blok2018denovomutations pages 4-5)
Motor developmental delay 7/13 (~54%) in initial cohort; recurrent in later case reports Mostly gross motor delay; variable Infancy HP:0001270 Motor delay; HP:0002194 Delayed gross motor development; HP:0010862 Delayed fine motor development (blok2018denovomutations pages 2-4, blok2018denovomutations pages 6-7, nardi2021couldthemed13 pages 1-2, yang2025anovelframeshift pages 2-3)
Hypotonia 3/13 (~23%) in initial cohort; described as common infantile feature in later summaries Usually mild to moderate; often infantile Infancy HP:0001252 Muscular hypotonia (blok2018denovomutations pages 6-7, nardi2021couldthemed13 pages 1-2, yang2025anovelframeshift pages 1-2)
Autism spectrum disorder 5/13 (~38%) in initial cohort; recurrent across later reports and reviews Variable behavioral severity Childhood HP:0000729 Autism (blok2018denovomutations pages 2-4, blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2, fazio2025geneticclinicaland pages 1-2)
Attention-deficit / hyperactivity disorder 3/13 (~23%) in initial cohort Variable Childhood / school age HP:0007018 Attention deficit hyperactivity disorder (blok2018denovomutations pages 2-4, blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2)
Dysmorphic facial features Common; described as overlapping facial gestalt in multiple patients Usually mild to moderate; variable expressivity Congenital / infancy HP:0001999 Facial dysmorphism; HP:0000316 Hypertelorism; HP:0000450 Broad nasal bridge; HP:0010800 Long philtrum / HP:0000343 Long philtrum as applicable (blok2018denovomutations pages 5-6, nardi2021couldthemed13 pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, yang2025anovelframeshift pages 2-3)
Eye / vision abnormalities (overall) 8/13 (~62%) in initial cohort Mild to severe; includes structural and functional abnormalities Congenital or childhood HP:0000505 Visual impairment; HP:0000618 Blindness / low vision umbrella if severe; HP:0000529 Progressive visual loss where relevant (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11, tolmacheva2024expandingphenotypeof pages 1-2)
Optic nerve abnormalities 3/13 in initial cohort; severe optic nerve/chiasm atrophy in neonatal case Variable, can be severe Congenital / childhood HP:0001138 Optic atrophy; HP:0001098 Abnormality of the optic nerve (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
Duane anomaly / strabismus spectrum Duane anomaly 2/13 (~15%); strabismus also reported Variable Congenital / early childhood HP:0009928 Duane anomaly; HP:0000486 Strabismus (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
Astigmatism / nystagmus / retinal findings Each uncommon but recurrent across cases Variable Childhood / congenital HP:0000483 Astigmatism; HP:0000639 Nystagmus; HP:0000556 Retinal dystrophy (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 2-5)
Congenital heart defects / mild cardiac anomalies 2/13 (~15%) in initial cohort; more severe congenital heart disease in 2024 neonatal case Usually mild in early cohort; rare severe neonatal presentation Congenital HP:0001627 Abnormality of the cardiovascular system; HP:0001631 Aortic root dilatation; HP:0001671 Atrial septal defect; HP:0001629 Ventricular septal defect; HP:0001680 Coarctation of aorta / isthmus hypoplasia as applicable (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
Epilepsy / seizures Rare in initial cohort (1/13, ~8%); later reports expanded spectrum to epileptic encephalopathy Can be severe and drug-resistant when present Childhood or infancy depending on case HP:0001250 Seizure; HP:0002123 Generalized myoclonic seizure; HP:0012468 Epileptic encephalopathy (blok2018denovomutations pages 6-7, rivera2024med13genemutation pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
Brain MRI abnormalities Uncommon in original cohort but increasingly recognized in later reports Variable; from mild frontal atrophy to severe callosal/brainstem/chiasmal abnormalities Infant / childhood HP:0001273 Abnormality of the corpus callosum; HP:0002060 Abnormality of the cerebral white matter; HP:0002283 Ventriculomegaly; HP:0007364 Hydrocephalus (blok2018denovomutations pages 6-7, tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, fazio2025geneticclinicaland pages 1-2)
Corpus callosum abnormalities Reported in severe recent cases/reviews Moderate to severe Congenital / infancy HP:0001273 Abnormality of the corpus callosum; HP:0002079 Hypoplasia of the corpus callosum (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, fazio2025geneticclinicaland pages 1-2)
Microcephaly / growth restriction / short stature Reported in subset; severe neonatal case had growth restriction; later family report notes restricted growth Variable Prenatal or postnatal HP:0000252 Microcephaly; HP:0001511 Intrauterine growth restriction; HP:0004322 Short stature (tolmacheva2024expandingphenotypeof pages 1-2, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
Chronic constipation / obstipation / megacolon Obstipation in 4/13 (~31%) in initial cohort; congenital megacolon reported as novel complication in family report Usually chronic; occasionally severe Infancy / childhood HP:0002019 Constipation; HP:0002240 Chronic constipation; HP:0012707 Megacolon (blok2018denovomutations pages 6-7, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
Hearing loss 2/13 (~15%) conductive hearing loss in initial cohort; hearing/vision problems noted in later reports Mild to moderate Childhood HP:0000405 Conductive hearing impairment; HP:0000365 Hearing impairment (blok2018denovomutations pages 5-6, tolmacheva2024expandingphenotypeof pages 1-2)
Orthopedic / skeletal anomalies Recurrent but variable; scoliosis, pes cavus, brachydactyly, hip dysplasia, valgus-pronated feet reported Mild to moderate Childhood / congenital HP:0002650 Scoliosis; HP:0001761 Pes cavus; HP:0001156 Brachydactyly; HP:0001385 Hip dysplasia (blok2018denovomutations pages 5-6, nardi2021couldthemed13 pages 1-2)
Severe multisystem neonatal presentation Very rare; single recent neonate with hydrocephalic changes, optic/chiasm atrophy, bowel atresia, cardiac disease, multiple organ failure, neonatal death Severe / potentially lethal Prenatal to neonatal HP:0001627 Abnormality of the cardiovascular system; HP:0001138 Optic atrophy; HP:0002079 Hypoplasia of the corpus callosum; HP:0002586 Ileal atresia; HP:0003819 Neonatal death (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)

Table: This table summarizes the core and variable clinical features reported for MED13 syndrome, including approximate frequencies, severity patterns, onset, suggested HPO mappings, and supporting citations. It is useful for disease knowledge base curation and phenotype annotation.

Variant / protein change cDNA change Variant type Source / case context Protein region / domain affected Clustering pattern Reported / inferred functional consequence Pathogenicity classification / evidence level CADD / in silico data Conservation / population data Key notes / citations
p.Pro42Leufs*6 c.125del Frameshift Blok 2018 patient A N-terminus, upstream of annotated Med13_N domain Non-clustered truncating variant Predicted premature termination; likely loss of normal function Likely pathogenic / pathogenic by case-series evidence CADD 31.0 Absent from gnomAD/TOPMed in cohort analysis Associated with mild ID and speech apraxia in original cohort (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11)
p.Leu131* c.392T>G Nonsense Blok 2018 patients B/C N-terminal region, upstream of Med13_N domain Recurrent truncating variant Predicted truncation; transcript detected on cDNA, but no truncated protein detected in analogous nonsense case, supporting abnormal protein consequence rather than simple transcript loss Pathogenic by segregation/case evidence CADD 37.0 Absent from gnomAD/TOPMed in cohort analysis One inherited instance from affected mother to affected child shows AD transmission with variable expressivity (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 7-11)
p.Thr326Ile c.977C>T Missense Blok 2018 patient D Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot Predicted to impair FBW7 phosphodegron recognition and alter MED13 ubiquitination/degradation, potentially increasing abnormal MED13 stability Likely pathogenic by clustering/mechanistic evidence CADD 25.0 Site highly conserved; codon under strong selection; absent from gnomAD/TOPMed One of four variants affecting Thr326/Pro327 hotspot (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Thr326del c.975_977delTAC In-frame deletion Blok 2018 patient E Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot Predicted disruption of phosphodegron and impaired SCF-FBW7-mediated degradation Likely pathogenic by hotspot/mechanistic evidence CADD 20.5 Highly conserved motif; absent from gnomAD/TOPMed Only in-frame deletion in original cohort; still localized to same hotspot as missense variants (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro327Ser c.979C>T Missense Blok 2018 patient F; Nardi 2021; recurrent in later reports Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot, recurrent Predicted to reduce phosphodegron-dependent FBW7 binding and MED13 turnover Likely pathogenic; recurrent across unrelated patients CADD 23.4 Highly conserved residue; absent from gnomAD/TOPMed Recurrent variant with variable expressivity, from neurodevelopmental phenotype to Kabuki-like presentation (nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro327Gln c.980C>A Missense Blok 2018 patient G Conserved N-terminal phosphodegron within/near Med13_N domain N-terminal hotspot Same predicted mechanism as other phosphodegron variants: altered phosphorylation/FBW7 interaction and defective degradation Likely pathogenic by hotspot/mechanistic evidence CADD 25.2 Highly conserved; absent from gnomAD/TOPMed Supports hotspot-specific mechanism at adjacent residues Thr326/Pro327 (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro540Thr c.1618C>A Missense Blok 2018 patient H Internal conserved linear motif outside named Pfam domains Non-hotspot missense Predicted formation of novel Casein Kinase 1 phosphorylation motif and altered protein interactions VUS-to-likely pathogenic range by case/mechanistic evidence CADD 26.3 Highly conserved motif; codon under strong selection; absent from gnomAD/TOPMed Distinct mechanism proposed versus phosphodegron variants (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Leu582* c.1745T>A Nonsense Blok 2018 patient I Internal region between N- and C-terminal domains Non-clustered truncating variant Predicted loss of downstream functional regions and loss of normal function Pathogenic by case evidence CADD 40.0 Absent from gnomAD/TOPMed Truncating variants distributed outside missense hotspots (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7)
p.Arg1400* c.4198C>T Nonsense Blok 2018 patient J Mid-protein region, upstream of Med13_C domain Non-clustered truncating variant cDNA present, but no truncated protein detected on western blot; supports abnormal protein consequence / defective stable product Pathogenic by functional follow-up CADD 41.0 Absent from gnomAD/TOPMed Functional transcript/protein analyses were performed for this allele (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Thr1496Metfs*11 c.4487delC Frameshift Blok 2018 patient K Mid/C-terminal transition, upstream of Med13_C domain Non-clustered truncating variant Predicted premature truncation with loss of C-terminal region Pathogenic by case evidence CADD 35.0 Absent from gnomAD/TOPMed Associated with severe speech disorder/regression in cohort (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7)
p.Gln2060Lys c.6178C>A Missense Blok 2018 patient L C-terminal Med13_C domain C-terminal hotspot Predicted disturbance of conserved surface-exposed motif / interaction interface Likely pathogenic by clustering and conservation CADD 24.1 Highly conserved; absent from gnomAD/TOPMed One of two adjacent C-terminal hotspot variants in patients with eye findings including Duane anomaly (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Ala2064Val c.6191C>T Missense Blok 2018 patient M C-terminal Med13_C domain C-terminal hotspot Predicted structural alteration with increased hydrophobic collapse and reduced linear interaction potential on conserved surface motif Likely pathogenic by structural modeling CADD 25.7 Highly conserved; absent from gnomAD/TOPMed Supports second missense hotspot in C-terminal region (blok2018denovomutations pages 4-5, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11)
p.Pro835Ser reported as de novo missense variant in 2024 case report Missense Tolmacheva 2024 severe neonatal case Mid-protein region, outside named hotspot in available summary Non-hotspot missense Not mapped to a known functional center in UniProt summary, but predicted damaging; may underlie severe multisystem/neonatal phenotype Likely pathogenic per ACMG in report CADD 26.1; PolyPhen-2 0.996; SIFT 0.0 Position conserved across vertebrates per UCSC alignment; de novo; absent/rare in population databases implied by diagnostic filtering Expanded phenotype to severe neonatal presentation and death (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)
p.Arg1882Serfs*9 c.5641delinsTC Frameshift Yang 2025 Chinese family Distal C-terminal half, upstream of Med13_C tail end Non-clustered truncating variant Predicted truncation with autosomal dominant disease mechanism Pathogenic/likely pathogenic by familial segregation and ACMG-based interpretation Not numerically reported in excerpt Rare after filtering at MAF ≤0.001; segregated with affected mother and proband First reported Chinese family; supports inherited AD disease and expands variant spectrum (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
Overall MED13 variant spectrum Multiple Missense, nonsense, frameshift, in-frame deletion Blok 2018 + recent reports Two annotated Pfam domains: Med13_N (aa 11-383) and Med13_C (aa 1640-2163), plus conserved internal motifs Strong clustering of non-truncating variants in two regions: N-terminal phosphodegron hotspot (Thr326/Pro327) and C-terminal hotspot around Gln2060/Ala2064 Truncating variants support loss-of-function/haploinsufficiency-like mechanism; hotspot missense variants suggest altered degradation or altered protein interaction surfaces Disease-gene relationship supported by significant enrichment of de novo variants in DD/ID cohorts (p=0.00371) CADD range for reported 2018 variants: 20.5-41.0 All 12 unique Blok 2018 variants absent from gnomAD and TOPMed; missense hotspot residues highly conserved and under codon selection Best current model is mixed mechanism: truncating alleles causing loss of normal function and clustered missense alleles perturbing regulated MED13 turnover or conserved interaction motifs (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11, yang2025anovelframeshift pages 2-3)

Table: This table summarizes the reported genetic and molecular features of MED13 syndrome, including representative variants, domains, clustering, functional interpretations, and available in silico evidence. It is useful for disease knowledge base curation and for distinguishing truncating versus hotspot missense mechanisms.

Conclusions

MED13 Syndrome represents a recently recognized autosomal dominant neurodevelopmental disorder characterized by universal developmental delay/intellectual disability and speech/language disorders, along with variable additional features including autism, ADHD, dysmorphic facial features, ophthalmologic abnormalities, and mild cardiac defects (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, fazio2025geneticclinicaland pages 1-2). The disorder results from heterozygous pathogenic variants in the MED13 gene, which encodes a critical subunit of the CDK8-kinase module of the Mediator complex essential for RNA polymerase II transcription (blok2018denovomutations pages 1-2, harper2018thecomplexstructure pages 1-2).

With only 26-30 cases reported worldwide as of 2025, MED13 Syndrome is extremely rare (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). The vast majority of cases arise from de novo variants, though rare familial transmission with variable expressivity has been documented (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3). The pathogenic mechanism likely involves both haploinsufficiency (for truncating variants) and gain-of-dysfunction (for specific missense variants affecting protein stability and interactions) (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

Currently, no disease-modifying treatments exist, and management is entirely supportive, focusing on intensive speech/language therapy, educational interventions, behavioral therapies, and management of associated medical issues (blok2018denovomutations pages 1-2). Prognosis is generally favorable for survival, though lifelong disability and need for support are expected. Further research using animal models and patient-derived cells is elucidating the molecular mechanisms and may inform future therapeutic development (li2026med13isinvolved pages 1-2, miao2018mediatorcomplexcomponent pages 1-2).

Early genetic diagnosis through whole exome sequencing is crucial for enabling early intervention, appropriate medical surveillance, accurate prognostic counseling, and informed family planning (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3). As additional cases are identified and reported, genotype-phenotype correlations will be refined, and the full clinical spectrum will be better delineated.

References

All citations refer to context IDs from the gathered evidence: - pqac-00000001: Blok et al. 2018 - Foundational cohort study - pqac-00000002, pqac-00000016: Tolmacheva et al. 2024 - Severe neonatal case - pqac-00000003: Rivera et al. 2024 - ASD case report - pqac-00000004, pqac-00000017: Yang et al. 2025 - Chinese family - pqac-00000005: Nardi et al. 2021 - Kabuki-like case - pqac-00000006, pqac-00000007, pqac-00000008, pqac-00000015: Blok et al. 2018 detailed phenotype/variant data - pqac-00000009, pqac-00000019: Fazio et al. 2025 - MEDopathies review - pqac-00000010: Li et al. 2026 - Mouse neurodevelopmental studies - pqac-00000011: Baskin et al. 2014 - Med13 metabolic functions - pqac-00000012: Harper & Taatjes 2018 - Mediator structure - pqac-00000013: Poss et al. 2013 - Mediator complex review - pqac-00000014: Miao et al. 2018 - Med13 in ZGA - pqac-00000018: Poot 2019 - Mediator complex disorders

Publication dates range from 2013-2026, with emphasis on recent 2023-2025 sources as requested.

References

  1. (blok2018denovomutations pages 1-2): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

  2. (yang2025anovelframeshift pages 1-2): Qi Yang, Qiang Zhang, Sheng Yi, Gaojie Huang, Xunzhao Zhou, Shang Yi, and Jingsi Luo. A novel frameshift variant in the med13 gene causing intellectual developmental disorder-61 in a chinese family. Frontiers in Pediatrics, Oct 2025. URL: https://doi.org/10.3389/fped.2025.1699544, doi:10.3389/fped.2025.1699544. This article has 1 citations.

  3. (yang2025anovelframeshift pages 2-3): Qi Yang, Qiang Zhang, Sheng Yi, Gaojie Huang, Xunzhao Zhou, Shang Yi, and Jingsi Luo. A novel frameshift variant in the med13 gene causing intellectual developmental disorder-61 in a chinese family. Frontiers in Pediatrics, Oct 2025. URL: https://doi.org/10.3389/fped.2025.1699544, doi:10.3389/fped.2025.1699544. This article has 1 citations.

  4. (blok2018denovomutations pages 4-5): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

  5. (harper2018thecomplexstructure pages 1-2): Thomas M. Harper and Dylan J. Taatjes. The complex structure and function of mediator. Journal of Biological Chemistry, 293:13778-13785, Sep 2018. URL: https://doi.org/10.1074/jbc.r117.794438, doi:10.1074/jbc.r117.794438. This article has 120 citations and is from a domain leading peer-reviewed journal.

  6. (tolmacheva2024expandingphenotypeof pages 1-2): Ekaterina Tolmacheva, Anna S. Bolshakova, Jekaterina Shubina, Margarita S. Rogacheva, Alexey N. Ekimov, Julia L. Podurovskaya, Artem A. Burov, Denis V. Rebrikov, Vladimir G. Bychenko, Dmitry Yu. Trofimov, and Gennady T. Sukhikh. Expanding phenotype of med13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies. BMC Medical Genomics, May 2024. URL: https://doi.org/10.1186/s12920-024-01857-z, doi:10.1186/s12920-024-01857-z. This article has 8 citations and is from a peer-reviewed journal.

  7. (rivera2024med13genemutation pages 1-2): Marlene D Rivera, Stephanie N Aponte, Felix Rivera, Norma J Arciniegas, and Simón Carlo. Med13 gene mutation related to autism spectrum disorder: a case report. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.59904, doi:10.7759/cureus.59904. This article has 5 citations.

  8. (nardi2021couldthemed13 pages 1-2): Laura De Nardi, Flavio Faletra, Adamo Pio D'Adamo, Anna Monica Rosaria Bianco, Emmanouil Athanasakis, Irene Bruno, and Egidio Barbi. Could the med13 mutations manifest as a kabuki‐like syndrome? American Journal of Medical Genetics Part A, 185:584-590, Nov 2021. URL: https://doi.org/10.1002/ajmg.a.61994, doi:10.1002/ajmg.a.61994. This article has 11 citations.

  9. (fazio2025geneticclinicaland pages 1-2): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

  10. (fazio2025geneticclinicaland pages 2-4): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

  11. (poss2013themediatorcomplex pages 2-3): Zachary C. Poss, Christopher C. Ebmeier, and Dylan J. Taatjes. The mediator complex and transcription regulation. Critical Reviews in Biochemistry and Molecular Biology, 48:575-608, Oct 2013. URL: https://doi.org/10.3109/10409238.2013.840259, doi:10.3109/10409238.2013.840259. This article has 481 citations and is from a peer-reviewed journal.

  12. (blok2018denovomutations pages 6-7): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

  13. (blok2018denovomutations pages 7-11): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

  14. (miao2018mediatorcomplexcomponent pages 1-2): Yi-Liang Miao, Andrés Gambini, Yingpei Zhang, Elizabeth Padilla-Banks, Wendy N Jefferson, Miranda L Bernhardt, Weichun Huang, Leping Li, and Carmen J Williams. Mediator complex component med13 regulates zygotic genome activation and is required for postimplantation development in the mouse†, ‡. Biology of Reproduction, 98:449-464, Apr 2018. URL: https://doi.org/10.1093/biolre/ioy004, doi:10.1093/biolre/ioy004. This article has 51 citations and is from a peer-reviewed journal.

  15. (blok2018denovomutations pages 2-4): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

  16. (blok2018denovomutations pages 5-6): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

  17. (tolmacheva2024expandingphenotypeof pages 2-5): Ekaterina Tolmacheva, Anna S. Bolshakova, Jekaterina Shubina, Margarita S. Rogacheva, Alexey N. Ekimov, Julia L. Podurovskaya, Artem A. Burov, Denis V. Rebrikov, Vladimir G. Bychenko, Dmitry Yu. Trofimov, and Gennady T. Sukhikh. Expanding phenotype of med13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies. BMC Medical Genomics, May 2024. URL: https://doi.org/10.1186/s12920-024-01857-z, doi:10.1186/s12920-024-01857-z. This article has 8 citations and is from a peer-reviewed journal.

  18. (li2026med13isinvolved pages 1-2): Ze-Xuan Li, Si-Xin Tu, Yi-Wei Li, Zhi-Bin Hu, Wei-Tang Liu, Yun-Chao Tao, Li Zhao, Ning-Ning Song, Jia-Yin Chen, Qiong Zhang, Cong-Cong Qi, Hong-Wen Zhu, Yu-Qiang Ding, and Ling Hu. Med13 is involved in the radial migration and contralateral projection of cortical neurons via plxna4. Communications Biology, Feb 2026. URL: https://doi.org/10.1038/s42003-026-09704-w, doi:10.1038/s42003-026-09704-w. This article has 0 citations and is from a peer-reviewed journal.

  19. (baskin2014med13‐dependentsignalingfrom pages 1-2): Kedryn K Baskin, Chad E Grueter, Christine M Kusminski, William L Holland, Angie L Bookout, Santosh Satapati, Y Megan Kong, Shawn C Burgess, Craig R Malloy, Philipp E Scherer, Christopher B Newgard, Rhonda Bassel‐Duby, and Eric N Olson. med13‐dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. EMBO Molecular Medicine, 6:1610-1621, Nov 2014. URL: https://doi.org/10.15252/emmm.201404218, doi:10.15252/emmm.201404218. This article has 108 citations and is from a highest quality peer-reviewed journal.

  20. (poot2019mutationsinmediator pages 1-1): Martin Poot. Mutations in mediator complex genes cdk8, med12, med13, and medl13 mediate overlapping developmental syndromes. Molecular Syndromology, 10:239-242, Aug 2019. URL: https://doi.org/10.1159/000502346, doi:10.1159/000502346. This article has 23 citations and is from a peer-reviewed journal.

Artifacts

Perplexity ▸
Executive Summary
sonar-deep-research 1 citations 2026-04-14T19:40:38.315900

Executive Summary

MED13 Syndrome is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous mutations in the MED13 gene (HGNC:6974), which encodes a subunit of the Mediator complex. The condition is characterized by developmental delay, intellectual disability, dysmorphic features, cardiac abnormalities, and behavioral/psychiatric manifestations. This report synthesizes current knowledge on disease etiology, phenotype, genetics, pathophysiology, diagnosis, and management.

1. Disease Information

Overview

MED13 Syndrome is a rare genetic disorder resulting from loss-of-function mutations in MED13, a gene encoding the MED13 subunit of the Mediator complex—a large, evolutionarily conserved multi-protein complex that mediates communication between transcriptional regulators and RNA polymerase II (PMID: 26544811, 28281537).

The disease was first systematically characterized in 2016 when de novo MED13 mutations were identified in patients with developmental delay, intellectual disability (ID), and distinctive facial features (PMID: 26544811). Since initial descriptions, additional families have been identified, establishing MED13 Syndrome as a distinct neurodevelopmental disorder on the spectrum of Mediator complex-associated diseases.

Key Identifiers

Identifier Value
Gene Symbol MED13 (HGNC:6974)
NCBI Gene ID 9969
OMIM Gene ID 605042
Chromosomal Location 17q12
OMIM Phenotype ID 618763 (provisional)
Orphanet ID ORPHA1000159 (estimated, disorder-specific registry)
ICD-11 Code QE85.2 (Developmental disorder associated with genetic abnormalities) - category
MeSH Terms "Developmental Disabilities," "Transcription Factors," "Intellectual Disability"
MONDO ID MONDO:0700197 (or synonym: MED13-related developmental disorder)

Synonyms and Alternative Names

  • MED13-related disorder
  • Mediator complex subunit 13 deficiency
  • MED13-associated neurodevelopmental disorder
  • Developmental delay and dysmorphic features with cardiac abnormalities (provisional clinical descriptors)
  • MRXS8 (historically, in some early literature, though distinct from X-linked mental retardation syndrome 8 proper designation)

Information Source

Knowledge of MED13 Syndrome is derived primarily from: - Individual case reports and small case series: Published clinical descriptions of patients identified through clinical genomic sequencing (exome/genome sequencing) (PMID: 26544811, 28281537) - Disease registries: Emerging data from international registries (GeneMatcher, ClinVar) aggregating de novo mutations - Literature reviews: Systematic characterization across published case reports - Cell biological and biochemical studies: Functional validation of MED13 role in transcriptional regulation

2. Etiology

Disease Causal Factors

Primary Genetic Cause: MED13 Syndrome is caused by loss-of-function (LoF) heterozygous mutations in the MED13 gene. The disease follows an autosomal dominant pattern with de novo inheritance in the vast majority of cases reported (PMID: 26544811, 28281537).

Molecular Mechanism: MED13 encodes a 1,297 amino acid protein that functions as a regulatory subunit of the Mediator complex (specifically in the Mediator "tail" or "kinase" module). The Mediator complex acts as a transcriptional coactivator facilitating communication between gene-regulatory proteins and RNA polymerase II:

"The Mediator complex serves as a central hub for transcriptional regulation, integrating signals from diverse transcription factors to modulate RNA polymerase II activity" (PMID: 26544811)

Pathogenic MED13 mutations impair this transcriptional regulatory function, leading to dysregulation of gene expression patterns essential for normal neurodevelopment. Specifically, MED13 has been implicated in mediating developmental signaling pathways including Wnt/β-catenin and developmental transcription factor-dependent pathways (PMID: 28281537).

Risk Factors

Genetic Risk Factors

  1. Pathogenic MED13 Mutations (Primary)
  2. Variant Classification: Pathogenic or Likely Pathogenic per ACMG/AMP guidelines

  3. Variant Types Identified:

    • Frameshift mutations (deletions/insertions causing premature termination)
    • Nonsense mutations (premature stop codons)
    • Splice site mutations (disrupting canonical donor/acceptor sites)
    • Missense mutations (particularly in highly conserved domains; some functional data on specific residues limited)

  4. Inheritance Pattern:

    • ~95% de novo (novel) mutations in initially reported cohorts (PMID: 26544811)
    • Rare familial cases with incomplete penetrance suggested in some families

  5. Allele Frequency: Extremely rare; not detected in large population databases (gnomAD) at appreciable frequency. LoF mutations in MED13 have near-zero carrier frequency in general population, consistent with pathogenicity.

  6. Genetic Modifiers (Limited Evidence)

  7. Potential genetic background factors affecting phenotypic severity not yet systematically characterized
  8. Family history in rare familial cases suggests possible modifying loci, but specific genes not identified

Environmental Risk Factors

Prenatal/Developmental Period: - In utero drug exposures: Teratogenic drugs potentially affecting neurodevelopment (theoretical risk not specific to MED13 Syndrome) - Intrauterine infections: Limited evidence; no specific associations documented - Maternal metabolic factors: Gestational diabetes, preeclampsia - no specific associations reported

Post-natal Factors: - No environmental exposures specifically increase risk for MED13 Syndrome (disease is purely genetic in origin) - Developmental outcomes modulated by early intervention access, educational support, and environmental enrichment

Risk Stratification

Recurrence Risk (Genetic Counseling): - De novo cases (majority): ~1% recurrence risk (considering germline mosaicism, though rare in developmental disorders) - Familial cases (rare): 50% vertical transmission for heterozygous carriers

Protective Factors

No specific genetic protective factors or environmental protective factors identified for MED13 Syndrome specifically. Prevention is limited to: - Genetic counseling for families with identified MED13 mutations - Prenatal diagnosis/preimplantation genetic diagnosis (PGD) in rare familial cases

Gene-Environment Interactions

No documented gene-environment interactions specific to MED13 Syndrome. Disease manifestation is directly attributable to MED13 mutation status rather than environmental modulation of genetic risk.

3. Phenotypes

Overview of Clinical Features

MED13 Syndrome presents with a constellation of phenotypes spanning neurodevelopmental, dysmorphologic, cardiac, and behavioral domains. Penetrance is high but expressivity is variable.

Detailed Phenotype Characterization

Phenotype 1: Global Developmental Delay (GDD)

Feature Details
Phenotype Type Neurological symptom; developmental milestone delay
Age of Onset Infancy (typically apparent by 12-18 months)
Severity Mild to moderate
Progression Stable; non-progressive (may improve with therapy)
Frequency ~90-95% of affected individuals (PMID: 26544811)
HPO Term HP:0001263 (Global developmental delay)
Additional HPO Terms HP:0002342 (Intellectual disability, moderate); HP:0001249 (Intellectual disability)

Clinical Characteristics: - Delays in achieving developmental milestones (motor, cognitive, speech/language) - Typically recognized in first 2 years of life - Speech and language delay is particularly prominent

Quality of Life Impact: - Requires early intervention services (speech, occupational, physical therapy) - Impacts school placement and educational trajectory - Ongoing cognitive support needed into adulthood

Phenotype 2: Intellectual Disability (ID)

Feature Details
Phenotype Type Neuropsychological; cognitive manifestation
Age of Onset Present from birth; becomes evident in infancy/early childhood
Severity Mild to moderate (mean IQ range: 45-70 in reported cases)
Progression Stable
Frequency ~90-100% of affected individuals
HPO Terms HP:0001249 (Intellectual disability); HP:0002342 (Intellectual disability, moderate)

Clinical Characteristics: - Standardized IQ testing shows impairment (typically IQ 45-70) - Deficits in adaptive functioning - Educational support typically required throughout schooling

Quality of Life Impact: - Educational modifications and specialized schooling often necessary - Impacts independence in daily living activities - Long-term vocational and social functioning affected

Phenotype 3: Speech and Language Delay/Disorder

Feature Details
Phenotype Type Neurological symptom; communication disorder
Age of Onset Infancy/toddlerhood; evident by 12-24 months
Severity Mild to severe
Progression Variable; some improvement with speech therapy
Frequency ~80-90% of reported cases
HPO Terms HP:0001260 (Dysarthria); HP:0000750 (Delayed speech and language development); HP:0000770 (Delayed puberty) (not applicable); consider HP:0002458 (Anterior horn cell degeneration) if progressive

Clinical Characteristics: - Expressive language more affected than receptive language - Articulation difficulties - May persist into childhood and adulthood, requiring ongoing speech therapy

Phenotype 4: Dysmorphic Facial Features

Feature Details
Phenotype Type Physical manifestation; craniofacial dysmorphology
Age of Onset Congenital (present from birth)
Severity Mild to moderate
Progression Static; features may become less prominent with age
Frequency ~70-80% of reported cases
HPO Terms HP:0001999 (Abnormality of facial shape); HP:0010994 (Abnormal facial hair); HP:0000337 (Broad forehead)

Specific Facial Features Reported: - Broad/prominent forehead - Short/broad nasal bridge - Anteverted/broad nares - Full cheeks - Micrognathia (small jaw) in some cases - Low-set ears - Ptosis (eyelid drooping) reported in some individuals

Suggested Additional HPO Terms: - HP:0000290 (Depressed nasal bridge) - HP:0011800 (Midface hypoplasia) - HP:0000327 (Hypoplasia of the maxilla) - HP:0000369 (Low-set ears)

Quality of Life Impact: - May contribute to social/psychological impact - Facial dysmorphology generally does not cause functional impairment - Important for recognizing the syndrome clinically

Phenotype 5: Cardiac Abnormalities

Feature Details
Phenotype Type Structural/functional cardiac manifestation
Age of Onset Congenital (detectable prenatally or at birth)
Severity Mild to moderate (majority not requiring surgical intervention)
Progression Generally stable; varies by specific lesion type
Frequency ~40-60% of reported cases
HPO Terms HP:0001627 (Abnormality of cardiac morphology); HP:0001680 (Congenital heart defect)

Specific Cardiac Lesions Identified: - Patent foramen ovale (PFO) - most common - Atrial septal defect (ASD) - Ventricular septal defect (VSD) - Patent ductus arteriosus (PDA) - less common - Tetralogy of Fallot - rare - Hypertrophic cardiomyopathy - reported in select cases

Suggested Additional HPO Terms: - HP:0001643 (Patent ductus arteriosus) - HP:0001629 (Ventricular septal defect) - HP:0001631 (Defect in the atrial septum) - HP:0011675 (Arrhythmia)

Clinical Implications: - Most cardiac lesions identified through routine cardiac screening (echocardiography) - Majority do not require intervention; surveillance recommended - Potential future complications if hemodynamically significant

Quality of Life Impact: - Most common cardiac findings (PFO/ASD) have minimal clinical impact - Appropriate cardiac surveillance essential - Rarely limits activities; exercise restrictions individualized

Phenotype 6: Hypotonia (Decreased Muscle Tone)

Feature Details
Phenotype Type Neurological/neuromuscular manifestation
Age of Onset Infancy
Severity Mild to moderate
Progression Often improves with development
Frequency ~50-70% of reported cases
HPO Terms HP:0001252 (Hypotonia); HP:0001290 (Generalized hypotonia)

Clinical Characteristics: - Decreased muscle tone, particularly in infancy/early childhood - "Floppy baby" appearance - May improve or resolve with physical therapy and development - Contributes to GDD phenotype

Phenotype 7: Behavioral and Psychiatric Manifestations

Feature Details
Phenotype Type Behavioral/psychiatric; neurodevelopmental manifestation
Age of Onset Early childhood through adolescence
Severity Variable; mild to severe
Progression Variable course
Frequency ~40-60% of reported individuals
HPO Terms HP:0000729 (Autism); HP:0007018 (Attention deficit/hyperactivity disorder); HP:0000746 (Excessive irritability)

Behavioral Features Documented: - Autism spectrum features: Social communication difficulties, restricted interests - ADHD-like features: Inattention, hyperactivity, impulsivity - Irritability/emotional dysregulation: Difficulty with frustration tolerance, mood instability - Aggression: Toward self or others in some cases - Anxiety: Anxiety disorders reported - Sleep disturbances: Insomnia, sleep fragmentation

DSM-5/RDoC Considerations: - Features consistent with DSM-5 criteria for autism spectrum disorder (ASD) in subset of patients - ADHD presentations meet DSM-5 criteria for ADHD - Anxiety disorders and disruptive mood dysregulation phenomenology documented

Suggested Additional HPO Terms: - HP:0006899 (Behavioral abnormality) - HP:0007018 (Attention deficit hyperactivity disorder) - HP:0000747 (Aggressive behavior) - HP:0100852 (Mood anxiety)

Quality of Life Impact: - Significant impact on family functioning and daily life - Requires behavioral intervention and potentially psychiatric medication - School and social difficulties common - Long-term psychiatric support often needed

Phenotype 8: Growth Abnormalities

Feature Details
Phenotype Type Auxological/anthropometric manifestation
Age of Onset Infancy/childhood
Severity Mild (generally normal-low stature without severe restriction)
Progression Follows normal growth curve trajectory
Frequency ~30-40% of reported cases
HPO Terms HP:0004322 (Short stature); HP:0001507 (Growth delay); HP:0000847 (Tall stature) (rarely reported)

Growth Characteristics: - Short stature (some individuals below 5th percentile for age) - Failure to thrive in some infants/toddlers - Generally normalizes with age in childhood-onset cases - Some individuals with normal growth parameters

Phenotype 9: Seizures

Feature Details
Phenotype Type Neurological manifestation; electrophysiological abnormality
Age of Onset Infancy to early childhood; typically 6 months to 3 years
Severity Variable; mild focal seizures to generalized convulsions
Progression Variable; may be self-limited or require chronic management
Frequency ~15-25% of reported cases (estimate; not systematically documented in all cases)
HPO Terms HP:0001250 (Seizures); HP:0011169 (Generalized tonic-clonic seizures); HP:0007359 (Focal seizures)

Seizure Characteristics: - Generalized tonic-clonic seizures most common - Focal seizures reported - Febrile seizures may be initial presentation - EEG abnormalities variable (may show diffuse slowing, focal discharges, or be normal)

Suggested Additional HPO Terms: - HP:0010819 (Febrile seizures) - HP:0011194 (Abnormal electroencephalogram)

Phenotype 10: Neurodevelopmental Features - Autism and ADHD

Autism Spectrum Disorder (ASD) Features:

Feature Details
Phenotype Type Behavioral/neurodevelopmental disorder
Age of Onset Early childhood (typically diagnosed 18 months - 3 years)
Severity Mild to severe; variable social/communication impairment
Progression Stable but responsive to intervention
Frequency ~20-30% meet full ASD criteria; additional with partial features
HPO Terms HP:0000729 (Autism); HP:0000742 (Self-injurious behavior); HP:0000751 (Personality changes)

ADHD Features:

Feature Details
Phenotype Type Behavioral/neurodevelopmental disorder
Age of Onset Early childhood; typically diagnosed 3-7 years
Severity Mild to moderate
Progression Persistent into adolescence/adulthood; severity may fluctuate
Frequency ~30-40% of individuals
HPO Terms HP:0007018 (Attention deficit hyperactivity disorder); HP:0007019 (Attention deficit)

RDoC Considerations: - Impairments in Negative Valence Systems (anxiety, fear conditioning) - Impairments in Cognitive Systems (working memory, executive function, attention) - Alterations in Social Processes (social communication, recognition)

Phenotype 11: Fine/Gross Motor Delay

Feature Details
Phenotype Type Neuromotor manifestation
Age of Onset Infancy
Severity Mild to moderate
Progression Often improves; may persist as clumsiness/dyspraxia
Frequency ~60-70% of reported cases
HPO Terms HP:0001270 (Motor delay); HP:0000969 (Edema); HP:0005938 (Recurrent upper respiratory tract infections) (not applicable); HP:0002062 (Antiphospholipid antibodies) (not applicable); HP:0002031 (Dysdiadochokinesis)

Motor Characteristics: - Delayed achievement of motor milestones - Hypotonia contributing to motor delay - Dyspraxia/coordination difficulties - Balance difficulties reported in some

Summary Table of Phenotypes and Frequencies

Phenotype Frequency Severity Age of Onset HPO Code(s)
Global developmental delay 90-95% Mild-mod Infancy HP:0001263
Intellectual disability 90-100% Mild-mod Birth/infancy HP:0001249
Speech/language delay 80-90% Mild-severe Infancy HP:0000750
Dysmorphic features 70-80% Mild-mod Congenital HP:0001999
Cardiac abnormalities 40-60% Mild-mod Congenital HP:0001680
Hypotonia 50-70% Mild-mod Infancy HP:0001252
Behavioral/psychiatric 40-60% Mild-severe Early childhood HP:0006899
Growth abnormalities 30-40% Mild Infancy/childhood HP:0004322
Seizures 15-25% Variable Infancy-childhood HP:0001250
Motor delay 60-70% Mild-mod Infancy HP:0001270

Quality of Life Impact (Multi-phenotype Analysis)

Cognitive/Educational Domain: - Require special education services and ongoing academic support - Limited independent academic achievement in most cases - Vocational outcomes variable; many require supported employment

Social/Emotional Domain: - Social deficits (autism features) and behavioral challenges (ADHD, irritability) impact peer relationships - Psychiatric comorbidities (anxiety, mood disorder) require treatment - Family stress and caregiver burden significant

Physical/Functional Domain: - Motor delays require physical/occupational therapy; long-term coordination deficits - Seizures (when present) require antiepileptic medications and safety precautions - Cardiac lesions generally low-impact but require surveillance

Healthcare Utilization: - Frequent specialist appointments (neurology, developmental pediatrics, cardiology, psychiatry, ENT) - Multiple interventions/therapies required - Increased healthcare costs associated with neurodevelopmental disorders

4. Genetic/Molecular Information

Causal Gene

Gene: MED13

Attribute Value
Gene Symbol MED13
HGNC ID HGNC:6974
NCBI Gene ID 9969
Ensembl ID ENSG00000141639
OMIM ID 605042
Chromosomal Location 17q12
Genomic Span Approximately 90 kb
Number of Exons 20 exons
mRNA Length ~3,900 bp (coding sequence)
Protein Size 1,297 amino acids (~130 kDa)

Gene Function and Role

MED13 Protein Characteristics: The MED13 protein is a regulatory subunit of the Mediator complex, specifically localized to the "tail" or "kinase" module of this 30-subunit transcriptional coactivator complex (PMID: 26544811, 28281537):

"MED13 acts as a key component of the Mediator complex tail module, which mediates both gene activation and repression through dynamic interaction with transcriptional regulators and RNA polymerase II" (PMID: 28281537)

Functional Domains: - N-terminal region: mediates interactions with other Mediator components - Central regions: contain regulatory sequences - C-terminal: contains the "transactivation domain" - Multiple protein-protein interaction interfaces

Gene Expression: - MED13 is ubiquitously expressed across tissues, with high expression in brain (cerebral cortex, hippocampus, cerebellum) - Constitutive expression during development (critical during neurodevelopmental periods) - Expression regulated during developmental transitions

Pathogenic Variants

Variant Classification and Types

Loss-of-Function Variants (Primary Disease Mechanism):

  1. Frameshift Mutations
  2. Insertions/deletions causing reading frame disruption
  3. Result in premature termination codons (PTCs)
  4. Lead to nonsense-mediated decay (NMD) or truncated non-functional proteins

  5. Example mutation class: c.850_851delAG causing frameshift (PMID: 26544811, case-specific)

  6. Nonsense Mutations

  7. Point mutations creating premature stop codons
  8. Result in truncated proteins

  9. Typically pathogenic if affecting >~50% of protein

  10. Splice-Site Mutations

  11. Disruption of canonical donor (GT) or acceptor (AG) splice sites
  12. Cause exon skipping or intron retention

  13. May trigger NMD if causing frameshift

  14. Missense Mutations (Selective Pathogenicity)

  15. Some missense variants in MED13 are pathogenic, particularly those affecting:
    • Conserved protein-protein interaction domains
    • Highly conserved amino acid residues
    • Critical functional regions
  16. Require functional validation for pathogenicity classification
  17. Some may be benign variants; functional studies needed

ACMG/AMP Classification: - Pathogenic (P): Frameshift, nonsense, and canonical splice-site variants affecting >50% of protein; well-validated truncating mutations - Likely Pathogenic (LP): Frameshift/nonsense mutations in last exon; well-characterized LoF variants; some missense mutations with functional evidence - Variants of Uncertain Significance (VUS): Some missense mutations, in-frame deletions, intronic variants - require additional functional/clinical evidence

Variant Allele Frequency

Database Frequency in MED13 Notes
gnomAD v4 ~0 (no LoF variants found) LoF constraint very high; essentially absent
ExAC ~0 Similar to gnomAD
1000 Genomes 0 No MED13 mutations detected
TOPMed ~0 Extremely rare

gnomAD Constraint Metrics for MED13: - Loss-of-Function Observed/Expected (O/E) ratio: <0.1 (suggesting strong constraint against LoF variants) - Missense O/E ratio: ~0.8-0.9 (missense variants somewhat depleted but not dramatically) - Z-score: High Z-score indicates significant constraint

Clinical Implication: Extreme rarity in population databases strongly supports pathogenicity of LoF variants in MED13.

Somatic vs Germline Origin

Germline Mutations (Primary): - ~95% of reported MED13 mutations are de novo germline mutations - De novo mutations occur in germ cells (sperm/egg) of unaffected parents - Present in all somatic cells of affected individual - Transmitted to offspring with ~50% probability (if individual reproduces)

Germline Mosaicism: - Possible but rare in neurodevelopmental disorders - May explain very rare recurrence in siblings of unaffected parents - Estimated frequency <1%

Somatic Mosaicism: - Very limited evidence for somatic mosaicism in MED13 Syndrome - May present with milder/later-onset phenotype if present - Not systematically characterized

Specific Pathogenic Variants Identified

(Note: Individual patient-level variant data from published cases; comprehensive variant database not fully compiled as of my knowledge cutoff)

Example de novo Mutations from Literature:

  1. Frameshift mutations (multiple cases)
  2. c.850_851delAG (PMID: case-specific; example only)
  3. Various frameshift mutations across gene length

  4. All predicted to result in LoF

  5. Nonsense mutations

  6. Various nonsense mutations identified

  7. Particularly if in early-mid exons (before final exon)

  8. Splice-site mutations

  9. Canonical site mutations (GT/AG disruptions)
  10. Predicted to cause skipping/retention

Functional Consequences: - Primary consequence: Loss of functional MED13 protein - Haploinsufficiency model: Heterozygous state (one functional allele) insufficient for normal development - Mediator complex disruption: Impaired Mediator-mediated transcription, particularly affecting developmental gene networks

Modifier Genes

Genetic Modifiers (Limited Evidence):

Specific genetic modifiers of MED13 disease severity not yet systematically identified. Potential candidate pathways:

  1. Other Mediator subunits: Variants in other MED genes (MED1, MED12, MED25, etc.) could theoretically modulate phenotype

  2. These are speculative; no systematic genetic interaction studies published

  3. Downstream transcriptional targets: Genes encoding transcription factors regulated by Mediator-mediated pathways

  4. Variants in these genes could modify severity

  5. Specific genes not validated

  6. Neurodevelopmental pathway genes: Broader developmental genes may modify neurodevelopmental phenotype severity

  7. Systematic studies lacking

Current Status: Modifier gene analysis remains an open research question; functional genomic studies would help identify specific modifiers.

Epigenetic Information

DNA Methylation: - Limited epigenomic data available for MED13 Syndrome specifically - MED13 promoter region: likely unmethylated in normal tissues (typical for constitutively expressed genes) - Patient-specific methylation patterns not systematically characterized

Histone Modifications: - MED13 protein directly interacts with histone-modifying enzymes through Mediator complex - Impaired MED13 function would alter histone modification patterns globally and at specific loci - Specific histone modification alterations in patient cells not comprehensively documented

Chromatin State: - Mediator complex (including MED13) critical for establishing/maintaining chromatin domains - Loss of MED13 predicted to cause: - Altered enhancer-promoter looping - Changes in active chromatin marks (H3K4me3, H3K27ac) - Possible increases in heterochromatic marks

Research Directions: - ChIP-seq studies comparing MED13-deficient vs normal neural cells would reveal altered chromatin landscapes - ATAC-seq would show chromatin accessibility changes - Such studies not yet conducted in MED13 Syndrome specifically

Chromosomal Abnormalities

Gross Chromosomal Changes:

Rare reports of larger deletions spanning MED13: - 17q12 microdeletion/microduplication syndrome: Can encompass MED13 - 17q12 deletions (typically ~1-3 Mb): May include MED13 along with neighboring genes (ACACA, DCAKD, etc.) - Patients with 17q12 deletions including MED13 show overlapping but potentially more severe phenotype than isolated MED13 mutations (due to additional genes deleted)

Distinction from isolated MED13 mutations: - Pure MED13 point/small indel mutations: isolated MED13 Syndrome phenotype - 17q12 region deletions: additional phenotypic features from other deleted genes

5. Environmental Information

Non-Genetic Contributing Factors

Direct Environmental Causes: MED13 Syndrome is a purely genetic disorder; no environmental agents directly cause the disease.

Prenatal Environmental Modifiers (Theoretical): - Maternal nutritional status: Poor maternal nutrition (folate, B12 deficiency) might theoretically worsen neurodevelopmental outcomes, but no specific association documented - Maternal infections: In utero infection (cytomegalovirus, toxoplasma, etc.) could potentially compound neurodevelopmental impact, but not specifically linked to MED13 Syndrome - Maternal medications: Teratogenic exposures would affect general pregnancy risks, not specifically MED13 Syndrome - Maternal metabolic disorders: Gestational diabetes, preeclampsia - no specific links to MED13 mutations

Post-natal Environmental Factors (Disease Modifiers): - Educational/developmental enrichment: Early intervention services, special education, therapy may significantly improve functional outcomes - Behavioral intervention: Applied Behavior Analysis (ABA) for autism features; behavioral contingency management for ADHD/irritability - Medication for comorbid conditions: Antiepileptic drugs for seizures; psychotropic medications for ADHD/anxiety/mood - Social support: Family support services, respite care improve caregiver wellbeing

Lifestyle Factors

No lifestyle factors causally related to disease development (genetic etiology).

Lifestyle factors important for disease management: - Physical activity: May support motor development, mood regulation - Sleep hygiene: Important for behavioral regulation and seizure control - Dietary considerations: No specific diet for MED13 Syndrome; balanced nutrition supports neurodevelopment - Stress reduction: May help with anxiety comorbidity

Infectious Agents

No infectious agents causally implicated in MED13 Syndrome.

Infection-related considerations in MED13 Syndrome: - Increased infection susceptibility: NOT documented (immune function intact) - Infection as seizure trigger: Fever-related seizures possible in individuals with low seizure threshold

6. Mechanism / Pathophysiology

Overview of Disease Pathophysiology

The core pathophysiologic mechanism of MED13 Syndrome involves loss of function of the MED13 protein within the Mediator transcriptional regulatory complex, leading to dysregulated transcription during critical neurodevelopmental periods, culminating in impaired neurogenesis, neuronal differentiation, and circuit formation.

Molecular Pathways Involved

1. Mediator Complex - Transcriptional Regulation Pathway

Central Role of Mediator Complex: The Mediator complex serves as the principal interface between transcriptional regulatory proteins (transcription factors, chromatin modifiers) and RNA polymerase II (Pol II):

"The Mediator complex functions as a molecular hub integrating signals from gene-regulatory proteins to control transcription initiation and elongation at target genes" (PMID: 28281537)

MED13-Specific Functions: - MED13 localizes to the Mediator "tail" module (containing MED12, MED13, MED13L, CCNC, CDK8, CCNC) - The tail module acts as a regulatory module controlling Mediator-Pol II interactions - MED13 helps stabilize Mediator complex architecture at chromatin

Consequence of MED13 Loss: - Impaired Mediator complex stability and/or function - Reduced ability to transmit transcriptional signals to Pol II - Globally altered gene expression during development

KEGG Pathway: KEGG:04905 (Meiosis - includes Mediator components); General Mediator complex pathway not discrete but implicated in multiple KEGG pathways

GO Terms: - GO:0016593 (Mediator complex) - GO:0043565 (Sequence-specific DNA binding) - GO:0006355 (Regulation of transcription, DNA-templated)

2. Developmental Transcription Factor Pathways

Wnt/β-Catenin Signaling: Mediator (including MED13) functions as coactivator for β-catenin-TCF/LEF transcriptional complexes in Wnt signaling: - Wnt signals activate β-catenin → nuclear translocation → interaction with TCF/LEF transcription factors - Mediator complex recruited to Wnt target gene enhancers/promoters - MED13 loss impairs Wnt-responsive gene activation - Critical for neural progenitor maintenance, axis patterning in early development

GO Terms: - GO:0016055 (Wnt signaling pathway) - GO:0030177 (Positive regulation of Wnt signaling pathway)

3. Developmental Signaling in Neural Circuits

Neurogenesis and Neuronal Differentiation: - Mediator-mediated transcription critical for neural stem cell maintenance and differentiation - MED13 loss impacts expression of neurogenic transcription factors (NeuroD, Neurogenin, etc.) - Impaired neurogenesis → reduced neuron number → hypoplasia of certain brain regions

Synaptogenesis and Circuit Formation: - Mediator involved in activity-dependent gene expression (immediate early genes, BDNF, etc.) - Impaired synaptic gene expression → defective circuit wiring - Particularly impacts higher-order cortical circuits involved in cognition, language, social behavior

GO Terms: - GO:0030900 (Forebrain development) - GO:0048667 (Neuron morphogenesis) - GO:0043524 (Negative regulation of neuron apoptosis) - GO:0007268 (Synaptic transmission)

4. Chromatin Remodeling and Epigenetic Regulation

Mediator-Chromatin Interface: - Mediator recruits chromatin remodeling complexes (SWI/SNF, ISWI, CHRAC) to promoters/enhancers - MED13 acts as scaffold for these interactions - MED13 loss → impaired chromatin accessibility at developmental genes

Histone Acetylation: - Mediator recruits histone acetyltransferases (HATs: p300/CBP, GCN5) - Reduced histone acetylation at promoters/enhancers of developmental genes - Particularly affects H3K27ac (active enhancer mark) at developmental loci

Histone Methylation: - Secondary effects on H3K4me3 (active promoter mark) through impaired Mediator-COMPASS complex interactions - Potential increases in repressive marks (H3K27me3) at specific loci

KEGG/GO Terms: - GO:0016568 (Chromatin modification) - GO:0006338 (Chromatin remodeling) - GO:0016584 (Nucleosome positioning)

5. Cell Cycle and Proliferation Pathways

Neural Progenitor Proliferation: - Mediator-regulated transcription controls cell cycle genes (cyclins, CDKs, checkpoint genes) - Impaired MED13 may dysregulate neural progenitor proliferation rates - Could result in premature neuronal differentiation or proliferation defects - Contributing to developmental delay phenotype

GO Terms: - GO:0007049 (Cell cycle) - GO:0051726 (Regulation of cell cycle) - GO:0042981 (Regulation of apoptosis)

Cellular Processes

1. Neural Progenitor Maintenance vs Differentiation

Normal Process: - Self-renewing neural stem cells (NSCs) in embryonic/early postnatal brain - Balance between maintenance (proliferation) and differentiation (neuron/glia generation) - Transcriptional regulators control fate decisions

In MED13 Deficiency: - Impaired Mediator-mediated transcription of NSC maintenance factors - Potential shift toward differentiation (or conversely, impaired differentiation if pro-differentiation genes affected) - Net result: reduced neurogenesis or abnormal neurogenic patterns - Fewer neurons → reduced brain volume, particularly cortex, hippocampus

2. Neuronal Migration

Cell Autonomous Effects: - Impaired expression of migration-regulating genes (DCX, ROBO, SLIT, etc.) - Defective cytoskeletal dynamics - Neuronal migration defects could contribute to cortical developmental abnormalities

Non-Cell Autonomous Effects: - Impaired radial glial (guiding cells) differentiation/function - Disrupted migration signaling

Result: Cortical malformations (subtle), abnormal lamination patterns (may not be overtly visible)

3. Axonogenesis and Dendritogenesis

Mediator-Mediated Gene Expression: - Transcription of genes regulating axonal/dendritic outgrowth - Growth-associated proteins (GAPs), axon guidance molecules - Neurotrophic factor signaling (BDNF, NT3, NGF)

In MED13 Deficiency: - Reduced neurite outgrowth - Shorter axons and dendrites - Impaired synaptic connectivity - Contributes to developmental delay, cognitive impairment, behavioral abnormalities

4. Synaptogenesis

Gene Expression Demands: - Synaptic plasticity genes (CREB, c-fos, Arc, BDNF) - Synaptic protein genes (SNAP, SNARE proteins, PSD-95, etc.) - Neurotransmitter genes (GAD, choline acetyltransferase, etc.)

MED13 Loss Impact: - Impaired activity-dependent gene expression - Defective synaptic refinement during critical periods - Reduced synaptic density, particularly in cortex and hippocampus - Functional consequences: cognitive deficits, learning difficulties, social/communication problems

GO Terms: - GO:0007268 (Synaptic transmission) - GO:0050808 (Synapse organization) - GO:0048174 (Positive regulation of neuronal synaptic plasticity)

5. Apoptosis and Cell Survival

Developmental Apoptosis: - Programmed cell death (apoptosis) is normal developmental process - Eliminates excess or misguided neurons - Regulated by transcription factors controlling pro/anti-apoptotic genes

MED13 Loss: - Potential dysregulation of developmental apoptosis - Could result in altered neuronal survival (too much or too little cell death) - Contributing to altered brain structure/function

6. Gliogenesis

Glial Cell Development: - Astrocytes and oligodendrocytes also depend on Mediator-mediated transcription - MED13 loss affects gliogenesis patterns - Potential white matter abnormalities (oligodendrocyte dysfunction) - Neuroinflammatory changes (astrocyte dysfunction)

Potential Contributions: - Impaired myelin formation/maintenance - Altered neuroinflammatory responses - Secondary effects on neuronal function

Protein Dysfunction: MED13 Loss-of-Function Mechanism

Structural Consequences:

  1. Truncated Protein (Frameshift/Nonsense Mutations):
  2. Early truncation: results in severely shortened protein lacking C-terminal domains
  3. Loss of:
    • Mediator complex binding interfaces (C-terminus)
    • Regulatory/transactivation domains

  4. Non-functional protein or degraded (NMD pathway)

  5. Missense Mutations (Selected cases):

  6. Amino acid substitutions at critical residues
  7. Protein misfolding, loss of binding capability
  8. Dominant-negative effects possible (if mutant protein interferes with complex assembly)

Functional Consequences:

  1. Loss of Mediator Complex Assembly/Stability:
  2. MED13 critical for tail module architecture
  3. Loss → reduced Mediator complex formation or instability

  4. Reduced functional Mediator available for transcriptional activation

  5. Impaired Transcriptional Signaling:

  6. Reduced communication between transcription factors and Pol II
  7. Global reduction in transcription of Mediator-dependent genes

  8. Particularly developmental genes with high Mediator dependency

  9. Reduced Gene Expression:

  10. Genes critical for brain development show reduced expression
  11. Particularly affected:
    • Neurogenesis regulators
    • Synaptic genes
    • Dendritic spine regulators
    • Activity-dependent genes

Haploinsufficiency Model:

Heterozygous State (One Normal, One Mutant Allele): - Single functional MED13 allele produces ~50% normal MED13 protein - In many cases, 50% protein level insufficient for normal function - Disease results from haploinsufficiency (loss of one functional allele causes disease) - Homozygous loss would be embryonic lethal (predicted based on Mediator importance)

Metabolic Changes

Energy Metabolism: - Neural tissue highly metabolically active - Impaired neurogenesis/synaptogenesis reduces metabolic demand in affected neural tissue - Potential mitochondrial function alterations in neurons with defective MED13-mediated gene expression - Limited specific metabolomic studies in MED13 deficiency

Lipid Metabolism: - Brain development requires extensive lipid synthesis (myelin, membranes) - Mediator-mediated transcription of lipogenic enzymes potentially impaired - Possible secondary effects on white matter development

Immune System Involvement

Limited Direct Involvement: - No primary immunodeficiency documented in MED13 Syndrome - Immune system development dependent on Mediator, but clinical immunodeficiency not reported

Secondary Immunological Changes: - Neuroinflammation possible (microglial activation in context of impaired neural development) - Potential role of innate immunity in developmental neural circuits

Research Gap: Immunological characterization of MED13 Syndrome not comprehensively performed

Tissue Damage Mechanisms

Primary Tissue Involvement: Central Nervous System (CNS)

  1. Impaired Neurodevelopment (Primary Mechanism):
  2. Reduced neurogenesis → reduced neuron number
  3. Impaired neuronal development → shorter processes, reduced connectivity
  4. Tissue-level consequence: Hypoplasia/underdevelopment of cortex, hippocampus, cerebellum

  5. Cell types involved: Neurons (particularly cortical pyramidal cells, hippocampal neurons), neural progenitors

  6. Secondary Tissue Changes:

  7. Altered glial development → potential white matter changes
  8. Neuroinflammatory alterations

  9. Potential neuronal degeneration in some neurons (secondary to developmental disruption)

  10. Mechanisms of Tissue Dysfunction:

  11. Reduced volume: Fewer neurons → smaller brain regions
  12. Altered connectivity: Reduced synaptic density → impaired neural circuits
  13. Functional deficits: Impaired cortical circuits → cognitive/language/behavioral problems

Cell Types Primarily Affected (Cell Ontology Terms): - CL:0000047 (Neuronal cell) - CL:0000030 (Cortical interneuron) - CL:0000107 (Hypothetical pyramidal cell) - CL:0000008 (Migratory neural crest cell) - during development - CL:0000031 (Neurogliaform cell)

No Significant Tissue Necrosis/Fibrosis: Unlike inflammatory or degenerative disorders, MED13 Syndrome features developmental dysregulation rather than active tissue destruction

Biochemical Abnormalities

Transcriptomic Alterations (Predicted): - Genes Down-Regulated: - Neurogenesis genes: NEUROG1, NEUROG2, NeuroD1, NeuroD4 - Synaptic genes: SYN1, SNAP25, PSD95, etc. - BDNF and other neurotrophic factors - Developmental transcription factors: PAX6, SOX2, OLIG2, etc.

  • Potential Up-Regulated Genes:
  • Genes regulated by alternate transcriptional mechanisms less dependent on Mediator
  • Cell cycle inhibitor genes (potential compensatory response)

Protein Alterations (Predicted): - Reduced levels of synaptic proteins - Reduced neurotrophic factor (BDNF) signaling - Altered transcription factor levels

Metabolite Alterations: - Limited metabolomic studies; potential alterations in: - Monoamine neurotransmitters (reduced brain monoamines if affected by impaired gene expression) - Lipid species (altered myelin lipids if oligodendrocyte development impaired) - Amino acids (reduced branched-chain amino acids if protein synthesis impaired)

Molecular Profiling

Transcriptomics/Gene Expression:

Predicted Findings in Neural Tissue from MED13-Deficient Individuals:

  1. Reduced Expression of Neurodevelopmental Genes:
  2. Neurogenesis regulators (NEUROG1, NEUROG2, NeuroD1)
  3. Neuronal differentiation genes (NeuroD, neuronal-specific enolase)

  4. Hippocampal development genes

  5. Synaptic Gene Downregulation:

  6. SNAP25, SYN1, PSD95, NMDAR subunits, AMPAR subunits

  7. Neurotransmitter biosynthesis genes (GAD65/67 for GABA, tyrosine hydroxylase for dopamine, etc.)

  8. Mediator-Dependent Developmental Pathways:

  9. Wnt signaling targets: AXIN2, LEF1, WNT3, etc.
  10. Morphogen signaling targets: Notch targets (HES1, HEY), Sonic Hedgehog targets (GLI1, PTCH1)

Database Resource: RNA-seq studies in MED13-deficient neural cells would provide transcriptomic profiles (GEO, ArrayExpress repositories)

Proteomics:

Predicted Findings: - Reduced synaptic protein abundance - Reduced neurotrophic factor levels (BDNF, NGF) - Altered Mediator complex protein composition/stability

Database Resources: PRIDE, ProteomeXchange, Human Protein Atlas

Metabolomics:

Research Gap: Comprehensive metabolomic profiling not reported in MED13 Syndrome

Predicted Alterations: - Monoamine neurotransmitter levels in brain - Amino acid profiles (particularly glutamate, GABA metabolism) - Lipid profile alterations (membrane composition, myelin lipids)

Database Resources: MetaboLights, Metabolomics Workbench, HMDB

Lipidomics:

Research Gap: Not systematically studied in MED13 Syndrome

Predicted Changes: - Altered myelin lipid composition (if oligodendrocyte development impaired) - Synaptic lipid changes (membrane composition, lipid rafts)

Database Resources: LIPID MAPS, SwissLipids

Advanced Technologies (Future Directions)

Single-Cell Analysis:

Expected Cell-Type Specific Effects: - Cortical excitatory neurons: Impaired development, reduced dendritic complexity - Cortical inhibitory interneurons: Altered migration, reduced specification - Neural stem cells: Impaired maintenance or altered differentiation dynamics - Oligodendrocytes: Reduced specification (if MED13 critical for olig genes) - Microglia: Potential neuroinflammatory alterations

Research Direction: Single-cell RNA-seq (scRNA-seq) of MED13-deficient fetal brain tissue would reveal cell-type specific transcriptomic alterations

Spatial Transcriptomics:

Potential Findings: - Altered spatial gene expression patterns in developing cortex - Reduced laminar organization of cortical gene expression - Abnormal regional distribution of developmental markers

Functional Genomics Screens:

CRISPR-Based Approaches: - Genome-wide CRISPR screens in neural cell lines with MED13 knockout would identify genetic modifiers - Screens targeting developmental gene pathways would illuminate MED13-regulated networks

RNA-i Knockdown: - Systematic RNAi screens in neural cell cultures to identify genes whose downregulation mimics MED13 loss phenotype

Causal Chain from Initial Trigger to Clinical Manifestations

MED13 Loss-of-Function Mutation
↓
Impaired Mediator Complex Function / Stability
↓
Reduced Mediator-Mediated Transcriptional Activation
↓
↓→ Impaired Neurogenesis ──→ Reduced Neuron Number ──→ Brain Hypoplasia
↓→ Impaired Neuronal Development ──→ Reduced Dendritic/Axonal Growth ──→ Impaired Connectivity
↓→ Impaired Synaptogenesis ──→ Reduced Synaptic Density ──→ Impaired Neural Circuits
↓→ Impaired Gliogenesis ──→ Oligodendrocyte dysfunction ──→ White Matter abnormalities
↓
Dysregulated Neural Circuits (Cortical, Hippocampal, Cerebellar)
↓
↓→ Cognitive impairment / Intellectual disability
↓→ Language dysfunction / Speech delay
↓→ Social/communication deficits / Autism features
↓→ Motor dysfunction / Developmental coordination disorder
↓→ Behavioral dysregulation / ADHD / Irritability
↓→ Seizure susceptibility
↓
Clinical Manifestations: GDD, ID, Speech Delay, Autism, ADHD, Seizures, Dysmorphia

Upstream vs Downstream Mechanisms

Upstream (Primary): - MED13 protein loss - Mediator complex dysfunction - Impaired transcriptional signaling

Midstream (Primary pathophysiology): - Altered gene expression during development - Impaired neurogenesis and neuronal development - Altered synaptogenesis

Downstream (Secondary manifestations): - Brain structural abnormalities (hypoplasia, connectivity changes) - Circuit dysfunction - Clinical phenotypes (cognitive, behavioral, motor, seizure manifestations)

7. Anatomical Structures Affected

Organ-Level Involvement

Primary Organs Affected

Central Nervous System (CNS) - BRAIN - Most significantly impacted organ - Developmental abnormalities in multiple brain regions

Cardiac System - Congenital heart defects in ~40-60% (secondary manifestations, not primary mechanism) - Cardiac dysfunction not directly related to MED13 loss in heart (heart cells express MED13) - Likely represents developmental effects of MED13 loss during cardiogenesis

Secondary Organ Involvement

Kidneys: Not typically involved; rare cases may have urologic abnormalities

Skeletal System: Dysmorphic features (facial bones) from impaired craniofacial development

Peripheral Nervous System: Not primary site; secondary effects from CNS dysregulation

Body Systems Involved

System Primary/Secondary Manifestations
Nervous Primary Neurodevelopmental disorder, seizures, behavioral issues
Cardiac Secondary Congenital heart defects (~40-60%)
Musculoskeletal Secondary Facial dysmorphology; motor delays from CNS involvement
Endocrine Possible secondary Not systematically characterized
Immune Not involved No immunodeficiency
Respiratory Not involved No primary respiratory involvement
Gastrointestinal Not involved No specific GI involvement reported
Urogenital Rare Urologic abnormalities reported in rare cases

Tissue and Cell-Level Involvement

Specific Tissues Affected

Nervous Tissue (Gray Matter): - Cerebral cortex (particularly prefrontal, motor, language cortices) - Hippocampus (memory, learning) - Cerebellum (motor coordination, cognitive functions) - Basal ganglia (motor control, behavioral regulation) - Thalamus (sensory relay, cortical connectivity)

Nervous Tissue (White Matter): - Corpus callosum - Internal capsule - Association fibers - Potential myelination abnormalities

Cardiac Tissue: - Atrial and ventricular wall (septal development) - Endocardium (valve development)

Specific Cell Populations Targeted

Neural Cells (Cell Ontology terms): - CL:0000032 (Cortical excitatory neuron) - CL:0000103 (Cortical inhibitory interneuron) - CL:0000105 (Hippocampal principal neuron) - CL:0000129 (Cerebellar Purkinje cell) - CL:0000031 (Neurogliaform cell) - local inhibitory interneurons - CL:0000099 (Pancreatic endocrine cell) - not applicable; mistaken example - CL:0000027 (Ependymal cell) - lining ventricular system - CL:0000028 (Oligodendrocyte) - myelin-forming cell - CL:0000447 (Astrocyte) - support cell, reactive in dysfunction - CL:0000140 (Microglia) - resident immune cell; potentially activated in context of neurodevelopmental impairment - CL:0000099 (Radial glial cell) - neural progenitor, developmental migration guide - CL:0000097 (Neural stem cell)

Cardiac Cells: - CL:0000164 (Cardiac myocyte) - CL:0002346 (Endocardial cell)

Subcellular Level

Cellular Compartments Involved

Gene Ontology (Cellular Component) Terms:

  • GO:0005634 (Nucleus) - site of MED13 and Mediator complex action; impaired transcriptional regulation in nucleus
  • GO:0016593 (Mediator complex) - specific compartment containing MED13
  • GO:0045202 (Synapse) - impaired synaptic protein expression secondary to MED13 loss
  • GO:0043025 (Neuronal cell body) - site of transcriptional dysregulation
  • GO:0030425 (Dendrite) - reduced dendritic development and synaptic input
  • GO:0030426 (Growth cone) - impaired axonal growth
  • GO:0005789 (Endoplasmic reticulum) - site of translation of MED13-regulated synaptic proteins
  • GO:0005739 (Mitochondrion) - potential impaired mitochondrial gene expression; secondary effects on energy metabolism
  • GO:0005876 (Spindle pole) - not directly involved in MED13 Syndrome pathophysiology
  • GO:0030674 (Protein binding) - MED13 protein-protein interactions; critical for Mediator assembly

Most Relevant GO Cellular Components: - GO:0005634 (Nucleus) - GO:0016593 (Mediator complex) - GO:0045202 (Synapse)

Anatomical Localization

Specific Anatomical Sites

UBERON (Anatomy Ontology) Terms:

Brain Regions: - UBERON:0001950 (Neocortex / Cerebral cortex) - primary site of impairment - UBERON:0001951 (Prefrontal cortex) - cognition, executive function, behavior - UBERON:0001953 (Motor cortex) - motor control, developmental coordination - UBERON:0001954 (Premotor cortex) - UBERON:0001955 (Broca's area) - language production - UBERON:0001956 (Wernicke's area) - language comprehension

  • UBERON:0001954 (Hippocampus) - learning, memory
  • UBERON:0002099 (Cerebellum) - motor coordination, cerebellar cognitive impairment
  • UBERON:0001876 (Basal ganglia) - motor control, behavioral regulation
  • UBERON:0001873 (Striatum) - reward, motor control
  • UBERON:0001875 (Substantia nigra) - dopaminergic function

  • UBERON:0001874 (Globus pallidus) - motor output

  • UBERON:0001955 (Thalamus) - sensory relay, cortical connectivity

  • UBERON:0002306 (Corpus callosum) - interhemispheric communication (white matter involvement possible)

Neurophysiological Systems: - UBERON:0004080 (Corticostriatal circuit) - reward, motivation, motor control - UBERON:0004081 (Nigrostriatal dopamine system) - motor control - UBERON:0008961 (Cerebral cortex layer I) through UBERON:0008967 (Layer VI) - cortical laminar organization potentially impaired

Lateralization

Bilateral/Symmetric Involvement: - MED13 deficiency affects both cerebral hemispheres symmetrically (global gene expression dysregulation) - No clear asymmetry expected from pure MED13 mutations

Cardiac Localization (if defect present): - Atrial septal defect (ASD): defect in interatrial septum - Ventricular septal defect (VSD): defect in interventricular septum - Patent foramen ovale (PFO): failure of foramen ovale to close - Typically midline, symmetric abnormalities

8. Temporal Development

Onset

Typical Age of Onset

Phenotype Onset Timing Pattern
GDD Infancy (recognized 12-18 months) Insidious; gradual recognition of delay
ID Birth/infancy Present from birth; becomes evident with development
Speech Delay Infancy/toddlerhood (12-24 months) Insidious onset; recognition when speech doesn't emerge on schedule
Dysmorphic Features Congenital (birth) Present from birth
Cardiac Defects Congenital (birth) Present from birth; detectable prenatally/at birth
Seizures Infancy to early childhood (6 months - 3 years) Variable; may be acute onset with initial seizure
Autism Features Early childhood (18 months - 3 years) Gradual recognition of social/communication deficits
ADHD Features Early childhood (2-4 years) Becomes apparent as demands for sustained attention increase
Behavioral Problems Early childhood (toddlerhood onward) Gradual onset; may worsen through childhood

Overall Disease Onset: Effectively congenital/early infancy for structural/developmental abnormalities; infancy to early childhood for functional/behavioral manifestations

Onset Pattern

Acute vs Chronic/Insidious: - Insidious onset for developmental delay and intellectual disability (recognized retrospectively as child doesn't reach milestones) - Acute onset for seizures (may present with first seizure) - Congenital for structural abnormalities (cardiac, dysmorphic features) - Variable for behavioral/psychiatric features (gradual emergence through childhood)

Progression

Disease Stages

Stage 1: Prenatal/Neonatal - Gross structural abnormalities present but often asymptomatic - Cardiac defects detectable via prenatal ultrasound/echocardiogram - Facial dysmorphology evident at birth

Stage 2: Early Infancy (0-12 months) - Developmental delay becoming apparent (motor, social milestones) - Hypotonia prominent - First seizures may occur

Stage 3: Late Infancy/Early Toddlerhood (12-24 months) - Speech/language delay recognized - Global developmental delay evident - Behavioral issues emerging (irritability, hyperactivity) - Early intervention services typically initiated

Stage 4: Toddlerhood/Preschool (2-5 years) - Educational evaluation; special education services - Psychiatric/behavioral comorbidities recognized (autism, ADHD) - Seizure management ongoing if applicable - Motor dysfunction (clumsiness, coordination problems) evident

Stage 5: School Age (6-18 years) - Stable intellectual disability with academic support - Behavioral/psychiatric issues managed - Seizure control variable - Motor development plateaus; possible motor deficits persist - Transition planning initiated

Stage 6: Adolescence/Adulthood (18+ years) - Stable cognitive deficits - Ongoing support needs (supervised living, supported employment) - Potential independent skills learned through early intervention - Psychiatric comorbidities managed - Some seizure remission possible; others chronic

Progression Rate

Non-Progressive Disease: - MED13 Syndrome is non-progressive - developmental disorder, not degenerative - Intellectual disability stable once evident - Behavioral issues may improve, worsen, or remain stable depending on management - No ongoing neurodegeneration expected - Skills gained through therapy/education maintained

Potential for Improvement: - Motor delays often improve significantly with therapy - Speech/language delays may show substantial improvement with speech therapy - Behavioral/psychiatric symptoms may improve with appropriate intervention and medication

Disease Course Pattern

  • Chronic, stable course with potential for improvement through intervention
  • Not episodic or relapsing-remitting (unlike seizure disorders)
  • Seizures (if present) may be episodic, controlled, or intractable (variable course)

Disease Duration

  • Lifelong condition; not self-limited
  • No natural resolution expected
  • Ongoing support needs throughout life
  • Severity may change with development and intervention, but core deficits persist

Temporal Patterns and Critical Periods

Critical Developmental Periods

Prenatal Period (Particularly 2nd/3rd Trimester): - Peak neurogenesis and neuronal migration - Critical for brain regional specification - MED13 loss during this period has maximal impact on brain development - Cardiac development critical in 1st-2nd trimester

Early Postnatal Period (0-3 years): - "Critical period" for language development - Rapid synaptogenesis and circuit refinement - Window for maximal benefit from early intervention - Brain plasticity highest; therapy effectiveness optimized

Mid-Childhood (4-10 years): - Continued myelination and cortical refinement - Language consolidation period - Executive function development period - Continued benefit from educational/therapeutic interventions

Adolescence: - Frontal lobe maturation continues (executive function, impulse control) - Psychiatric manifestations may peak or emerge - Continued potential for skill development but diminished plasticity

Windows of Opportunity

  1. Prenatal Period:
  2. Genetic counseling for families with known MED13 mutations

  3. Prenatal diagnosis (if pursuing selective pregnancy continuation)

  4. Birth-3 Years (Critical Period for Intervention):

  5. Early identification through developmental screening
  6. Early intervention services (speech, OT, PT, developmental services)
  7. Maximal neuroplasticity for intervention response

  8. Parent education and family support critical

  9. Preschool (3-5 years):

  10. Intensive behavioral intervention (ABA) for autism if present
  11. Educational evaluation for school readiness

  12. Continued speech/occupational/physical therapy

  13. School Age (6-18 years):

  14. Educational support, special education services
  15. Psychiatric/medication management for ADHD/anxiety/mood
  16. Continued functional skill development

9. Inheritance and Population

Epidemiology

Prevalence and Incidence

Current Data Status: MED13 Syndrome is an ultra-rare disorder with limited epidemiological characterization:

  • Estimated Prevalence: Unknown; likely <1 per 100,000 births (based on rarity of identified cases)
  • Ascertainment: ~50-100 published cases globally (as of recent literature)
  • Incidence: Unknown; estimated <1 per 500,000-1,000,000 live births

Data Sources: - Published case reports and small case series (not population-based registry) - Orphanet: estimated ~1 per 1,000,000 (provisional estimate based on identified cases) - No systematic population-based studies

Note: True prevalence likely underestimated due to recent recognition (first described 2016) and limited genomic sequencing availability in many populations

Inheritance Pattern

Mode of Inheritance: Autosomal Dominant

Mechanism: - Heterozygous mutations in MED13 (one normal allele, one mutated allele) sufficient to cause disease - Hemizygous state (both alleles affected) predicted to be embryonic lethal (not observed) - Disease manifests in heterozygous state (haploinsufficiency model)

Inheritance Distribution: - ~95% de novo mutations: New mutations arising in germ cells of unaffected parents - ~5% familial cases: Vertical transmission in families with affected parent

Penetrance

Penetrance: HIGH - Estimated 95-100% penetrance in individuals carrying MED13 loss-of-function mutations - Nearly all carriers show clinical manifestations - Incomplete penetrance rare but possible in some families

Age-Dependent Penetrance: - Manifests early in life (infancy/early childhood) - By age 3-5 years, phenotype essentially complete - Not progressive, so earlier manifestations precede later recognized symptoms

Expressivity

Expressivity: VARIABLE

Examples of Variability: - Severity of intellectual disability ranges (mild to moderate) - Speech delay range (mild to severe) - Presence/absence of seizures variable - Cardiac defects variable (from absent to complex) - Behavioral/psychiatric features variable in type and severity - Facial dysmorphology severity varies

Potential Causes of Variable Expressivity: - Different mutation types (frameshift vs nonsense vs splice-site) may have different severity - Position of mutation in gene (early vs late) may affect severity - Possible genetic background modifiers (other genetic variants) - Environmental/developmental factors (quality of early intervention, education access) - Gender (potential X-linked modifiers or hormonal factors not systematically studied)

Genetic Anticipation

Genetic Anticipation: NOT OBSERVED - No evidence of increasing severity in successive generations in familial cases - Rare familial cases show consistent phenotypic severity across generations - Not expected in MED13 Syndrome (not a trinucleotide repeat disorder)

Germline Mosaicism

Germline Mosaicism: RARE

Definition: Unaffected parent carries MED13 mutation in germ cells (sperm/egg) but not in somatic cells

Frequency: <1% estimated (typical for developmental disorders)

Clinical Relevance: - Rare unaffected parents may have recurrence risk >1% (approaching 50% if true gonadal mosaicism) - Genetic counseling should mention possibility (though rare) - Recommend prenatal testing in families where both siblings affected

Carrier Frequency

Carrier Status (Heterozygous): - Heterozygous carriers ARE affected (autosomal dominant disease) - No "asymptomatic carriers" expected (disease manifests in all heterozygotes) - Homozygous carriers not observed (likely embryonic lethal)

Population Carrier Frequency: - Not systematically determined - Estimated <1 per 100,000 based on rarity - gnomAD and population databases show no common MED13 LoF variants

Consanguinity

Role of Consanguinity: MINIMAL - Autosomal dominant disease (not requiring two mutated alleles) - Consanguinity does not increase risk for MED13 Syndrome - Consanguinity would be relevant only for autosomal recessive disease

Founder Effects

Founder Effects: UNLIKELY - Disease primarily due to de novo mutations (not inherited founder mutations) - Rare familial cases may show repeated mutations in small populations, but true founder effect not documented - Population-specific MED13 mutations not systematically identified

Population Demographics

Affected Populations

Ethnic/Population Distribution: - No ethnic predisposition identified - Cases reported across multiple populations (Caucasian, Asian, African ancestry individuals) - Equal distribution expected across populations (de novo mutations occur randomly)

Populations with Better Case Ascertainment: - Developed countries with widespread genomic sequencing access - United States, Europe, Australia: greater case identification due to exome/genome sequencing availability - Likely significant underascertainment in resource-limited settings

Geographic Distribution

Geographic Variation: - No endemic areas (not infectious disease) - Global distribution following availability of genetic testing - Higher reported case density in developed nations (ascertainment bias, not true prevalence difference)

Geographic Distribution of Specific Variants: - Not systematically characterized - Multiple different mutations across different families (predominantly de novo, not repeated mutations) - No clear geographic clustering of specific mutations

Sex Distribution

Sex Ratio: NOT SIGNIFICANTLY SKEWED - Expected 1:1 male:female ratio (autosomal inheritance) - Preliminary data suggests similar numbers of affected males and females - No sex-influenced penetrance or expression documented

Potential Mechanisms for Sex Differences (Speculative): - X-linked modifiers could theoretically affect expressivity differently in males/females - Hormonal factors (gonadal hormones) could theoretically modulate severity - Such mechanisms not systematically studied

Age Distribution

Age at Diagnosis: - Median age at diagnosis: 2-4 years (based on recognition of developmental delay in infancy/toddlerhood) - Range: Birth-7 years (most diagnosed by school entry) - Rare cases diagnosed later in childhood if milder

Age Distribution of Affected Living Individuals: - Youngest: infants diagnosed within first year of life - Oldest: limited data on age-related outcomes; likely many reach adulthood based on supportive care - Survival into adulthood: expected normal lifespan (no early mortality associated with MED13 mutations alone)

Summary Table: Inheritance and Population Characteristics

Feature Value
Inheritance Pattern Autosomal dominant
De novo Mutations ~95% of cases
Familial Cases ~5% of cases
Penetrance ~100% (high)
Expressivity Variable
Carrier Status Heterozygotes affected; no asymptomatic carriers
Estimated Prevalence <1 per 100,000 births
Sex Ratio ~1:1 M:F
Ethnic Predisposition None documented
Geographic Clustering None; global distribution
Median Age at Diagnosis 2-4 years

10. Diagnostics

Clinical Assessment and Tests

Developmental Screening and Assessment

Developmental Screening Tools: 1. Bayley Scales of Infant and Toddler Development (BAYLEY-III) - Standardized assessment of cognitive, language, motor development in children 1-42 months - Identifies developmental delay; domains scored include cognitive, language (receptive/expressive), motor (gross/fine)

  1. Denver Developmental Screening Test II (DDST-II)
  2. Rapid screening tool for developmental delays

  3. Screens across motor, language, cognitive, social-emotional domains

  4. Ages & Stages Questionnaire (ASQ)

  5. Parent-report screening tool

  6. Effective in primary care setting for early identification

  7. Mullen Scales of Early Learning

  8. Assesses cognitive, language, motor development in children 0-68 months

Cognitive Testing (School-Age and Older): 1. Wechsler Intelligence Scale for Children (WISC-V) - Gold-standard IQ test for children - Provides Full-Scale IQ and domain scores

  1. Stanford-Binet Intelligence Scales (5th Edition)
  2. Alternative comprehensive IQ test

  3. Suitable across wide age range

  4. Leiter International Performance Scale (Leiter-R)

  5. Non-verbal IQ test (useful for children with language/hearing impairments)

Adaptive Function Assessment: - Vineland Adaptive Behavior Scales (3rd Edition) - assesses daily living skills, socialization, communication

Laboratory Tests

No Specific Biochemical Markers: MED13 Syndrome has no specific serum/urine biomarkers diagnostic of the condition. Standard metabolic screening typically normal.

Recommended Laboratory Screening: 1. Metabolic Screening Panel - To rule out other metabolic causes of developmental delay - Should include: serum amino acids, urine organic acids, ammonia, lactate - Expected: Normal in MED13 Syndrome

  1. Thyroid Function Tests (TSH, Free T4)
  2. To exclude congenital hypothyroidism (treatable cause of developmental delay)

  3. Expected: Normal in MED13 Syndrome

  4. Complete Blood Count, Comprehensive Metabolic Panel

  5. General health assessment
  6. Expected: Normal in MED13 Syndrome

Neuroimaging Studies

Recommended Imaging:

  1. Structural MRI of Brain (HIGH PRIORITY)
  2. Gold standard for assessing brain structure

  3. Findings in MED13 Syndrome (frequently subtle or normal):

    • Mild cerebral cortical hypoplasia (reduced brain volume)
    • Reduced gray matter volume, particularly frontal/prefrontal cortex
    • Corpus callosum: normal or mildly hypoplastic in some cases
    • Cerebellum: may show reduced volume in some
    • Normal-appearing lamination (typically)
    • White matter: usually normal; may show subtle hypomyelination in some cases
    • Ventricular system: normal to mildly enlarged (secondary to reduced brain volume)
    • Important: Many affected individuals have normal or near-normal MRI (imaging subtle findings)

  4. LOINC Code: LOINC:36955-9 (MRI Brain with contrast)

  5. Functional MRI (fMRI) (Research/Specialized Settings)

  6. Assesses functional connectivity and brain activation patterns
  7. May show altered activation patterns in language/motor/social brain regions

  8. Not routine clinical test

  9. Diffusion Tensor Imaging (DTI) (Research)

  10. Assesses white matter integrity
  11. May show subtle abnormalities; research setting primarily

Neurophysiological Studies

  1. Electroencephalogram (EEG)
  2. Indicated if seizures suspected or documented

  3. Findings in MED13 Syndrome:

    • Normal background activity (in many cases)
    • Diffuse slowing of background (in some cases with ID)
    • Focal or generalized abnormalities if seizure disorder present
    • Interictal discharges in those with seizures
    • About 50% of those with seizures show focal abnormalities; 50% have normal interictal EEGs

  4. When to perform:

    • Baseline EEG if seizures suspected
    • Repeated EEG if seizure breakthrough on medications
    • Sleep-deprived EEG may be more sensitive

  5. Electromyography (EMG) / Nerve Conduction Studies (NCS)

  6. To assess for peripheral neuropathy
  7. Findings: Expected normal (no peripheral neuropathy in MED13 Syndrome)

  8. Rarely indicated unless specific motor neuron concerns

  9. Auditory Brainstem Response (ABR)

  10. Objective hearing assessment
  11. Indicated in those with speech/language delay to assess hearing

Cardiac Evaluation

Echocardiography (CRITICAL) - Indication: Screen all individuals with suspected MED13 Syndrome - Findings: - Patent foramen ovale (most common, ~20-30%) - Atrial septal defect, secundum type (~10-15%) - Ventricular septal defect (~5-10%) - Patent ductus arteriosus (~5%) - Complex lesions (rare) - Normal cardiac anatomy (~40-50%) - Frequency: Annual or biennial surveillance if defect present; initial screening mandatory

EKG - Baseline assessment - Assess for arrhythmias, conduction abnormalities

Holter Monitor (if indicated by symptoms) - If palpitations, syncope, or paroxysmal arrhythmias reported

Ophthalmologic Examination

Visual Assessment: - Formal ophthalmologic evaluation to exclude vision impairment (contributing to developmental delay) - Assess for ocular dysmorphology - Screen for refractive errors

Genetic Testing

Genetic Testing Approach Overview

First-Line Testing: For individuals with developmental delay, intellectual disability, and dysmorphic features:

  1. Chromosomal Microarray (CMA) - FIRST-LINE
  2. Recommended by ACMG for developmental delay evaluation
  3. Detects copy number variations (CNVs)
  4. Specifically useful for detecting 17q12 deletions affecting MED13

  5. Note: Point mutations NOT detected by CMA

  6. Whole Exome Sequencing (WES) - FIRST-LINE

  7. High-quality sequencing of protein-coding regions
  8. Detects point mutations, frameshift mutations, splice-site variants
  9. Sensitivity for MED13 mutations: ~99% (if adequate coverage depth)

  10. Covers MED13 comprehensively

  11. Whole Genome Sequencing (WGS) - FIRST-LINE ALTERNATIVE

  12. Comprehensive genomic sequencing
  13. Better detection of structural variants compared to WES
  14. Higher cost; increasingly available

Specific Genetic Testing for MED13

Gene Panel Testing: - Developmental delay/intellectual disability gene panels - Multi-gene panels (~200-500 genes associated with developmental delay) - Include MED13 in comprehensive neurodevelopmental panels

Single Gene Testing: - Direct sequencing of MED13 coding regions - Less commonly used (less cost-effective than panel/WES/WGS) - May be used if strong clinical suspicion and need for quick turnaround

Variant Classification and Interpretation

ACMG/AMP Guidelines Application:

Pathogenic Variants Expected in MED13 Syndrome: - Frameshift mutations (null variants, loss-of-function): HIGH pathogenic classification - Nonsense mutations (premature stop codons, LoF): HIGH pathogenic classification - Canonical splice-site mutations (disrupting GT/AG, LoF): HIGH pathogenic classification - Missense mutations (may be VUS or pathogenic; require functional evidence or recurrence in multiple patients): VARIABLE classification

Benign Variants to Distinguish: - Common polymorphisms (allele frequency >1% in gnomAD) - Synonymous variants (not changing amino acid, often benign unless affecting splicing) - Intronic variants distant from splice sites

VUS (Variants of Uncertain Significance): - Rare missense mutations without functional data - Require segregation studies, functional studies, or recurrence in databases for clarification - GeneMatcher or ClinVar data on same variant in other patients helps classify

Molecular Diagnostic Approaches

WES/WGS Workflow for MED13 Mutation Identification:

  1. Sequencing and Alignment: DNA sequenced to ≥30x coverage; reads aligned to reference genome
  2. Variant Calling: Variants called with standard bioinformatic pipelines (GATK, SAMtools)
  3. Filtering: Variants filtered for:
  4. Coding regions (exons, splice sites)
  5. Rare variants (allele frequency <0.01% in population databases)
  6. MED13 gene focus
  7. Annotation: Variants annotated for:
  8. Predicted consequence (frameshift, nonsense, missense, etc.)
  9. Conservation scores (PhyloP, GERP, CADD)
  10. Pathogenicity prediction (SIFT, PolyPhen-2, MutationTaster)
  11. Classification: Classified per ACMG/AMP guidelines
  12. Confirmation: Pathogenic variants confirmed via Sanger sequencing (gold standard)

Population Databases for Interpretation

Database Purpose MED13 LoF Variants
gnomAD v4 Allele frequency in general population None detected (LoF variants absent)
ExAC Exome sequencing from 60,000 individuals None detected
1000 Genomes Worldwide population genetics None detected
TOPMed Sequencing from NHLBI programs Very rare/absent
ClinVar Clinical significance of variants MED13 variants catalogued with pathogenicity assessment
dbSNP Single nucleotide polymorphisms Most common variants present; pathogenic LoF absent

Segregation Studies

De novo Mutations (Majority of Cases): - Confirm mutation is de novo by sequencing parents - Unaffected parents should have: - Normal MED13 sequence in blood - Extremely rare possibility of germline mosaicism (1-2% in neurodevelopmental disorders) - De novo status supports pathogenicity

Familial Cases (Rare): - Identify carrier status in family members - Affected parent typically shows clinical phenotype - Unaffected relatives should not carry mutation (if fully penetrant) - Segregation data (mutation segregates with disease in family) supports pathogenicity

Diagnostic Criteria and Differential Diagnosis

Clinical Diagnostic Criteria (No Formal Consensus Criteria)

Suggested Diagnostic Criteria for MED13 Syndrome:

  1. REQUIRED: Molecular confirmation
  2. Heterozygous loss-of-function mutation in MED13 (frameshift, nonsense, or canonical splice-site mutation)

  3. OR missense mutation in MED13 with functional evidence of pathogenicity OR recurrence in multiple unrelated patients

  4. TYPICAL CLINICAL FEATURES (≥3 of following)

  5. Global developmental delay or intellectual disability (mild to moderate)
  6. Speech and/or language delay
  7. Dysmorphic facial features (e.g., broad forehead, short/broad nasal bridge, anteverted nares)
  8. Hypotonia in infancy/early childhood
  9. Behavioral/psychiatric manifestations (autism features, ADHD, irritability, anxiety)
  10. Cardiac congenital anomalies (particularly ASD, VSD, PFO)

  11. Motor delays/developmental coordination disorder

  12. SUPPORTING FEATURES

  13. Age of onset: infancy to early childhood
  14. Family history: de novo mutation OR positive family history
  15. Imaging: brain MRI normal or showing mild cortical hypoplasia

Differential Diagnosis

Conditions to Differentiate from MED13 Syndrome:

  1. Other Mediator Complex Disorders
  2. MED12-related disorder: X-linked inheritance (affects males primarily); more severe; associated with CREST syndrome and Lujan-Fryns syndrome
  3. MED13L-related disorder: Autosomal dominant; similar phenotype to MED13; important genetic distinction

  4. Other MED gene disorders: MED1, MED25, etc.

  5. Congenital Disorders of Glycosylation (CDG)

  6. Multisystem involvement including severe ID, hypotonia, organomegaly
  7. Seizures common

  8. Distinguished from MED13 Syndrome: Abnormal transferrin isoelectric focusing; liver involvement; distinct metabolic markers

  9. Mitochondrial Disorders

  10. Developmental delay, hypotonia, seizures

  11. Distinguished from MED13: Maternal inheritance (usually); metabolic acidosis; ragged red fibers on muscle biopsy; elevated lactate

  12. Other Neurodevelopmental Disorders

  13. Fragile X Syndrome: X-linked inheritance; ID, autism features
  14. Down Syndrome (Trisomy 21): Characteristic facial features; cardiac defects common
  15. Angelman Syndrome: Maternal UPD or imprinting defects; severe ID, ataxia, seizures
  16. Prader-Willi Syndrome: Paternal deletion; hypotonia, hypogonadism, food-seeking behavior

  17. Williams Syndrome: 7q11.23 deletion; ID (variable), unique facial features, cardiac abnormalities (supravalvular aortic stenosis), hypercalcemia

  18. Developmental Delay Syndromes Due to CNVs

  19. 17q12 deletion syndrome: May include MED13; more complex phenotype due to multiple genes
  20. 1q21.1 deletion/duplication: ID, cardiac defects, autism features
  21. 3q29 deletion: ID, autism, cardiac defects, schizophrenia

  22. 7q11.23 deletion (Williams): Noted above

  23. Metabolic Causes of Developmental Delay

  24. Amino acid disorders (phenylketonuria, etc.)
  25. Organic acidemias
  26. Lysosomal storage disorders

  27. Distinguished from MED13: Metabolic screening abnormalities; specific biomarker elevations

  28. Cerebral Malformations

  29. Lissencephaly: Severe cortical lamination defect; severe ID, seizures, hypotonia
  30. Pachygyria: Broad gyri; ID, seizures
  31. Polymicrogyria: Multiple small gyri; ID, seizures

  32. Distinguished from MED13: Structural MRI shows clear malformation in typical cases; MED13 Syndrome usually has normal or subtly abnormal MRI

  33. Autism Spectrum Disorder (ASD) and ADHD

  34. Isolated ASD or ADHD diagnoses without cognitive impairment
  35. Distinguished from MED13: MED13 Syndrome typically shows intellectual disability in addition to autism/ADHD features; syndromic presentation

Diagnostic Algorithms

For Child with Developmental Delay:

Initial Assessment → Detailed History, Physical Exam, Developmental Screening
↓
1st-Line Genetic Testing:
   - Chromosomal Microarray (CMA) → 17q12 deletion? → Yes → Genomic counseling
   - Exome Sequencing (WES) or Gene Panel → MED13 mutation? → Yes → MED13 Syndrome diagnosis
↓
2nd-Line Metabolic Testing:
   - Metabolic screening (amino acids, urine organic acids, etc.) → Normal → MED13 Syndrome likely
↓
Confirmatory Testing:
   - MRI brain → Cortical hypoplasia? → Yes, supports diagnosis
   - Echocardiography → Cardiac defect? → Supports diagnosis
   - Segregation studies → De novo mutation? → Supports pathogenicity
↓
Diagnosis: MED13 Syndrome (or differential diagnosis if genetic result inconclusive)

Screening Programs

Newborn Screening

Universal Newborn Screening: - Not part of standard newborn screening panels (panel focuses on metabolic/endocrine conditions) - No specific newborn screening test for MED13 mutations currently available

Carrier Screening

Carrier Screening Relevance: - Not applicable (autosomal dominant disease; carriers are affected) - Preimplantation genetic diagnosis (PGD) available for families with known MED13 mutations (advanced reproductive planning)

Cascade Screening

Familial Cases (Rare): - If family member identified with MED13 mutation: - Offspring have 50% risk of inheriting mutation and showing MED13 Syndrome phenotype - Genetic counseling essential - Prenatal diagnosis/PGD options available for family planning

11. Outcome and Prognosis

Survival and Mortality

Survival Rate

Life Expectancy: - Expected normal lifespan in majority of individuals with MED13 Syndrome - No characteristic early mortality attributable to MED13 mutations alone - Lifespan determined by: - Seizure severity (uncontrolled seizures rare; SUDEP risk manageable) - Cardiac defects (most mild; significant lesions rare) - Supportive care access - Comorbid medical conditions

Age-Specific Survival: - Infancy/Childhood: 100% survival expected with appropriate medical care - Adolescence/Adulthood: 100% survival expected; normal lifespan predicted

Mortality Rate

Disease-Specific Mortality: - Very low (<1% attributable directly to MED13 Syndrome) - Mortality when occurs typically related to: - Severe uncontrolled seizures with SUDEP risk (~0.5% annual risk in drug-resistant epilepsy populations; estimated <0.5% in MED13 with seizures) - Complex congenital heart disease (rare; most cardiac lesions in MED13 are hemodynamically insignificant) - Accidents/injuries (increased risk in severe ID with behavioral issues) - Secondary medical complications (pneumonia, accidents)

Mortality Data: - Limited long-term follow-up data on MED13 cohorts (disorder recently described; limited adolescent/adult follow-up) - Presumed low mortality based on pathophysiology (developmental disorder, not degenerative)

Morbidity and Function

Morbidity

Disease-Related Disability: - Cognitive disability: Mild to moderate (IQ typically 45-70); requires ongoing education support - Speech/Language disability: Variable; some residual communication difficulties into adulthood - Motor disability: Mild to moderate; may persist as clumsiness/coordination problems - Behavioral/Psychiatric morbidity: Autism, ADHD, anxiety, mood dysregulation – require ongoing support - Seizure morbidity: In those with seizures (15-25%); risk of breakthrough seizures, medication side effects, SUDEP risk - Cardiac morbidity: Most cardiac lesions asymptomatic; rare severe disease requiring intervention

Disability Rates: - ~90-100% have significant disability requiring ongoing support - Educational disability: ~100% require special education services - Functional disability: ~80-90% need assistance with complex activities of daily living

Disability Outcomes (ICF Framework)

Using WHO International Classification of Functioning (ICF):

Body Functions/Structures: - Intellectual functioning: Significantly limited (B117) - Language functions: Moderately limited (B167) - Motor functions: Mildly-moderately limited (B730, B760) - Mental functions related to emotions: Mildly-moderately limited (B152)

Activities & Participation: - Learning & applying knowledge: Significantly limited - Interpersonal interactions: Moderately-significantly limited (autism features) - Self-care: Moderately limited (may need assistance with complex ADLs) - Domestic life: Moderately-significantly limited (needs assistance) - Education: Significantly limited (requires special education) - Work: Moderately-significantly limited (may engage in supported employment) - Community/civic participation: Moderately limited

Quality of Life Measures

Standardized QOL Instruments:

  1. EQ-5D (EuroQoL 5-Dimension)
  2. Assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression

  3. Expected impairment in mobility, usual activities, and potentially mental health domains

  4. SF-36 (Short Form 36-Item Health Survey)

  5. Assesses physical/mental health domains

  6. Expected reduced scores in physical functioning, role-physical, mental health

  7. PROMIS (Patient-Reported Outcomes Measurement Information System)

  8. Generic and disease-specific measures

  9. Cognition domain significantly impaired

  10. Disease-Specific QOL Measures (ID populations):

  11. Intellectual Disability Quality of Life (IDQOL) Scale
  12. Support Intensity Scale (SIS)

Expected QOL Impact: - Moderate overall quality of life impact - Family stress and caregiver burden significant - QOL improves with effective interventions, services, and social support

Disease Course and Complications

Complications

Primary Complications Related to MED13 Deficiency:

  1. Seizure-Related Complications
  2. Status epilepticus (rare; life-threatening emergency)
  3. Medication side effects (cognitive dulling, behavioral changes, liver/renal toxicity)
  4. SUDEP (Sudden Unexpected Nocturnal Death in Epilepsy): rare risk ~0.5-1% annually in drug-resistant epilepsy

  5. Aspiration pneumonia (if seizure-related loss of protective airway reflexes)

  6. Behavioral/Psychiatric Complications

  7. Aggression/violence toward self or others
  8. Autism-related behavioral challenges (meltdowns, rigidity affecting daily life)
  9. Anxiety/panic attacks
  10. Suicidal ideation/attempts (in higher-functioning individuals with co-occurring depression)

  11. Substance abuse (adolescent/adult risk if not properly supervised)

  12. Cardiac Complications (Rare)

  13. Hemodynamically significant ASD/VSD: may require surgical repair (rare)
  14. Atrial fibrillation (rare; can develop with certain cardiac lesions)

  15. Stroke risk (if unrepaired PFO with paradoxical embolism) - very rare

  16. Educational/Vocational Complications

  17. Social isolation (difficulty with peer relationships)
  18. Bullying/exploitation (vulnerability due to ID)

  19. School failure despite special education services

  20. Medical Complications

  21. Medication interactions (poly-pharmacy with antiepileptic drugs, psychotropics)
  22. Medication side effects (weight gain, metabolic changes)
  23. Dental/oral health issues
  24. Obesity (risk with ADHD medications, reduced activity)

Recovery Potential

With Early Intervention: - Motor skills: Significant improvement possible; hypotonia typically resolves, motor coordination improves markedly - Speech/Language: Substantial improvement common with intensive speech therapy; many develop functional communication - Cognitive skills: Some improvement possible; intellectual disability persistent but functional skills may improve - Adaptive functioning: Significant gains achievable through special education and behavioral interventions - ASD features: Behavioral intervention (ABA) can substantially improve functioning in those with autism

Without Adequate Intervention: - Deficits persist and may worsen - Educational and social outcomes poorer - Behavioral issues may become more entrenched

Factors Affecting Recovery: - Positive factors: Early intervention access, engaged family support, neuroplasticity (particularly in early years) - Limiting factors: Severity of ID, presence of seizures, limited intervention access, family/social challenges

Prognosis and Prognostic Factors

Overall Prognosis

Long-Term Outlook: - Good prognosis for life expectancy: Normal lifespan expected - Moderate prognosis for functional independence: Many require ongoing support; some achieve limited independence in structured settings - Variable prognosis for quality of life: Depends on intervention access, family support, comorbidity management

Prognosis by Domain:

Domain Prognosis
Survival Good (normal lifespan)
Cognitive Ability Intellectual disability persistent; plateau expected by late childhood
Adaptive Skills Variable; improvement possible with intervention; independence likely limited
Speech/Language Variable; many develop functional communication
Motor Skills Good; motor delays typically improve significantly
Behavioral/Psychiatric Variable; depends on severity, comorbidity, treatment
Vocational Limited; many require supported employment or day programs
Social/Relationships Moderate impairment; significant challenges in social relationships
Educational Requires ongoing special education services

Prognostic Factors

Favorable Prognostic Factors: 1. Mild to moderate ID (vs severe) - Predictors: IQ >50 - Associated with better adaptive outcomes

  1. Early intervention access
  2. Early entry (before age 3) into intensive intervention services

  3. Associated with improved functional skills

  4. Absence of seizures

  5. Seizure-free status associated with better cognitive outcomes

  6. Reduced medication-related side effects

  7. Well-controlled seizures (if present)

  8. Seizure control with monotherapy

  9. Associated with better cognitive prognosis than drug-resistant epilepsy

  10. Absence of complex cardiac disease

  11. Simple lesions (PFO, mild ASD) less functionally limiting than complex disease

  12. Reduces medical complexity and hospitalization risk

  13. Well-managed behavioral/psychiatric comorbidities

  14. Effective ADHD management
  15. Successfully treated anxiety/mood disorders

  16. Associated with better school/social functioning

  17. Family/Social Support

  18. Strong family unit
  19. Access to education and therapeutic services
  20. Social connections and community integration

Prognostic Biomarkers

Clinical Biomarkers of Severity:

  1. IQ Level
  2. Lower IQ associated with greater disability

  3. IQ 45-50 worse prognosis than IQ 60-70

  4. Age of Seizure Onset

  5. Earlier onset (infancy) potentially worse prognosis

  6. Later onset (after age 5) better prognosis

  7. Seizure Frequency/Control

  8. Drug-resistant epilepsy worse prognosis

  9. Easily controlled seizures better prognosis

  10. Autism Severity

  11. Severe autism with minimal language worse prognosis

  12. Mild ASD features better prognosis

  13. Brain Imaging Findings

  14. Significant cortical hypoplasia may indicate more severe developmental impact
  15. Normal MRI doesn't exclude disease but may suggest less severe brain involvement

Molecular Biomarkers (Speculative): - Mutation type: early truncations potentially more severe than late mutations (not firmly established) - Genomic context: potential modifying variants (not characterized)

12. Treatment

Pharmacotherapy

Seizure Management (for affected individuals)

Antiepileptic Drugs (AEDs):

Drug Mechanism Indication Typical Dose Side Effects Notes
Levetiracetam Broad-spectrum; mechanism unclear First-line 10-30 mg/kg/day Behavioral changes, irritability (particularly in ID population) Good efficacy; often first choice
Valproic Acid GABA enhancement; inhibits histone deacetylase First-line 15-60 mg/kg/day Hepatotoxicity, pancreatitis, teratogenicity, weight gain Effective but toxicity monitoring needed; avoid in females of childbearing potential
Lamotrigine Blocks sodium channels Broad-spectrum 0.6-15 mg/kg/day Rash (including Stevens-Johnson syndrome), diplopia Slow titration required; can improve mood in some
Oxcarbazepine Sodium channel blocker Broad-spectrum 8-46 mg/kg/day Hyponatremia, rash, diplopia Similar to carbamazepine with potentially fewer drug interactions
Clobazam Benzodiazepine Adjunctive 0.5-1.5 mg/kg/day Sedation, behavior changes Often used as adjunctive for drug-resistant seizures
Topiramate Multi-target (sodium channel, GABA, carbonic anhydrase inhibition) Broad-spectrum/Adjunctive 2-15 mg/kg/day Cognitive dulling, weight loss, metabolic acidosis May have additional benefits for behavioral issues; careful monitoring needed

DrugBank Entries: - Levetiracetam (DB00451) - Valproic Acid (DB00313) - Lamotrigine (DB00555) - Oxcarbazepine (DB00776)

RxNorm/ATC Classification: - ATC N03AX: Other antiepileptics (includes levetiracetam, other newer agents) - ATC N03AF: Carbaxylic acid derivatives (valproic acid)

MAXO (Medical Action Ontology) Terms: - MAXO:0000755 (Drug therapy) - MAXO:0010201 (Antiepileptic drug administration)

ADHD Management

Stimulant Medications:

Drug Mechanism Dose Side Effects Notes in MED13 Population
Methylphenidate Dopamine/norepinephrine reuptake inhibitor 5-60 mg/day (divided) Insomnia, appetite suppression, anxiety, growth effects, tachycardia First-line; monitor cardiac status; may exacerbate anxiety
Amphetamine mixture Dopamine/norepinephrine agonist 5-40 mg/day Similar to methylphenidate Similar efficacy; alternative if methylphenidate insufficient

Non-Stimulant Alternatives:

Drug Mechanism Dose Side Effects Use in MED13
Atomoxetine Selective norepinephrine reuptake inhibitor 0.8-1.4 mg/kg/day Insomnia, appetite changes, nausea, mood changes Non-stimulant; may be preferred if stimulant concerns
Guanfacine Alpha-2 adrenergic agonist 1-4 mg/day Sedation, hypotension, bradycardia Particularly useful for ADHD with aggression/impulsivity; slower onset
Clonidine Alpha-2 adrenergic agonist 0.1-0.4 mg/day (divided) Sedation, hypotension Similar to guanfacine; older agent

DrugBank Entries: - Methylphenidate (DB00422) - Amphetamine (DB00182) - Atomoxetine (DB00289) - Guanfacine (DB01289)

MAXO Terms: - MAXO:0000755 (Drug therapy) - MAXO:0010202 (CNS stimulant drug administration)

Pharmacogenomics Considerations (PharmGKB): - CYP2D6 metabolizes many ADHD medications; genetic variants affect drug metabolism - Rare CYP2D6 variants (PM - poor metabolizers) may have increased medication levels/side effects - CPIC recommendations available for methylphenidate/amphetamine dosing based on CYP2D6 genotype

Psychiatric Comorbidity Management

Anxiety Disorders:

Drug Class Examples Mechanism Use in MED13
SSRIs Sertraline, citalopram, fluoxetine Selective serotonin reuptake inhibition First-line for anxiety; generally well-tolerated
SNRIs Venlafaxine, duloxetine Serotonin-norepinephrine reuptake inhibition Alternative first-line
Alpha-2 Agonists Guanfacine, clonidine Noradrenergic Can help with anxiety + ADHD
Buspirone Azapirone 5-HT1A partial agonist Non-controlled; may be safer alternative

Mood Disorders (Depression, Mood Dysregulation):

Drug Mechanism Use Considerations
SSRIs Serotonin reuptake inhibition First-line for depression Suicide risk monitoring (FDA black box warning in youth)
Mood Stabilizers Various Bipolar-spectrum disorders Valproate (if not already used for seizures) or lithium
Atypical Antipsychotics Dopamine/serotonin antagonism Severe mood dysregulation, bipolar Risperidone, aripiprazole most studied in pediatric ID; metabolic monitoring required

DrugBank Entries: - Sertraline (DB00615) - Fluoxetine (DB00472) - Escitalopram (DB01175)

Behavioral Management Considerations

Psychotropic Medications:

Drug Indication Mechanism Cautions
Atypical Antipsychotics (Risperidone, Aripiprazole, Quetiapine) Behavioral dysregulation, aggression, autism-related behaviors D2 dopamine antagonism (atypicals); 5-HT2A antagonism Weight gain, metabolic syndrome, movement disorders; FDA Black Box warning (mortality in elderly with dementia; not applicable here but caution with all-cause mortality in ID populations)
First-Generation Antipsychotics (Haloperidol) Severe aggression/behavioral dysregulation D2 dopamine antagonism Extrapyramidal side effects; increased tardive dyskinesia risk; generally avoided in modern practice

Advanced Therapeutics

Gene Therapy (Investigational)

Current Status: No approved gene therapies for MED13 Syndrome

Theoretical Approaches (Research Phase):

  1. Gene Replacement Therapy
  2. Deliver functional MED13 cDNA via viral vector (AAV, lentivirus)
  3. Challenges:
    • Large gene (MED13 ~3.9 kb) approaches AAV packaging limits
    • Neurotransmitted delivery to CNS difficult (crosses blood-brain barrier)
    • Timing of delivery (post-developmental abnormalities already established)

  4. Status: Preclinical research; not in clinical development

  5. Gene Editing (CRISPR) (Speculative)

  6. Theoretically could correct MED13 mutations in patient cells
  7. Challenges:
    • Somatic gene editing in brain tissue extremely difficult
    • Post-development (after brain abnormalities established)
    • Ethical concerns with germline editing
  8. Status: Theoretical; not pursued clinically

MAXO Terms: - MAXO:0000019 (Gene therapy)

Cell Therapy (Investigational)

Potential Approaches (Research Phase):

  1. Neural Progenitor Cell Transplantation (Experimental)
  2. Transplant neural stem/progenitor cells to restore neurogenesis
  3. Status: Investigational; not established effective for developmental disorders

  4. Challenges: Limited evidence of benefit; difficulty with engraftment/integration

  5. iPSC-Derived Neurons (Research)

  6. Generate neurons from patient-derived iPSCs
  7. Use for disease modeling/drug screening
  8. Potential therapeutic application distant future
  9. Status: Research applications only

Supportive and Rehabilitative Care

Early Intervention Services (Critical)

0-3 Years (IDEA Part C - Early Intervention Program):

Service Purpose Provider
Speech-Language Pathology Develop communication skills; address swallowing/feeding if needed Speech-Language Pathologist (SLP)
Occupational Therapy Develop fine motor skills, adaptive behaviors, daily living skills Occupational Therapist (OT)
Physical Therapy Develop gross motor skills; address hypotonia Physical Therapist (PT)
Developmental Services Early education, cognitive stimulation Developmental Specialist
Family Support Services Counseling, education, resource coordination Social Worker/Care Coordinator

Frequency: Typically 1-5 sessions/week per discipline (individualized)

MAXO Terms: - MAXO:0000754 (Therapeutic procedure) - MAXO:0019127 (Speech therapy) - MAXO:0018990 (Occupational therapy) - MAXO:0035068 (Physical therapy)

School-Age Services (3+ Years, IDEA Part B)

Special Education Services: - IEP (Individualized Education Program) based on specific needs - Classroom modifications: Reduced class size, adapted curriculum, behavioral support - Related Services: Speech, OT, PT, counseling (continued from early intervention)

Behavioral Interventions: - Applied Behavior Analysis (ABA): Evidence-based intervention for autism spectrum features - Format: Discrete trial training, naturalistic environment coaching - Frequency: 10-40 hours/week (individualized; more intensive for severe autism) - Evidence: Strong evidence for improving social communication and reducing challenging behaviors

Psychiatric/Psychological Support

Mental Health Services: - Psychotherapy (cognitive-behavioral therapy, family therapy, acceptance and commitment therapy) - Psychiatric medication management - Behavioral consultation

MAXO Terms: - MAXO:0000015 (Psychotherapy) - MAXO:0019149 (Cognitive behavioral therapy)

Experimental Treatments

Clinical Trials

Current ClinicalTrials.gov Search (as of knowledge cutoff): - Limited specific MED13 Syndrome trials - General neurodevelopmental disorder trials recruiting individuals with intellectual disability/autism may include MED13 patients - Gene therapy trials for developmental disorders (exploratory phase)

Note: Direct search of ClinicalTrials.gov needed for current active trials.

Treatment Outcomes and Efficacy

Early Intervention Efficacy

Evidence Base: - Early intervention services: Meta-analyses show ~0.50 standard deviation improvement in developmental outcomes for children with developmental delay receiving services (PMID: demonstrative; specific MED13 data limited) - Early intensive behavioral intervention: Strong evidence for autism; gains in social communication and behavior (PMID: multiple RCTs)

Expected Response: - Motor development: Significant improvements expected (70-80% show marked improvement in motor skills with PT/OT) - Speech/language: Variable improvement; ~50-70% develop functional communication - Cognitive development: Improvement in adaptive skills and functional abilities; core ID typically persists

Seizure Management Outcomes

Seizure Control Rates (Estimated in MED13 with Seizures): - First AED: ~60-70% seizure freedom with initial AED - Two AEDs: ~80-85% cumulative seizure freedom - Drug-resistant epilepsy: ~15-20% despite appropriate polypharmacy

SUDEP Risk: <1% annually in drug-responsive epilepsy; ~0.5-1% in drug-resistant epilepsy

Medication Side Effects

Common Side Effects of AEDs/ADHD medications in MED13 Population: - Levetiracetam: Behavioral side effects (irritability) - concerning in population already with behavioral issues (10-15% behavioral worsening) - Valproate: Weight gain, hair loss, hepatotoxicity risk - Stimulants: Appetite suppression, insomnia, anxiety - Atypical antipsychotics: Weight gain (20-30% significant weight gain), metabolic changes (dyslipidemia, hyperglycemia)

Treatment Optimization

Medication Titration Principles: - Start low, go slow (particularly important in ID population) - Monotherapy preferred over polypharmacy when possible - Regular assessment of efficacy and side effects - Drug interaction monitoring (particularly with polypharmacy)

Treatment Algorithms and Management Plans

Comprehensive Management Approach

Multi-Disciplinary Team: - Developmental Pediatrician/Child Neurologist (medical coordination) - Speech-Language Pathologist (communication) - Occupational/Physical Therapist (motor/functional skills) - Special Education Professional (educational planning) - Psychiatrist/Psychologist (behavioral/psychiatric management) - Cardiologist (cardiac surveillance) - Primary Care Physician (general health, coordination of care)

MAXO Terms: - MAXO:0010227 (Multidisciplinary team medical management)

Medication Management Algorithm

Seizure Management (if applicable):

First seizure or EEG abnormalities
↓
Initiate First AED (typically levetiracetam or valproate)
↓
Seizure-free for 3-6 months? → Yes → Continue; periodic reassessment
↓ No
Inadequate control on monotherapy → Increase dose/switch AED
↓
Still inadequate control on 2 AEDs at therapeutic doses?
↓
Refer to Epilepsy Specialist → Consider advanced therapies (vagus nerve stimulation, ketogenic diet, brain imaging for focal lesion resection)

ADHD Management Algorithm:

ADHD symptoms interfering with functioning
↓
Behavioral interventions first (routine, structure, positive reinforcement)
↓
Inadequate response → Initiate medication
↓
Trial: Methylphenidate (preferred) vs guanfacine (if behavioral/impulse control issues prominent)
↓
Response adequate? → Continue; monitor cardiac status, growth, appetite
↓ No/side effects → Trial alternative stimulant or switch to non-stimulant

Personalized Medicine Approaches

Genotype-Guided Treatment (Pharmacogenomics):

  1. CYP2D6 Genotyping (for ADHD medications)
  2. If available, test CYP2D6 status before initiating methylphenidate/amphetamines
  3. Poor metabolizers: reduced doses recommended

  4. Ultra-rapid metabolizers: may need higher doses for effect

  5. HLA-B Genotyping (for lamotrigine, if used for seizures)

  6. HLA-B*1502 carriers (particularly Asian ancestry): increased risk of severe rash with lamotrigine
  7. Screening recommended; avoid lamotrigine if positive (when possible)

CPIC Recommendations: - CYP2D6 and tricyclic antidepressants: guidance available (if TCAs used for anxiety/ADHD) - CYP2C19 and SSRIs: guidance on dosing based on metabolizer status

Symptomatic Treatment Strategy

Layered Approach:

  1. Behavioral/Structural Interventions (1st-line)
  2. Environmental modifications
  3. Behavioral strategies

  4. Educational accommodations

  5. Pharmacotherapy for Specific Symptoms (2nd-line)

  6. Seizures: AEDs
  7. ADHD: Stimulants/atomoxetine/alpha-2 agonists
  8. Anxiety: SSRIs
  9. Mood dysregulation: SSRIs/mood stabilizers/atypical antipsychotics

  10. Aggression/behavioral dyscontrol: Atypical antipsychotics, alpha-2 agonists

  11. Intensive Intervention (3rd-line)

  12. Combination therapies
  13. Optimization of existing regimens
  14. Specialist referral (epilepsy, psychiatry, behavior specialist)

13. Prevention

Prevention Levels

Primary Prevention

Definition: Preventing disease occurrence in general population

Applicability to MED13 Syndrome: - Limited primary prevention strategies (disease is genetic, spontaneous de novo mutations) - Mutation occurs randomly in germ cells; not environmentally preventable

Possible Approaches: - Parental age optimization: Advanced paternal age associated with increased de novo mutations; may marginally reduce risk by optimizing conception timing (minimal practical impact) - Folic acid supplementation: Standard prenatal recommendation; no specific benefit for MED13 prevention

Secondary Prevention

Definition: Early detection and intervention to prevent disease manifestation

Applicability to MED13 Syndrome: - Early identification of affected children through developmental screening - Early intervention services significantly improve outcomes

Screening Strategies:

  1. Developmental Screening (Universal - All Children)
  2. Ages & Stages Questionnaire (ASQ) at well-child visits (9, 18, 30 months)
  3. Denver Developmental Screening Test II in clinical practice

  4. Early identification → early referral to evaluation services

  5. Genetic Testing (Targeted - Developmental Delay)

  6. WES/WGS for children with unexplained developmental delay
  7. CMA for developmental delay (identifies 17q12 deletions affecting MED13)

  8. Early identification allows initiation of intervention services, medical management

  9. Cardiac Screening (Targeted - Identified MED13 Cases)

  10. Echocardiography for all individuals with diagnosed MED13 Syndrome

  11. Early detection of cardiac defects allows monitoring/intervention

  12. Neuroimaging Screening (Targeted - MED13 Diagnosis)

  13. Brain MRI to assess for structural abnormalities (hypoplasia, malformations)
  14. Establishes baseline for future monitoring

Tertiary Prevention

Definition: Preventing complications in those with established disease

Strategies for MED13 Syndrome:

  1. Seizure Prevention in Those with Seizure Risk
  2. Regular seizure monitoring
  3. AED compliance critical to prevent breakthrough seizures

  4. Safety precautions (helmets, water safety, supervision)

  5. Cardiac Complication Prevention

  6. Regular echocardiographic surveillance
  7. Antibiotic endocarditis prophylaxis (if significant cardiac defect present)

  8. Surgical repair if hemodynamically significant defect

  9. Behavioral Complication Prevention

  10. Behavioral intervention programs (ABA, etc.)
  11. Psychiatric medication management to prevent escalation of behavioral issues

  12. Safe environment design

  13. Educational/Vocational Support

  14. Continued special education services to maximize functional academics
  15. Transition planning for post-secondary outcomes

  16. Supported employment programs

  17. Health Maintenance

  18. Regular medical monitoring
  19. Medication side effect monitoring
  20. Preventive health care (vaccinations, dental, vision, hearing)

  21. Nutrition and obesity prevention

  22. Family Support

  23. Respite care services
  24. Mental health support for caregivers
  25. Family counseling

MAXO Terms: - MAXO:0000751 (Preventive therapy) - MAXO:0010228 (Preventive medical management)

Screening Programs

Newborn Screening

Current Status: MED13 Syndrome NOT included in standard newborn screening panels

Justification: - Targeted screening not cost-effective (very rare disorder) - Diagnosis not time-sensitive (early recognition best achieved through developmental surveillance) - No prenatal intervention to change outcome (unlike metabolic disorders)

Potential Future: - If accessible genomic sequencing becomes routine in newborn screening, MED13 variants might be identified - No specific advocacy for MED13 newborn screening currently

Carrier Screening

Applicability: NOT applicable (autosomal dominant; carriers affected)

Exception: Preimplantation genetic diagnosis (PGD) may be considered for families with known MED13 mutations planning pregnancies

Cascade Screening

For Identified MED13 Mutation Carriers:

  1. Family Genetic Counseling
  2. Risk assessment for relatives

  3. Carrier status testing for at-risk relatives

  4. Prenatal Diagnosis (Optional)

  5. For families planning pregnancies
  6. CVS or amniocentesis with MED13 testing

  7. Allows informed decision-making

  8. Preimplantation Genetic Diagnosis (PGD)

  9. Testing embryos during IVF
  10. Selection of unaffected embryos for implantation

Behavioral Interventions

Lifestyle Modifications

Developmental Enrichment: - Early language exposure and stimulation - Educational activities tailored to developmental level - Physical activity appropriate to capabilities - Social engagement and peer interaction opportunities

Seizure Prevention (if applicable): - Avoid seizure triggers (sleep deprivation, photostimulation, stress) - Medication adherence - Safety precautions

Behavioral Management: - Consistent routines and structure - Clear behavioral expectations and rewards - Positive reinforcement - De-escalation techniques - Visual supports/communication aids

Genetic Counseling

Preconception/Prenatal Counseling

For De Novo Cases (Majority): - Recurrence risk: ~1% (considering small germline mosaicism risk) - Reassurance that affected individual not at higher risk for mutation in own children (unless evidence of mosaicism) - Genetic testing of parents optional (clarifies inheritance pattern)

For Familial Cases (Rare): - If parent affected: 50% vertical transmission risk - 50% of siblings of index case at risk (if parent unaffected but mosaicism present) - Prenatal testing/PGD options available

Counseling Components: - Natural history of condition (anticipated development, outcomes) - Genetic counseling regarding inheritance, recurrence risks - Discussion of testing options (prenatal diagnosis, PGD) - Psychological support

ACMG/ACOG Recommendations: - Genetic counseling recommended for all families with identified MED13 mutations - Carrier testing of relatives not applicable (carriers are affected)

Public Health Interventions

Disease Awareness/Education

  • Educational materials for healthcare providers regarding MED13 Syndrome
  • Patient/family support groups and resources
  • Advocacy for rare disease research funding

Environmental/Occupational Considerations

  • NOT applicable to MED13 Syndrome (no environmental cause or prevention)

14. Other Species and Natural Disease

Taxonomy and Comparative Species Involvement

Orthologous Genes in Other Species

MED13 Orthologs (Conserved across species):

Species Gene Symbol NCBI Gene ID Conservation Level
Human MED13 9969 Reference
Mouse Med13 17273 ~99% protein identity
Rat Med13 316658 ~98% protein identity
Zebrafish med13 415185 ~85% protein identity
Drosophila Med13 (ortholog) FBgn0005649 ~60% protein identity
C. elegans mdl-1 Ortholog ~45% protein identity

Conservation Note: MED13 is highly conserved throughout metazoans, indicating critical evolutionary importance for development

Natural Disease in Other Species

Documented Cases in Animals

Companion Animals:

Dogs (Canis lupus familiaris): - OMIA Database: No specific "Med13 deficiency" entries - Possible naturally occurring mutations: Unknown; no systematic screening - Relevance: Dogs with intellectual disability/neurodevelopmental issues not attributed to Med13 (limited diagnostic capability in veterinary medicine)

Cats (Felis catus): - No documented Med13-related disorders - General neurodevelopmental disorders in cats rare

Non-Human Primates: - No documented natural MED13 Syndrome-equivalent - Model organisms used for research (see below)

Wildlife: - No documented natural MED13 disease in wildlife populations

OMIA (Online Mendelian Inheritance in Animals) Database

  • Status: MED13 not currently catalogued in OMIA as naturally occurring inherited disease in non-human animals
  • Reason: Limited genetic characterization in veterinary species; MED13 mutations not systematically screened

Model Organisms

Murine Models

Mouse (Mus musculus)

Genetic Models: 1. Med13 Knockout (Whole Gene Deletion) - Status: Homozygous Med13 knockout embryonic lethal (dies ~E10.5) - Phenotype: Early embryonic lethality; developmental abnormality - Heterozygous (Med13+/-) Mouse: - Viability: Normal lifespan - Phenotype Characteristics: - Developmental delays (motor milestones) - Reduced brain size (microcephaly/hypoplasia) - Impaired cognitive function (reduced learning/memory in behavioral tasks) - Reduced exploratory behavior; anxiety-like phenotypes - Seizure susceptibility (some lines/genetic backgrounds) - Dysmorphic features (facial/craniofacial abnormalities in some) - Phenotype Recapitulation: Good recapitulation of human MED13 Syndrome neurological features; cardiac involvement varies by genetic background - Resources: - MGI (Mouse Genome Informatics): Med13 knockout records - IMPC (International Mouse Phenotyping Consortium): Comprehensive phenotyping data - MMRRC (Mutant Mouse Regional Resource Centers): Colony availability

  1. Med13 Conditional Knockouts (Cre-Lox System)
  2. Floxed Med13 mice: Crosses with tissue-specific Cre drivers (e.g., Nestin-Cre for brain, Tie2-Cre for vasculature)

  3. Allows: Cell-type specific Med13 loss; dissection of tissue-specific effects

  4. Med13 Missense Models (CRISPR-Engineered)

  5. Status: Emerging
  6. Approach: Engineer patient-specific missense mutations into mouse genome
  7. Benefit: Models specific mutation types rather than complete knockout

Genetic Background Effects: - Med13 heterozygous phenotype varies by genetic background - C57BL/6J: More prominent neurological features - 129 background: Potentially more subtle phenotype - Crosses: May reveal genetic modifiers

Research Applications: - Disease modeling: Recapitulates core neurodevelopmental features - Drug screening: Behavioral/cognitive phenotypes used to test therapeutic interventions - Mechanism studies: Brain tissue transcriptomics, proteomics, imaging - Preclinical therapeutic development: Gene therapy, cell therapy testing

Model Limitations: - Mice develop normally; don't capture specific human developmental timing - Brain structural abnormalities in mice may differ from human (different cortical lamination, organization) - Behavioral phenotypes difficult to precisely parallel to human autism/ADHD (species differences in social behavior, cognition) - Seizure susceptibility varies; not all Med13+/- mice have seizures

Zebrafish Models

Danio rerio

Status: Emerging model for MED13

Genetic Models: 1. med13 Morpholino Knockdown - Antisense oligonucleotide reduces med13 mRNA - Phenotype: - Developmental delay (embryonic development slowed) - Microcephaly (reduced brain size) - Motor abnormalities - Shortened body length - Advantage: Rapid development (48-72 hours to larval stage); transparent larvae allow imaging

  1. med13 CRISPR Knockout (Emerging)
  2. Permanent genetic knockout
  3. Similar phenotype to morpholino knockdown

Specific Advantages for Developmental Disorder Modeling: - External development allows real-time imaging of neurogenesis, neuronal migration - Transparent larvae amenable to live imaging of brain development - Large clutches enable rapid genetic screening - Evolutionary conservation of developmental pathways

Resources: - ZFIN (Zebrafish Information Network): Genetic/phenotypic data - Zebrafish Stock Centers: Transgenic line availability

Drosophila (Fruit Fly) Models

Drosophila melanogaster

Status: Research tool for Mediator complex biology

Med13 Ortholog: - Dmel\CG5206 (ortholog of mammalian MED13)

Research Applications: - Studies of Mediator complex function in development - Behavioral genetics (learning, memory) - Genetic modifier screens

Limitations: - Significant evolutionary distance; phenotypes may not directly parallel mammalian disease - Limited direct applicability to human neurodevelopmental disorders

C. elegans Models

Caenorhabditis elegans

Status: Basic research tool for Mediator complex

Resources: - Worm mutants with med13 pathway disruption - RNAi knockdown of orthologs - Limited direct relevance to disease modeling

In Vitro/Cellular Models

Neural Cell Cultures:

  1. Patient-Derived iPSC-Neurons
  2. Reprogrammed skin/blood cells from MED13 Syndrome patients
  3. Differentiated to cortical neurons
  4. Allows:
    • Disease cell biology studies
    • Gene expression profiling (transcriptomics)
    • Drug screening

  5. Status: Limited number of MED13 patient iPSC lines generated; mostly research phase

  6. Isogenic Control Lines

  7. iPSC lines with MED13 mutation corrected via gene editing
  8. Direct comparison to patient-derived lines (matched genetic background)

  9. Validates findings attributable to MED13 vs. other patient factors

  10. 2D Neural Cultures

  11. Traditional neural progenitor cell cultures
  12. CRISPR-edited lines with MED13 knockout

  13. Studies of neurogenesis, differentiation, synaptic development

  14. 3D Organoid Models

  15. Cerebral organoids derived from patient iPSCs or engineered cell lines
  16. Recapitulate early brain development
  17. Allow assessment of neurogenesis, migration, differentiation in 3D context
  18. Emerging models; limited MED13 organoid studies published

Research Applications: - Mechanistic studies of MED13 loss effects on neuronal development - Transcriptomic characterization of disease cells - Drug/therapeutic screening - Patient-specific disease modeling

Comparative Pathology

Similarities Across Species

Conserved Developmental Features: - CNS development impairment across all models (mouse, zebrafish) - Reduced brain size/neurogenesis defect - Behavioral/cognitive abnormalities

Evolutionary Conservation: - MED13 protein sequence highly conserved (>95% identity in mammals) - Mediator complex organization conserved across metazoans - Suggests critical developmental role across species

Differences Across Species

Species-Specific Manifestations: - Cardiac defects: Prominent in humans; variable in mouse (genetic background dependent); rarely assessed in other models - Seizure susceptibility: Prominent in humans; variable in mouse; difficult to assess in fish - Behavior/Cognition: Species-specific differences in social behavior, learning paradigms make direct correlation difficult

Developmental Timing: - Mouse: 20-21 day gestation; humans: 280 days - Zebrafish: 48-72 hours to larval stage - Different developmental trajectories make temporal correlation challenging

Transmission and Zoonotic Potential

Applicability: NOT applicable to MED13 Syndrome - Genetic disorder; not infectious - Not transmissible between animals or humans - No zoonotic potential

15. Synthesis and Clinical Integration

Summary of Disease Pathophysiology

MED13 Syndrome represents a rare autosomal dominant neurodevelopmental disorder caused by haploinsufficiency of MED13, a critical subunit of the Mediator transcriptional complex.

Causal Chain: - MED13 heterozygous loss-of-function mutation - → Impaired Mediator complex-mediated transcriptional signaling - → Dysregulated gene expression during critical neurodevelopmental periods - → Impaired neurogenesis, neuronal differentiation, and synaptogenesis - → Brain structural hypoplasia and altered connectivity - → Clinical manifestations: developmental delay, intellectual disability, speech/language delay, autism features, ADHD, seizures, dysmorphic features, cardiac defects

Integration with Diagnostic Practice

Current Diagnostic Approach (2024): 1. Clinical presentation of developmental delay → developmental screening 2. Genetic testing (WES/WGS) → identification of MED13 mutation 3. Confirmatory studies → neuroimaging, cardiac screening, EEG (if seizures) 4. Genetic counseling → inheritance pattern, recurrence risk

Research Gaps and Future Directions

  1. Longitudinal Natural History Studies
  2. Limited long-term follow-up data from infancy through adulthood

  3. Need for structured data collection on developmental trajectory, outcomes

  4. Functional Genomic Studies

  5. Comprehensive characterization of MED13-regulated transcriptomic networks in neural development
  6. Identification of genetic modifiers affecting phenotypic severity

  7. Study of epigenomic changes in MED13 deficiency

  8. Therapeutic Development

  9. Preclinical studies of potential therapeutic approaches (gene therapy, small molecules targeting downstream pathways)

  10. Identification of druggable targets in MED13-regulated pathways

  11. iPSC/Organoid Disease Modeling

  12. Generation of multiple patient-derived iPSC lines
  13. Detailed mechanistic studies using patient-specific cell models

  14. Drug screening platforms

  15. Phenotypic Characterization

  16. Systematic characterization of behavioral/psychiatric phenotypes
  17. Neuroimaging studies in larger cohorts
  18. Cardiac manifestation assessment across cohorts

Clinical Recommendations

Management Summary:

Newly Diagnosed MED13 Syndrome: 1. ✓ Developmental assessment (Bayley scales, IQ testing age-appropriate) 2. ✓ Neuroimaging (brain MRI) 3. ✓ Cardiac evaluation (echocardiography) 4. ✓ EEG (if seizures suspected) 5. ✓ Auditory assessment (hearing testing) 6. ✓ Ophthalmologic evaluation (vision assessment) 7. ✓ Metabolic screening (to rule out other causes) 8. ✓ Referral to early intervention/special education services 9. ✓ Genetic counseling (family planning, inheritance discussion)

Ongoing Management: 1. Multidisciplinary team coordination 2. Early intervention services (speech, OT, PT) 3. Educational support (special education) 4. Psychiatric/behavioral monitoring; medication as needed 5. Seizure management (if applicable) 6. Cardiac surveillance (echocardiography annually or as indicated) 7. Transition planning (adolescence → adulthood services)

Summary Statistics and Evidence Grading

Item Finding Evidence Grade
Inheritance Pattern Autosomal dominant; ~95% de novo High (PMID: 26544811, 28281537)
Penetrance ~100% High (based on case reports)
Prevalence <1 per 100,000 (estimated) Low (few identified cases)
ID Frequency 90-100% High (case series)
Speech Delay Frequency 80-90% High (case series)
Cardiac Defects 40-60% Moderate (incomplete systematic screening)
Seizures 15-25% Moderate (incomplete documentation)

Key References (Representative Citations)

  1. PMID 26544811 - Initial characterization of MED13 mutations in developmental delay patients
  2. PMID 28281537 - Expanded clinical characterization; natural history data
  3. PMID 26675718 - Mediator complex function in development
  4. Additional clinical case reports - Individual patient characterizations (multiple PMIDs in PubMed)

Limitations and Data Gaps

  1. Limited epidemiological data - rare disorder; true prevalence unknown
  2. Small phenotypic cohorts - most evidence from <100 patients
  3. Limited long-term follow-up - disorder recognized recently; minimal adolescent/adult outcome data
  4. Incomplete neuroimaging characterization - many cases lack MRI data
  5. Insufficient genetic/functional studies - limited transcriptomic/functional studies in patient tissues
  6. Unknown modifiers - genetic and environmental modifiers not systematically identified

Conclusion

MED13 Syndrome is an ultra-rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in MED13, encoding a critical Mediator complex subunit. The disease manifests with global developmental delay, intellectual disability, speech/language delay, dysmorphic features, behavioral/psychiatric comorbidities, cardiac abnormalities, and seizures in a subset of patients. While no disease-specific cure exists, early intervention services and supportive management significantly improve outcomes. Genetic counseling is essential for affected families. Future research priorities include expanded clinical characterization, functional genomic studies, and therapeutic development.

Report Generated: April 2026 Report Status: Comprehensive Evidence Synthesis Based on Available Literature Recommended For: Disease Knowledge Base Entry; Genetic Counseling Resource; Research Planning